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Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14752. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled recep-
tors, ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological
tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to
mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International
Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human
drug targets, where appropriate.
Conﬂict of interest
The authors state that there are no conﬂicts of interest to disclose.
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Overview: Enzymes are protein catalysts facilitating the conver-
sion of substrates into products. The Nomenclature Committee of
the International Union of Biochemistry and Molecular Biology
(NC-IUBMB) classiﬁes enzymes into families, using a four num-
ber code, on the basis of the reactions they catalyse. There are six
main families:
EC 1.-.-.- Oxidoreductases;
EC 2.-.-.- Transferases;
EC 3.-.-.- Hydrolases;
EC 4.-.-.- Lyases;
EC 5.-.-.- Isomerases;
EC 6.-.-.- Ligases.
Although there are many more enzymes than receptors in biol-
ogy, and many drugs that target prokaryotic enzymes are effective
medicines, overall the number of enzyme drug targets is relatively
small [454, 492], which is not to say that they are of modest im-
portance.
The majority of drugs which act on enzymes act as inhibitors;
one exception is metformin, which appears to stimulate activity
of AMP-activated protein kinase, albeit through an imprecisely-
deﬁned mechanism. Kinetic assays allow discrimination of com-
petitive, non-competitive, and un-competitive inhibitors. The
majority of inhibitors are competitive (acting at the enzyme’s lig-
and recognition site), non-competitive (acting at a distinct site;
potentially interfering with co-factor or co-enzyme binding) or of
mixed type. One rare example of an uncompetitive inhibitor is
lithium ions, which are effective inhibitors at inositol monophos-
phatase only in the presence of high substrate concentrations.
Some inhibitors are irreversible, including a group known as sui-
cide substrates, which bind to the ligand recognition site and then
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couple covalently to the enzyme. It is beyond the scope of the
Guide to give mechanistic information about the inhibitors de-
scribed, although generally this information is available from the
indicated literature.
Many enzymes require additional entities for functional activity.
Some of these are used in the catalytic steps, while others pro-
mote a particular conformational change. Co-factors are tightly
bound to the enzyme and include metal ions and heme groups.
Co-enzymes are typically small molecules which accept or donate
functional groups to assist in the enzymatic reaction. Examples
include ATP, NAD, NADP and S-adenosylmethionine, as well as a
number of vitamins, such as riboﬂavin (vitamin B1) and thiamine
(vitamin B2). Where co-factors/co-enzymes have been identiﬁed,
the Guide indicates their involvement.
Family structure
– AAA ATPases
S301 Acetylcholine turnover
S302 Adenosine turnover
S303 Amino acid hydroxylases
S304 L-Arginine turnover
S304 2.1.1.- Protein arginine N-methyltransferases
S305 Arginase
S305 Arginine:glycine amidinotransferase
S305 Dimethylarginine dimethylaminohydrolases
S306 Nitric oxide synthases
S307 Carbonic anhydrases
S308 Carboxylases and decarboxylases
S308 Carboxylases
S309 Decarboxylases
S311 Catecholamine turnover
S313 Ceramide turnover
S313 Serine palmitoyltransferase
– 3-ketodihydrosphingosine reductase
S314 Ceramide synthase
S314 Sphingolipid 4-desaturase
S315 Sphingomyelin synthase
S315 Sphingomyelin phosphodiesterase
S316 Neutral sphingomyelinase coupling factors
S316 Ceramide glucosyltransferase
S316 Acid ceramidase
S317 Neutral ceramidases
S317 Alkaline ceramidases
S318 Ceramide kinase
– Chitinases
S319 Chromatin modifying enzymes
– 1.14.11.- Histone demethylases
S319 2.1.1.- Protein arginine N-methyltransferases
– 2.1.1.43 Histone methyltransferases (HMTs)
– 2.3.1.48 Histone acetyltransferases (HATs)
S320 3.5.1.- Histone deacetylases (HDACs)
– 3.6.1.3 ATPases
– Enzymatic bromodomain-containing proteins
– Bromodomain kinase (BRDK) family
– TAF1 family
– TIF1 family
S321 Cyclic nucleotide turnover/signalling
S321 Adenylyl cyclases (ACs)
S323 Exchange protein activated by cyclic AMP (EPACs)
S323 Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
S327 Cytochrome P450
S327 CYP1 family
S328 CYP2 family
S329 CYP3 family
S330 CYP4 family
S331 CYP5, CYP7 and CYP8 families
S332 CYP11, CYP17, CYP19, CYP20 and CYP21 families
S333 CYP24, CYP26 and CYP27 families
S333 CYP39, CYP46 and CYP51 families
– DNA glycosylases
S334 DNA topoisomerases
S335 Endocannabinoid turnover
S336 N-Acylethanolamine turnover
S337 2-Acylglycerol ester turnover
S338 Eicosanoid turnover
S338 Cyclooxygenase
S339 Prostaglandin synthases
S341 Lipoxygenases
S342 Leukotriene and lipoxin metabolism
S343 GABA turnover
S344 Glycerophospholipid turnover
S344 Phosphoinositide-speciﬁc phospholipase C
S346 Phospholipase A2
S348 Phosphatidylcholine-speciﬁc phospholipase D
S349 Lipid phosphate phosphatases
S349 Phosphatidylinositol kinases
S356 Haem oxygenase
S358 Hydrogen sulphide synthesis
S358 Hydrolases
S360 Inositol phosphate turnover
S360 Inositol 1,4,5-trisphosphate 3-kinases
– GEK subfamily
– Other DMPK family kinases
S362 Rho kinase
– G protein-coupled receptor kinases (GRKs)
– Beta-adrenergic receptor kinases (βARKs)
– Opsin/rhodopsin kinases
– GRK4 subfamily
– MAST family
– NDR family
– PDK1 family
– Protein kinase A (PKA) family
– Akt (Protein kinase B, PKB) family
S362 Protein kinase C (PKC) family
S363 Alpha subfamily
S363 Delta subfamily
S364 Eta subfamily
– Iota subfamily
– Protein kinase G (PKG) family
– Protein kinase N (PKN) family
– RSK family
– MSK subfamily
– p70 subfamily
– RSK subfamily
– RSKR subfamily
– RSKL family
– SGK family
– YANK family
– Atypical
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S350 1-phosphatidylinositol 4-kinase family
S352 1-phosphatidylinositol-3-phosphate 5-kinase family
S351 Phosphatidylinositol-4-phosphate 3-kinase family
S351 Phosphatidylinositol 3-kinase family
S351 Phosphatidylinositol-4,5-bisphosphate 3-kinase family
S360 Inositol polyphosphate phosphatases
S361 Inositol monophosphatase
– Itaconate biosynthesis
S361 Kinases (EC 2.7.x.x)
– AGC: Containing PKA, PKG, PKC families
– DMPK family
S353 Type I PIP kinases
(1-phosphatidylinositol-4-phosphate 5-kinase family)
S353 Type II PIP kinases
(1-phosphatidylinositol-5-phosphate 4-kinase family)
Sphingosine kinaseS354
S356 Phosphatidylinositol phosphate kinases
– ABC1 family
– Phosphatidyl inositol 3’ kinase-related kinases
(PIKK) family
– ATR subfamily
S364 FRAP subfamily
– SMG1 subfamily
– TRRAP subfamily
– Other PIKK family kinases
– RIO family
– RIO1 subfamily
– RIO2 subfamily
– RIO3 subfamily
– PDHK family
– Pyruvate dehydrogenase kinase (PDHK) family
– TAF1 family
– TIF1 family
– CAMK: Calcium/calmodulin-dependent protein kinases
– CAMK1 family
– CAMK2 family
– CAMK-like (CAMKL) family
– AMPK subfamily
– BRSK subfamily
– CHK1 subfamily
– HUNK subfamily
– LKB subfamily
– MARK subfamily
– MELK subfamily
– NIM1 subfamily
– NuaK subfamily
– PASK subfamily
– QIK subfamily
– SNRK subfamily
– CAMK-unique family
– CASK family
– DCAMKL family
– Death-associated kinase (DAPK) family
– MAPK-Activated Protein Kinase (MAPKAPK) family
– MAPKAPK subfamily
– MKN subfamily
– Myosin Light Chain Kinase (MLCK) family
– Phosphorylase kinase (PHK) family
– Trio family
– CK1: Casein kinase 1
– Casein kinase 1 (CK1) family
– Tau tubulin kinase (TTBK) family
– Vaccina related kinase (VRK) family
– CMGC: Containing CDK, MAPK, GSK3, CLK families
– CLK family
S365 Cyclin-dependent kinase (CDK) family
– CCRK subfamily
– CDK1 subfamily
S365 CDK4 subfamily
– CDK5 subfamily
– CDK7 subfamily
– CDK8 subfamily
– CDK9 subfamily
– CDK10 subfamily
– CRK7 subfamily
– PITSLRE subfamily
– TAIRE subfamily
– Cyclin-dependent kinase-like (CDKL) family
– Dual-speciﬁcity tyrosine-(Y)-phosphorylation
regulated kinase (DYRK) family
– Dyrk1 subfamily
– Dyrk2 subfamily
– HIPK subfamily
– PRP4 subfamily
– Glycogen synthase kinase (GSK) family
S366 GSK subfamily
– Mitogen-activated protein kinases (MAP kinases)
– ERK subfamily
– Erk7 subfamily
– JNK subfamily
– p38 subfamily
– nmo subfamily
– RCK family
– SRPK family
– Lipid modifying kinases
– Other protein kinases
– CAMKK family
– Meta subfamily
– Aurora kinase (Aur) family
– Bub family
– Bud32 family
– Casein kinase 2 (CK2) family
– CDC7 family
– Haspin family
– IKK family
– IRE family
– MOS family
– NAK family
– NIMA (never in mitosis gene a)-
related kinase (NEK) family
– NKF1 family
– NKF2 family
– NKF4 family
– NKF5 family
– NRBP family
– Numb-associated kinase (NAK) family
– Other-unique family
S367 Polo-like kinase (PLK) family
– PEK family
– GCN2 subfamily
– PEK subfamily
– Other PEK family kinases
– SgK493 family
– Slob family
– TBCK family
– TOPK family
– Tousled-like kinase (TLK) family
– TTK family
– Unc-51-like kinase (ULK) family
– VPS15 family
– WEE family
– Wnk family
– Miscellaneous protein kinases
– actin-binding proteins ADF family
– Twinﬁlin subfamily
– SCY1 family
– Hexokinases
– STE: Homologs of yeast Sterile 7,
Sterile 11, Sterile 20 kinases
S367 STE7 family
– STE11 family
– STE20 family
– FRAY subfamily
– KHS subfamily
– MSN subfamily
– MST subfamily
– NinaC subfamily
– PAKA subfamily
– PAKB subfamily
– SLK subfamily
– STE20 subfamily
– STLK subfamily
– TAO subfamily
– YSK subfamily
– STE-unique family
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– eEF2K subfamily
– Other alpha kinase family kinases
– BCR family
– Bromodomain kinase (BRDK) family
– G11 family
– Protein kinase D (PKD) family
– PSK family
– RAD53 family
– Testis speciﬁc kinase (TSSK) family
– Trbl family
– ABC1-A subfamily
– ABC1-B subfamily
– Alpha kinase family
– ChaK subfamily
– PIM family
– TK: Tyrosine kinase
– Non-receptor tyrosine kinases (nRTKs)
S368 Abl family
S368 Ack family
– Csk family
– Fak family
– Fer family
S369 Janus kinase (JakA) family
S369 Src family
– Syk family
S370 Tec family
– TKL: Tyrosine kinase-like
– Interleukin-1 receptor-associated kinase (IRAK) family
– Leucine-rich repeat kinase (LRRK) family
– LIM domain kinase (LISK) family
– LIMK subfamily
– TESK subfamily
– Mixed Lineage Kinase (MLK) family
– HH498 subfamily
– ILK subfamily
– LZK subfamily
– MLK subfamily
– TAK1 subfamily
S371 RAF family
– Receptor interacting protein kinase (RIPK) family
– TKL-unique family
S372 Lanosterol biosynthesis pathway
– LPA synthesis
– NADPH oxidases
S374 Nucleoside synthesis and metabolism
S376 Paraoxonase (PON) family
S377 Peptidases and proteinases
– AA: Aspartic (A) Peptidases
S377 A1: Pepsin
– AD: Aspartic (A) Peptidases
S377 A22: Presenilin
– CA: Cysteine (C) Peptidases
– C1: Papain
– C2: Calpain
– C12: Ubiquitin C-terminal hydrolase
– C19: Ubiquitin-speciﬁc protease
– C54: Aut2 peptidase
– C101: OTULIN peptidase
– CD: Cysteine (C) Peptidases
– C13: Legumain
S378 C14: Caspase
– CE: Cysteine (C) Peptidases
– C48: Ulp1 endopeptidase
– M-: Metallo (M) Peptidases
– M79: Prenyl protease 2
– MA: Metallo (M) Peptidases
S378 M1: Aminopeptidase N
S379 M2: Angiotensin-converting (ACE and ACE2)
S379 M10: Matrix metallopeptidase
S380 M12: Astacin/Adamalysin
– M13: Neprilysin
– M49: Dipeptidyl-peptidase III
– MC: Metallo (M) Peptidases
– M14: Carboxypeptidase A
– ME: Metallo (M) Peptidases
– M16: Pitrilysin
– MF: Metallo (M) Peptidases
– M17: Leucyl aminopeptidase
– MG: Metallo (M) Peptidases
– M24: Methionyl aminopeptidase
– MH: Metallo (M) Peptidases
– M18: Aminopeptidase I
– M20: Carnosine dipeptidase
S380 M28: Aminopeptidase Y
– MJ: Metallo (M) Peptidases
S381 M19: Membrane dipeptidase
– MP: Metallo (M) Peptidases
– M67: PSMD14 peptidase
– PA: Serine (S) Peptidases
S381 S1: Chymotrypsin
– PB: Threonine (T) Peptidases
– C44: Phosphoribosyl pyrophosphate amidotransferase
S382 T1: Proteasome
– T2: Glycosylasparaginase precursor
– PC: Cysteine (C) Peptidases
– C26: Gamma-glutamyl hydrolase
– SB: Serine (S) Peptidases
S382 S8: Subtilisin
– SC: Serine (S) Peptidases
S383 S9: Prolyl oligopeptidase
– S10: Carboxypeptidase Y
– S33: Prolyl aminopeptidase
– Phosphatases
– Protein tyrosine phosphatases
– Sugar phosphatases
S383 Poly ADP-ribose polymerases
S384 Prolyl hydroxylases
S384 Sphingosine 1-phosphate turnover
S385 Sphingosine kinase
S386 Sphingosine 1-phosphate phosphatase
S387 Sphingosine 1-phosphate lyase
S387 Thyroid hormone turnover
– UDP glucuronosyltransferases (UGT)
– 1.-.-.- Oxidoreductases
– 1.1.1.42 Isocitrate dehydrogenases
– 1.4.3.13 Lysyl oxidases
– 1.13.11.- Dioxygenases
S388 1.14.13.9 Kynurenine 3-monooxygenase
– 1.17.4.1 Ribonucleoside-diphosphate reductases
– 2.1.1.- Methyltransferases
– 2.1.2.- Hydroxymethyl-, formyl- and related transferases
– 2.3.1.- Acyltransferases
– 2.3.2.- Aminoacyltransferases
– 2.3.2.13 Transglutaminases
– 2.3.2.27 RING-type E3 ubiquitin transferase
– 2.4.2.1 Purine-nucleoside phosphorylase
S389 2.5.1.58 Protein farnesyltransferase
– 2.6.1.42 Branched-chain-amino-acid transaminase
– 2.7.1.40 Pyruvate kinases
– 3.1.-.- Ester bond enzymes
– 3.1.1.- Carboxylic Ester Hydrolases
– 3.2.1.- Glycosidases
– 3.4.21.46 Complement factor D
S390 3.5.1.- Histone deacetylases (HDACs)
– 3.5.1.2 Glutaminases
S391 3.5.3.15 Peptidyl arginine deiminases (PADI)
S391 3.6.5.2 Small monomeric GTPases
S391 RAS subfamily
S392 RAB subfamily
– 5.-.-.- Isomerases
– 5.2.-.- Cis-trans-isomerases
– 6.3.3.- Cyclo-ligases
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– S28: Lysosomal Pro-Xaa carboxypeptidase
Acetylcholine turnover
Enzymes → Acetylcholine turnover
Overview: Acetylcholine is familiar as a neurotransmitter in the
central nervous system and in the periphery. In the somatic ner-
vous system, it activates nicotinic acetylcholine receptors at the
skeletal neuromuscular junction. It is also employed in the au-
tonomic nervous system, in both parasympathetic and sympa-
thetic branches; in the former, at the smoothmuscle neuromuscu-
lar junction, activating muscarinic acetylcholine receptors. In the
latter, acetylcholine is involved as a neurotransmitter at the gan-
glion, activating nicotinic acetylcholine receptors. Acetylcholine
is synthesised in neurones through the action of choline O-
acetyltransferase and metabolised after release through the extra-
cellular action of acetylcholinesterase and cholinesterase. Choline
is accumulated from the extracellular medium by selective trans-
porters (see SLC5A7 and the SLC44 family). Acetylcholine is ac-
cumulated in synaptic vesicles through the action of the vesicular
acetylcholine transporter SLC18A3.
Nomenclature choline O-acetyltransferase acetylcholinesterase (Cartwright blood group) butyrylcholinesterase
Common abbreviation ChAT AChE BChE
HGNC, UniProt CHAT, P28329 ACHE, P22303 BCHE, P06276
EC number 2.3.1.6: acetyl CoA + choline = acetylcholine +
coenzyme A
3.1.1.7: acetylcholine + H2O = acetic acid + choline + H+ 3.1.1.7: acetylcholine + H2O = acetic acid + choline + H+
Inhibitors compound 2 (pIC50 6.5) [216] – Mouse tacrine (pKi 7.5) [67], galantamine (pIC50 6.3) [108],
rivastigmine (pIC50 5.4) [380]
rivastigmine (pIC50 7.4) [380], tacrine (pKi 7.2) [67]
Sub/family-selective inhibitors – physostigmine (pIC50 7.6–7.8) [380] physostigmine (pIC50 7.6–7.8) [380]
Selective inhibitors – donepezil (pIC50 7.7–8.3) [78, 193, 380], BW284C51
(pIC50 7.7) [205]
bambuterol (pIC50 8.5) [205]
Comments Splice variants of choline O-acetyltransferase are
suggested to be differentially distributed in the periphery
and CNS (see [40]).
– –
Comments: A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos-oxon, and nerve agents such as tabun,
soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule [644].
Further reading on Acetylcholine turnover
Li Q et al. (2017) Recent progress in the identiﬁcation of selective butyrylcholinesterase inhibitors
for Alzheimer’s disease. Eur J Med Chem 132: 294-309 [PMID:28371641]
Lockridge O. (2015) Review of human butyrylcholinesterase structure, function, genetic variants,
history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 148: 34-46
[PMID:25448037]
Masson P et al. (2016) Slow-binding inhibition of cholinesterases, pharmacological and toxicological
relevance. Arch Biochem Biophys 593: 60-8 [PMID:26874196]
Rotundo RL. (2017) Biogenesis, assembly and trafﬁcking of acetylcholinesterase. J Neurochem 142
Suppl 2: 52-58 [PMID:28326552]
Silman I et al. (2017) Recent developments in structural studies on acetylcholinesterase. J Neurochem
142 Suppl 2: 19-25 [PMID:28503857]
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Adenosine turnover
Enzymes → Adenosine turnover
Overview: A multifunctional, ubiquitous molecule, adenosine
acts at cell-surface G protein-coupled receptors, as well as numer-
ous enzymes, including protein kinases and adenylyl cyclase. Ex-
tracellular adenosine is thought to be produced either by export or
by metabolism, predominantly through ecto-5’-nucleotidase ac-
tivity (also producing inorganic phosphate). It is inactivated ei-
ther by extracellular metabolism via adenosine deaminase (also
producing ammonia) or, following uptake by nucleoside trans-
porters, via adenosine deaminase or adenosine kinase (requiring
ATP as co-substrate). Intracellular adenosine may be produced
by cytosolic 5’-nucleotidases or through S-adenosylhomocysteine
hydrolase (also producing L-homocysteine).
Nomenclature Adenosine deaminase Adenosine kinase Ecto-5’-Nucleotidase S-Adenosylhomocysteine hydrolase
Systematic nomenclature – – CD73 –
Common abbreviation ADA ADK NT5E SAHH
HGNC, UniProt ADA, P00813 ADK, P55263 NT5E, P21589 AHCY, P23526
EC number 3.5.4.4: adenosine + H2O = inosine + NH3 2.7.1.20 3.1.3.5 3.3.1.1
Rank order of afﬁnity 2’-deoxyadenosine > adenosine adenosine adenosine 5’-monophosphate, 5’-GMP,
5’-inosine monophosphate, 5’-UMP >
5’-dAMP, 5’-dGMP
–
Endogenous substrates – – – S-adenosylhomocysteine
Products 2’-deoxyinosine, inosine adenosine 5’-monophosphate uridine, inosine, guanine, adenosine adenosine
Inhibitors – – – DZNep (pKi 12.3) [208] – Hamster
Selective inhibitors pentostatin (pIC50 10.8) [6], EHNA (pKi
8.8) [6]
A134974 (pIC50 10.2) [403], ABT702 (pIC50
8.8) [287]
αβ-methyleneADP (pIC50 8.7) [65] 3-deazaadenosine (pIC50 8.5) [227]
Comments – The enzyme exists in two isoforms derived
from alternative splicing of a single gene
product: a short isoform, ADK-S, located in
the cytoplasm is responsible for the
regulation of intra- and extracellular levels of
adenosine and hence adenosine receptor
activation; a long isoform, ADK-L, located in
the nucleus contributes to the regulation of
DNA methylation [57, 642].
Pharmacological inhibition of CD73 is being
investigated as a novel cancer
immunotherapy strategy [622].
–
Comments: An extracellular adenosine deaminase activity,
termed ADA2 or adenosine deaminase growth factor (ADGF,
CECR1, Q9NZK5) has been identiﬁed [117, 387], which is insen-
sitive to EHNA [671]. Other forms of adenosine deaminase act on
ribonucleic acids and may be divided into two families: ADAT1
(Q9BUB4) deaminates transfer RNA; ADAR (EC 3.5.4.37, also
known as 136 kDa double-stranded RNA-binding protein, P136,
K88DSRBP, Interferon-inducible protein 4); ADARB1 (EC 3.5.-.-, ,
also known as dsRNA adenosine deaminase) and ADARB2 (EC 3.5.-
.-, also known as dsRNA adenosine deaminase B2, RNA-dependent
adenosine deaminase 3) act on double-stranded RNA. Particular
polymorphisms of the ADA gene result in loss-of-function and se-
vere combined immunodeﬁciency syndrome. Adenosine deami-
nase is able to complex with dipeptidyl peptidase IV (EC 3.4.14.5,
DPP4, also known as T-cell activation antigen CD26, TP103,
adenosine deaminase complexing protein 2) to form a cell-surface
activity [301].
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Further reading on Adenosine turnover
Boison D. (2016) Adenosinergic signaling in epilepsy. Neuropharmacology 104: 131-9
[PMID:26341819]
Cortés A et al. (2015) Moonlighting adenosine deaminase: a target protein for drug development.
Med Res Rev 35: 85-125 [PMID:24933472]
Nishikura K. (2016) A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol
17: 83-96 [PMID:26648264]
Sawynok J. (2016) Adenosine receptor targets for pain. Neuroscience 338: 1-18 [PMID:26500181]
Xiao Y et al. (2015) Role of S-adenosylhomocysteine in cardiovascular disease and its potential epi-
genetic mechanism. Int. J. Biochem. Cell Biol. 67: 158-66 [PMID:26117455]
Amino acid hydroxylases
Enzymes → Amino acid hydroxylases
Overview: The amino acid hydroxylases (monooxygenases), EC.1.14.16.-, are iron-containing enzymes which utilise molecular oxygen and sapropterin as co-substrate and co-factor, respectively. In
humans, as well as in other mammals, there are two distinct L-Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous
enzymes, TPH1 and TPH2.
Nomenclature L-Phenylalanine hydroxylase L-Tyrosine hydroxylase L-Tryptophan hydroxylase 1 L-Tryptophan hydroxylase 2
HGNC, UniProt PAH, P00439 TH, P07101 TPH1, P17752 TPH2, Q8IWU9
EC number 1.14.16.1: L-phenylalanine + O2 ->
L-tyrosine
1.14.16.2: L-tyrosine + O2 -> levodopa 1.14.16.4 1.14.16.4
Endogenous substrates L-phenylalanine L-tyrosine L-tryptophan L-tryptophan
Products L-tyrosine levodopa 5-hydroxy-L-tryptophan 5-hydroxy-L-tryptophan
Cofactors sapropterin sapropterin, Fe2+ – –
Endogenous activators Protein kinase A-mediated phosphorylation
(Rat) [2]
Protein kinase A-mediated phosphorylation
[290]
Protein kinase A-mediated phosphorylation
[291]
Protein kinase A-mediated phosphorylation
[291]
Inhibitors – – telotristat ethyl [311] –
Selective inhibitors α-methylphenylalanine [218] – Rat,
fenclonine
α-propyldopacetamide, 3-chlorotyrosine,
3-iodotyrosine, alpha-methyltyrosine
α-propyldopacetamide, 6-ﬂuorotryptophan
[434], fenclonine, fenﬂuramine
α-propyldopacetamide, 6-ﬂuorotryptophan
[434], fenclonine, fenﬂuramine
Comments PAH is an iron bound homodimer or
-tetramer from the same structural family as
tyrosine 3-monooxygenase and the
tryptophan hydroxylases. Deﬁciency or
loss-of-function of PAH is associated with
phenylketonuria
TH is a homotetramer, which is inhibited by
dopamine and other catecholamines in a
physiological negative feedback pathway
[127].
– –
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Further reading on Amino acid hydroxylases
Bauer IE et al. (2015) Serotonergic gene variation in substance use pharmacotherapy: a systematic
review. Pharmacogenomics 16: 1307-14 [PMID:26265436]
Daubner SC et al. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem
Biophys 508: 1-12 [PMID:21176768]
Flydal MI et al. (2013) Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life
65: 341-9 [PMID:23457044]
Roberts KM et al. (2013) Mechanisms of tryptophan and tyrosine hydroxylase. IUBMB Life 65: 350-7
[PMID:23441081]
Tekin I et al. (2014) Complex molecular regulation of tyrosine hydroxylase. J Neural Transm 121:
1451-81 [PMID:24866693]
Walen K et al. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease.
Expert Opin Ther Targets 21: 167-180 [PMID:27973928]
L-Arginine turnover
Enzymes → L-Arginine turnover
Overview: L-arginine is a basic amino acid with a guanidino
sidechain. As an amino acid, metabolism of L-arginine to form
L-ornithine, catalysed by arginase, forms the last step of the
urea production cycle. L-Ornithine may be utilised as a pre-
cursor of polyamines (see Carboxylases and Decarboxylases) or
recycled via L-argininosuccinic acid to L-arginine. L-Arginine
may itself be decarboxylated to form agmatine, although the
prominence of this pathway in human tissues is uncertain. L-
Arginine may be used as a precursor for guanidoacetic acid for-
mation in the creatine synthesis pathway under the inﬂuence of
arginine:glycine amidinotransferase with L-ornithine as a byprod-
uct. Nitric oxide synthase uses L-arginine to generate nitric oxide,
with L-citrulline also as a byproduct.
L-Arginine in proteins may be subject to post-translational mod-
iﬁcation through methylation, catalysed by protein arginine
methyltransferases. Subsequent proteolysis can liberate asymmet-
ric NG,NG-dimethyl-L-arginine (ADMA), which is an endogenous
inhibitor of nitric oxide synthase activities. ADMA is hydrol-
ysed by dimethylarginine dimethylhydrolase activities to generate
L-citrulline and dimethylamine.
2.1.1.- Protein arginine N-methyltransferases
Enzymes → L-Arginine turnover → 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT,
EC 2.1.1.-) encompass histone arginine N-methyltransferases
(PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein N-
methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric
or tetrameric enzymes which use S-adenosyl methionine as
a methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and di-
methylated products; these may be symmetric (SDMA) or asym-
metric (NG,NG-dimethyl-L-arginine) versions, where both guani-
dine nitrogens are monomethylated or one of the two is dimethy-
lated, respectively.
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp 2.1.1.- Protein arginine N-methyltransferases S304
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Arginase
Enzymes → L-Arginine turnover → Arginase
Overview: Arginase (EC 3.5.3.1) are manganese-containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is
associated more with the kidney.
Information on members of this family may be found in the online database.
Comments: Nω-hydroxyarginine, an intermediate in NOS metabolism of L-arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform-
selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are N -hydroxy-nor-L-arginineω [592], S-(2-boronoethyl)-L-cysteine [111, 312] and
2(S)-amino-6-boronohexanoic acid [32, 111].
Arginine:glycine amidinotransferase
Enzymes → L-Arginine turnover → Arginine:glycine amidinotransferase
Nomenclature Arginine:glycine amidinotransferase
Common abbreviation AGAT
HGNC, UniProt GATM, P50440
EC number 2.1.4.1
Dimethylarginine dimethylaminohydrolases
Enzymes → L-Arginine turnover → Dimethylarginine dimethylaminohydrolases
Overview: Dimethylarginine dimethylaminohydrolases (DDAH, EC 3.5.3.18) are cytoplasmic enzymes which hydrolyse NG,NG-dimethyl-L-arginine to form dimethylamine and L-citrulline.
Nomenclature NG,NG-Dimethylarginine dimethylaminohydrolase 1 NG,NG-Dimethylarginine dimethylaminohydrolase 2
Common abbreviation DDAH1 DDAH2
HGNC, UniProt DDAH1, O94760 DDAH2, O95865
EC number 3.5.3.18 3.5.3.18
Cofactors Zn2+ –
Inhibitors compound 2e (pKi 5.7) [324] –
Searchable database: http://www.guidetopharmacology.org/index.jsp Dimethylarginine dimethylaminohydrolases S305
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Nitric oxide synthases
Enzymes → L-Arginine turnover → Nitric oxide synthases
Overview: Nitric oxide synthases (NOS, E.C. 1.14.13.39) are a
family of oxidoreductases that synthesize nitric oxide (NO.) via
the NADPH and oxygen-dependent consumption of L-arginine
with the resultant by-product, L-citrulline. There are 3 NOS iso-
forms and they are related by their capacity to produce NO, highly
conserved organization of functional domains and signiﬁcant ho-
mology at the amino acid level. NOS isoforms are functionally
distinguished by the cell type where they are expressed, intra-
cellular targeting and transcriptional and post-translation mech-
anisms regulating enzyme activity. The nomenclature suggested
by NC-IUPHAR of NOS I, II and III [420] has not gained wide
acceptance, and the 3 isoforms are more commonly referred to
as neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial
NOS (eNOS) which reﬂect the location of expression (nNOS and
eNOS) and inducible expression (iNOS). All are dimeric enzymes
that shuttle electrons from NADPH, which binds to a C-terminal
reductase domain, through the ﬂavins FAD and FMN to the oxyge-
nase domain of the other monomer to enable the BH4-dependent
reduction of heme bound oxygen for insertion into the substrate,
L-arginine. Electron ﬂow from reductase to oxygenase domain is
controlled by calmodulin binding to canonical calmodulin bind-
ing motif located between these domains. eNOS and nNOS iso-
forms are activated at concentrations of calcium greater than
100 nM, while iNOS shows higher afﬁnity for Ca2+/calmodulin
(CALM1 CALM2 CALM3, P62158) with great avidity and is es-
sentially calcium-independent and constitutively active. Efﬁcient
stimulus-dependent coupling of nNOS and eNOS is achieved via
subcellular targeting through respective N-terminal PDZ and fatty
acid acylation domains whereas iNOS is largely cytosolic and func-
tion is independent of intracellular location. nNOS is primarily
expressed in the brain and neuronal tissue, iNOS in immune cells
such as macrophages and eNOS in the endothelial layer of the
vasculature although exceptions in other cells have been docu-
mented. L-NAME and related modiﬁed arginine analogues are in-
hibitors of all three isoforms, with IC50 values in the micromolar
range.
Nomenclature Endothelial NOS Inducible NOS Neuronal NOS
Common abbreviation eNOS iNOS nNOS
HGNC, UniProt NOS3, P29474 NOS2, P35228 NOS1, P29475
EC number 1.14.13.39 1.14.13.39 1.14.13.39
Endogenous Substrate L-arginine L-arginine L-arginine
Products NO, L-citrulline NO, L-citrulline L-citrulline, NO
Cofactors oxygen, BH4, Zn2+, ﬂavin mononucleotide, NADPH, heme,
ﬂavin adenine dinucleotide
heme, ﬂavin mononucleotide, ﬂavin adenine dinucleotide,
oxygen, NADPH, Zn2+, BH4
ﬂavin adenine dinucleotide, heme, oxygen, BH4,
ﬂavin mononucleotide, NADPH, Zn2+
Selective inhibitors – 1400W (pIC50 8.2) [201], 2-amino-4-methylpyridine (pIC50
7.4) [164], PIBTU (pIC50 7.3) [202], NIL (pIC50 5.5) [421],
aminoguanidine [115]
3-bromo-7NI (pIC50 6.1–6.5) [52], 7NI (pIC50 5.3) [24]
Comments: The reductase domain of NOS catalyses the reduction of cytochrome c and other redox-active dyes [400]. NADPH:O oxidoreductase catalyses the formation of superoxide anion/2 H O2 2 in
the absence of L-arginine and sapropterin.
Further reading on Nitric oxide synthases
Garcia-Ortiz A and Serrador JM (2018) Nitric Oxide Signaling in T Cell-Mediated Immunity Trends
Mol Med 24: 412-427 [PMID:29519621]
Lundberg JO et al. (2015) Strategies to increase nitric oxide signalling in cardiovascular disease. Nat
Rev Drug Discov 14: 623-41 [PMID:26265312]
Oliveira-Paula GH et al. (2016) Endothelial nitric oxide synthase: From biochemistry and gene struc-
ture to clinical implications of NOS3 polymorphisms. Gene 575: 584-99 [PMID:26428312]
Stuehr DJ and Haque MM (2019) Nitric oxide synthase enzymology in the 20 years after the Nobel
Prize. Br J Pharmacol 176: 177-188 [PMID:26390975]
Wallace JL (2019) Nitric oxide in the gastrointestinal tract: opportunities for drug development. Br
J Pharmacol 176: 147-154 [PMID:26499181]
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Further reading on L-Arginine turnover
Lai L et al. (2016) Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers. J
Diabetes Res 2016: 1982096 [PMID:26770984]
Moncada S et al. (1997) International Union of Pharmacology Nomenclature in Nitric Oxide Re-
search. Pharmacol. Rev. 49: 137-42 [PMID:9228663]
Pekarova M et al. (2015) The crucial role of l-arginine in macrophage activation: What you need to
know about it. Life Sci. 137: 44-8 [PMID:26188591]
Pudlo M et al. (2017) Arginase Inhibitors: A Rational Approach Over One Century. Med Res Rev 37:
475-513 [PMID:27862081]
Sudar-Milovanovic E et al. (2016) Beneﬁts of L-Arginine on Cardiovascular System. Mini Rev Med
Chem 16: 94-103 [PMID:26471966]
Carbonic anhydrases
Enzymes → Carbonic anhydrases
Overview: Carbonic anhydrases facilitate the interconversion of water and carbon dioxide with bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identiﬁed in man. The
enzymes function in acid-base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.
Nomenclature carbonic anhydrase 1 carbonic anhydrase 7 carbonic anhydrase 12 carbonic anhydrase 13 carbonic anhydrase 14
Common abbreviation CA I CA VII CA XII CA XIII CA XIV
HGNC, UniProt CA1, P00915 CA7, P43166 CA12, O43570 CA13, Q8N1Q1 CA14, Q9ULX7
EC number 4.2.1.1 4.2.1.1 4.2.1.1 4.2.1.1 4.2.1.1
Inhibitors chlorthalidone (pKi 6.5) methazolamide (pKi 8.7) [533],
acetazolamide (pKi 8.6) [23],
brinzolamide (pKi 8.6) [533],
chlorthalidone (pKi 8.6) [591]
SLC-0111 (pKi 8.4) [112] – –
Further reading on Carbonic anhydrases
Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F and Sly WS. (2013) Structure, function and appli-
cations of carbonic anhydrase isozymes. Bioorg Med Chem 21: 1570-70 [PMID:22607884]
Supuran CT (2017) Advances in structure-based drug discovery of carbonic anhydrase inhibitors.
Expert Opin Drug Discov 12: 61-88 [PMID:27783541]
Supuran CT (2018) Carbonic anhydrase activators. Future Med Chem 10: 561-573 [PMID:29478330]
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Carboxylases and decarboxylases
Enzymes → Carboxylases and decarboxylases
Carboxylases
Enzymes → Carboxylases and decarboxylases → Carboxylases
Overview: The carboxylases allow the production of new carbon-carbon bonds by introducing HCO3- or CO2 into target molecules. Two groups of carboxylase activities, some of which are bidirectional,
can be deﬁned on the basis of the cofactor requirement, making use of biotin (EC 6.4.1.-) or vitamin K hydroquinone (EC 4.1.1.-).
Nomenclature Pyruvate carboxylase Acetyl-CoA carboxylase 1 Acetyl-CoA carboxylase 2 Propionyl-CoA carboxylase γ-Glutamyl carboxylase
Common abbreviation PC ACC1 ACC2 PCCA,PCCB GGCX
HGNC, UniProt PC, P11498 ACACA, Q13085 ACACB, O00763 – GGCX, P38435
Subunits – – –
Propionyl-CoA carboxylase β subunit,
Propionyl-CoA carboxylase α subunit
–
EC number 6.4.1.1 6.4.1.2 6.4.1.2 6.4.1.3 4.1.1.90
Endogenous substrates ATP, pyruvic acid ATP, acetyl CoA acetyl CoA, ATP propionyl-CoA, ATP glutamyl peptides
Products Pi, ADP, oxalacetic acid Pi, ADP, malonyl-CoA Pi, ADP, malonyl-CoA ADP, methylmalonyl-CoA, Pi carboxyglutamyl peptides
Cofactors biotin biotin biotin biotin vitamin K hydroquinone, NADPH
Inhibitors – – – – anisindione
Selective inhibitors – compound 21 (pIC50 8) [219],
TOFA (pIC50 4.9) [676]
compound 21 (pIC50 8.4) [219],
TOFA (pIC50 4.9) [676]
– –
Comments – Citrate and other dicarboxylic acids
are allosteric activators of
acetyl-CoA carboxylase.
Citrate and other dicarboxylic acids
are allosteric activators of
acetyl-CoA carboxylase.
Propionyl-CoA carboxylase is able
to function in both forward and
reverse activity modes, as a ligase
(carboxylase) or lyase
(decarboxylase), respectively.
Loss-of-function mutations in
γ-glutamyl carboxylase are
associated with clotting disorders.
Comments: Dicarboxylic acids including citric acid are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase
(decarboxylase) activity, respectively. Loss-of-function mutations in GGCX are associated with clotting disorders.
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Decarboxylases
Enzymes → Carboxylases and decarboxylases → Decarboxylases
Overview: The decarboxylases generate CO2 and the indicated products from acidic substrates, requiring pyridoxal 5-phosphate or pyruvic acid as a co-factor.
Nomenclature Glutamic acid decarboxylase 1 Glutamic acid decarboxylase 2 Histidine decarboxylase
Common abbreviation GAD1 GAD2 HDC
HGNC, UniProt GAD1, Q99259 GAD2, Q05329 HDC, P19113
EC number 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.22
Endogenous substrates L-glutamic acid, L-aspartic acid L-glutamic acid, L-aspartic acid L-histidine
Products GABA GABA histamine
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate
Selective inhibitors s-allylglycine s-allylglycine AMA, FMH [198]
Comments L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-alanine [650]. Autoantibodies
against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).
–
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Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14752/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology (2019) 176, S297–S396
Nomenclature L-Arginine decarboxylase L-Aromatic amino-acid
decarboxylase
Malonyl-CoA decarboxylase Ornithine decarboxylase Phosphatidylserine
decarboxylase
S-Adenosylmethionine
decarboxylase
Common abbreviation ADC AADC MLYCD ODC PSDC SAMDC
HGNC, UniProt AZIN2, Q96A70 DDC, P20711 MLYCD, O95822 ODC1, P11926 PISD, Q9UG56 AMD1, P17707
EC number 4.1.1.19 4.1.1.28: levodopa ->
dopamine + CO2
5-hydroxy-L-tryptophan ->
5-hydroxytryptamine +
CO2
This enzyme also catalyses
the following reaction::
L-tryptophan -> tryptamine
+ CO2
4.1.1.9 4.1.1.17 4.1.1.65 4.1.1.50
Endogenous substrates L-arginine levodopa,
5-hydroxy-L-tryptophan,
L-tryptophan
malonyl-CoA L-ornithine phosphatidylserine S-adenosyl methionine
Products agmatine [678] 5-hydroxytryptamine,
dopamine
acetyl CoA putrescine phosphatidylethanolamine
S-adenosyl-L-methioninamine
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate pyruvic acid pyruvic acid
Selective inhibitors – 3-hydroxybenzylhydrazine,
L-α-methyldopa,
benserazide [125],
carbidopa
– APA (pIC50 7.5) [563],
eﬂornithine (pKd 4.9) [482]
– sardomozide (pIC50 8)
[562]
Comments The presence of a functional
ADC activity in human
tissues has been questioned
[110].
AADC is a homodimer. Inhibited by AMP-activated
protein kinase-evoked
phosphorylation [515]
The activity of ODC is
regulated by the presence
of an antizyme
(ENSG00000104904) and
an ODC antizyme inhibitor
(ENSG00000155096).
S-allylglycine is also an
inhibitor of SAMDC [455].
S-allylglycine is also an
inhibitor of SAMDC [455].
Further reading on Carboxylases and decarboxylases
Bale S et al. (2010) Structural biology of S-adenosylmethionine decarboxylase. Amino Acids 38: 451-
60 [PMID:19997761]
Di Bartolomeo F et al. (2017) Cell biology, physiology and enzymology of phosphatidylserine decar-
boxylase. Biochim Biophys Acta Mol Cell Biol Lipids 1862: 25-38 [PMID:27650064]
Jitrapakdee S et al. (2008) Structure, mechanism and regulation of pyruvate carboxylase. Biochem. J.
413: 369-87 [PMID:18613815]
Lietzan AD et al. (2014) Functionally diverse biotin-dependent enzymes with oxaloacetate decar-
boxylase activity. Arch. Biochem. Biophys. 544: 75-86 [PMID:24184447]
Sanchez-Jimenez F et al. (2016) Structural and functional analogies and differences between histi-
dine decarboxylase and aromatic l-amino acid decarboxylase molecular networks: Biomedical
implications Pharmacol Res 114: 90-102 [PMID:27769832]
Salie MJ and Thelen JJ (2016) Regulation and structure of the heteromeric acetyl-CoA carboxylase.
Biochim Biophys Acta 1861: 1207-1213 [PMID:27091637]
Tong L. (2013) Structure and function of biotin-dependent carboxylases. Cell. Mol. Life Sci. 70:
863-91 [PMID:22869039]
Vance JE et al. (2013) Formation and function of phosphatidylserine and phosphatidylethanolamine
in mammalian cells. Biochim. Biophys. Acta 1831: 543-54 [PMID:22960354]
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Catecholamine turnover
Enzymes → Catecholamine turnover
Overview: Catecholamines are deﬁned by the presence of
two adjacent hydroxyls on a benzene ring with a sidechain
containing an amine. The predominant catacholamines
in mammalian biology are the neurotransmitter/hormones
dopamine, (-)-noradrenaline (norepinephrine) and (-)-adrenaline
(epinephrine). These hormone/transmitters are synthe-
sized by sequential metabolism from L-phenylalanine via
L-tyrosine. Hydroxylation of L-tyrosine generates levodopa,
which is decarboxylated to form dopamine. Hydroxylation
of the ethylamine sidechain generates (-)-noradrenaline (nore-
pinephrine), which can be methylated to form (-)-adrenaline
(epinephrine). In particular neuronal and adrenal chromaf-
ﬁn cells, the catecholamines dopamine, (-)-noradrenaline and
(-)-adrenaline are accumulated into vesicles under the inﬂuence
of the vesicular monoamine transporters (VMAT1/SLC18A1 and
VMAT2/SLC18A2). After release into the synapse or the blood-
stream, catecholamines are accumulated through the action
cell-surface transporters, primarily the dopamine (DAT/SLC6A3)
and norepinephrine transporter (NET/SLC6A2). The primary
routes of metabolism of these catecholamines are oxidation via
monoamine oxidase activities of methylation via catechol O-
methyltransferase.
Nomenclature L-Phenylalanine hydroxylase Tyrosine aminotransferase L-Tyrosine hydroxylase Dopamine beta-hydroxylase
(dopamine beta-monooxygenase)
Common abbreviation – TAT – DBH
HGNC, UniProt PAH, P00439 TAT, P17735 TH, P07101 DBH, P09172
EC number 1.14.16.1: L-phenylalanine + O2 ->
L-tyrosine
2.6.1.5: L-tyrosine + α-ketoglutaric acid ->
4-hydroxyphenylpyruvic acid +
L-glutamic acid
1.14.16.2: L-tyrosine + O2 -> levodopa 1.14.17.1: dopamine + O2 =
(-)-noradrenaline + H2O
Endogenous substrates L-phenylalanine – L-tyrosine –
Products L-tyrosine – levodopa –
Cofactors sapropterin pyridoxal 5-phosphate sapropterin, Fe2+ Cu2+, L-ascorbic acid
Endogenous activators Protein kinase A-mediated phosphorylation
(Rat) [2]
– Protein kinase A-mediated phosphorylation
[290]
–
Selective inhibitors α-methylphenylalanine [218] – Rat,
fenclonine
– α-propyldopacetamide, 3-chlorotyrosine,
3-iodotyrosine, alpha-methyltyrosine
nepicastat (pIC50 8) [565]
Comments PAH is an iron bound homodimer or
-tetramer from the same structural family as
tyrosine 3-monooxygenase and the
tryptophan hydroxylases. Deﬁciency or
loss-of-function of PAH is associated with
phenylketonuria
Tyrosine may also be metabolized in the liver
by tyrosine transaminase to generate
4-hydroxyphenylpyruvic acid, which can be
further metabolized to homogentisic acid.
TAT is a homodimer, where loss-of-function
mutations are associated with
type II tyrosinemia.
TH is a homotetramer, which is inhibited by
dopamine and other catecholamines in a
physiological negative feedback pathway
[128].
DBH is a homotetramer.
A protein structurally-related to DBH
(MOXD1, Q6UVY6) has been described and
for which a function has yet to be identiﬁed
[87].
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Nomenclature L-Aromatic amino-acid decarboxylase Phenylethanolamine N-methyltransferase Catechol-O-methyltransferase
Common abbreviation AADC PNMT COMT
HGNC, UniProt DDC, P20711 PNMT, P11086 COMT, P21964
EC number 4.1.1.28: levodopa -> dopamine + CO2
5-hydroxy-L-tryptophan -> 5-hydroxytryptamine + CO2
This enzyme also catalyses the following reaction::
L-tryptophan -> tryptamine + CO2
2.1.1.28: (-)-noradrenaline -> (-)-adrenaline 2.1.1.6: S-adenosyl-L-methionine + a catechol =
S-adenosyl-L-homocysteine + a guaiacol
(-)-noradrenaline -> normetanephrine
dopamine -> 3-methoxytyramine
3,4-dihydroxymandelic acid -> vanillylmandelic acid
(-)-adrenaline -> metanephrine
Endogenous substrates levodopa, 5-hydroxy-L-tryptophan, L-tryptophan – S-adenosyl methionine
Products 5-hydroxytryptamine, dopamine – tolcapone (soluble enzyme) (pKi 9.6) [370], tolcapone
(membrane-bound enzyme) (pKi 9.5) [370], entacapone
(soluble enzyme) (pKi 9.5) [370], entacapone
(membrane-bound enzyme) (pKi 8.7) [370]
Cofactors pyridoxal 5-phosphate S-adenosyl methionine –
Inhibitors – LY134046 (pKi 7.6) [186] COMT appears to exist in both membrane-bound and soluble
forms. COMT has also been described to methylate steroids,
particularly hydroxyestradiols
Selective inhibitors 3-hydroxybenzylhydrazine, L-α-methyldopa, benserazide
[125], carbidopa
– –
Comments AADC is a homodimer. – –
Nomenclature Monoamine oxidase A Monoamine oxidase B
Common abbreviation MAO-A MAO-B
HGNC, UniProt MAOA, P21397 MAOB, P27338
EC number 1.4.3.4
(-)-adrenaline -> 3,4-dihydroxymandelic acid + NH3
(-)-noradrenaline -> 3,4-dihydroxymandelic acid + NH3
tyramine -> 4-hydroxyphenyl acetaldehyde + NH3
dopamine -> 3,4-dihydroxyphenylacetaldehyde + NH3
5-hydroxytryptamine -> 5-hydroxyindole acetaldehyde + NH3
1.4.3.4
Cofactors – ﬂavin adenine dinucleotide +
Inhibitors – rasagiline (pIC50 7.8) [668], phenelzine (Irreversible inhibition) (pKi 7.8) [49], lazabemide
(pKi 7.1) [230, 599], selegiline (pKi 5.7–6) [141, 413], tranylcypromine (pIC50 4.7) [664]
Selective inhibitors ﬂavin adenine dinucleotide saﬁnamide (pKi 6.3) [48]
Comments moclobemide (pKi 8.3) [284], phenelzine (Irreversible inhibition) (pKi 7.3) [49],
tranylcypromine (pIC50 4.7) [664], selegiline (pKi 4.2) [413], beﬂoxatone [124], clorgiline,
pirlindole [406]
–
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Further reading on Catecholamine turnover
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Ceramide turnover
Enzymes → Ceramide turnover
Overview: Ceramides are a family of sphingophospholipids syn-
thesized in the endoplasmic reticulum, which mediate cell stress
responses, including apoptosis, autophagy and senescence, Ser-
ine palmitoyltransferase generates 3-ketosphinganine, which is re-
duced to sphinganine (dihydrosphingosine). N-Acylation allows
the formation of dihydroceramides, which are subsequently re-
duced to form ceramides. Once synthesized, ceramides are traf-
ﬁcked from the ER to theGolgi bound to the ceramide transfer pro-
tein, CERT (COL4A3BP, Q9Y5P4). Ceramide can be metabolized
via multiple routes, ensuring tight regulation of its cellular lev-
els. Addition of phosphocholine generates sphingomyelin while
carbohydrate is added to form glucosyl- or galactosylceramides.
Ceramidase re-forms sphingosine or sphinganine from ceramide
or dihydroceramide. Phosphorylation of ceramide generates ce-
ramide phosphate. The determination of accurate kinetic param-
eters for many of the enzymes in the sphingolipid metabolic path-
way is complicated by the lipophilic nature of the substrates.
Serine palmitoyltransferase
Enzymes → Ceramide turnover → Serine palmitoyltransferase
Overview: The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic
activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb weremost active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA [234]. Complexes
involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with
C16, C18 and C20 acylCoAs [234].
Nomenclature serine palmitoyltransferase
long chain base subunit 1
serine palmitoyltransferase
long chain base subunit 2
serine palmitoyltransferase
long chain base subunit 3
serine palmitoyltransferase
small subunit A
serine palmitoyltransferase
small subunit B
Common abbreviation SPT1 SPT2 SPT3 SPTSSA SPTSSB
HGNC, UniProt SPTLC1, O15269 SPTLC2, O15270 SPTLC3, Q9NUV7 SPTSSA, Q969W0 SPTSSB, Q8NFR3
EC number 2.3.1.50: L-serine + palmitoyl-CoA
-> 3-ketosphinganine +
coenzyme A + CO2
2.3.1.50: L-serine + palmitoyl-CoA
-> 3-ketosphinganine +
coenzyme A + CO2
2.3.1.50: L-serine + palmitoyl-CoA
-> 3-ketosphinganine +
coenzyme A + CO2
– –
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate – –
Selective inhibitors myriocin (pKi 9.6) [414] – Mouse myriocin [414] myriocin [414] – –
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Ceramide synthase
Enzymes → Ceramide turnover → Ceramide synthase
Overview: This family of enzymes, also known as sphingosine N-acyltransferase, is located in the ER facing the cytosol with an as-yet undeﬁned topology and stoichiometry. Ceramide synthase in vitro
is sensitive to inhibition by the fungal derived toxin, fumonisin B1.
Nomenclature ceramide synthase 1 ceramide synthase 2 ceramide synthase 3 ceramide synthase 4 ceramide synthase 5 ceramide synthase 6
Common abbreviation CERS1 CERS2 CERS3 CERS4 CERS5 CERS6
HGNC, UniProt CERS1, P27544 CERS2, Q96G23 CERS3, Q8IU89 CERS4, Q9HA82 CERS5, Q8N5B7 CERS6, Q6ZMG9
EC number 2.3.1.24: acylCoA +
sphinganine ->
dihydroceramide +
coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
sphinganine ->
dihydroceramide +
coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
sphinganine ->
dihydroceramide +
coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
sphinganine ->
dihydroceramide +
coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
sphinganine ->
dihydroceramide +
coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
2.3.1.24: acylCoA +
sphinganine ->
dihydroceramide +
coenzyme A
sphingosine + acylCoA ->
ceramide + coenzyme A
Substrates C18-CoA [611] C24- and C26-CoA [338] C26-CoA and longer [417,
484]
C18-, C20- and C22-CoA
[501]
C16-CoA [334, 501] C14- and C16-CoA [416]
Sphingolipid 4-desaturase
Enzymes → Ceramide turnover → Sphingolipid 4-desaturase
Overview: DEGS1 and DEGS2 are 4TM proteins.
Nomenclature delta 4-desaturase, sphingolipid 1 delta 4-desaturase, sphingolipid 2
HGNC, UniProt DEGS1, O15121 DEGS2, Q6QHC5
EC number 1.14.-.- 1.14.-.-
Cofactors NAD NAD
Inhibitors SKI II (pKi 6.5) [107], RBM2-1B (pIC50 4.7) [73] –
Comments Myristoylation of DEGS1 enhances its activity and targets it to the mitochondria [37]. –
Comments: DEGS1 activity is inhibited by a number of natural products, including curcumin and 9-tetrahydrocannabinol [163].
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Sphingolipid 4-desaturase
Sphingomyelin synthase
Enzymes → Ceramide turnover → Sphingomyelin synthase
Overview: Following translocation from the ER to the Golgi under the inﬂuence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of
phosphocholine from the phospholipid phosphatidylcholine.
Sphingomyelin synthase-related protein 1 is structurally related but lacks sphingomyelin synthase activity.
Nomenclature sphingomyelin synthase 1 sphingomyelin synthase 2 sterile alpha motif domain containing 8
HGNC, UniProt SGMS1, Q86VZ5 SGMS2, Q8NHU3 SAMD8, Q96LT4
EC number 2.7.8.27: ceramide + phosphatidylcholine -> sphingomyelin +
diacylglycerol
2.7.8.27: ceramide + phosphatidylcholine -> sphingomyelin +
diacylglycerol
2.7.8.-: ceramide + phosphatidylethanolamine -> ceramide
phosphoethanolamine
Inhibitors compound 1j (pIC50 5.7) [350] compound D24 (pIC50 4.9) [134] –
Comments – Palmitoylation of sphingomyelin synthase 2 may allow
targeting to the plasma membrane [585].
–
Sphingomyelin phosphodiesterase
Enzymes → Ceramide turnover → Sphingomyelin phosphodiesterase
Overview: Also known as sphingomyelinase.
Nomenclature sphingomyelin
phosphodiesterase 1
sphingomyelin
phosphodiesterase 2
sphingomyelin
phosphodiesterase 3
sphingomyelin
phosphodiesterase 4
sphingomyelin
phosphodiesterase
acid-like 3A
sphingomyelin
phosphodiesterase acid-like 3B
HGNC, UniProt SMPD1, P17405 SMPD2, O60906 SMPD3, Q9NY59 SMPD4, Q9NXE4 SMPDL3A, Q92484 SMPDL3B, Q92485
EC number 3.1.4.12: sphingomyelin ->
ceramide + phosphocholine
3.1.4.12: sphingomyelin ->
ceramide + phosphocholine
3.1.4.12: sphingomyelin ->
ceramide + phosphocholine
3.1.4.12: sphingomyelin ->
ceramide + phosphocholine
3.1.4.-: sphingomyelin ->
ceramide + phosphocholine
3.1.4.-: sphingomyelin ->
ceramide + phosphocholine
Inhibitors – inhibitor A (pKi 5.8) [663] –
Bovine
– – – –
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Neutral sphingomyelinase coupling factors
Enzymes → Ceramide turnover → Neutral sphingomyelinase coupling factors
Overview: Protein FAN [4] and polycomb protein EED [469] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.
Nomenclature embryonic ectoderm development neutral sphingomyelinase activation associated factor
HGNC, UniProt EED, O75530 NSMAF, Q92636
Selective inhibitors A-395 (Binding) (pKi 9.4) [252] –
Ceramide glucosyltransferase
Enzymes → Ceramide turnover → Ceramide glucosyltransferase
Nomenclature UDP-glucose ceramide glucosyltransferase
HGNC, UniProt UGCG, Q16739
EC number 2.4.1.80: UDP-glucose + ceramide = uridine diphosphate + glucosylceramide
Inhibitors miglustat (pKi 5.1) [68]
Comments Glycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.
Acid ceramidase
Enzymes → Ceramide turnover → Acid ceramidase
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase 1
HGNC, UniProt ASAH1, Q13510
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid
Comments This lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product [318].
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Neutral ceramidases
Enzymes → Ceramide turnover → Neutral ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase 2 N-acylsphingosine amidohydrolase 2B
HGNC, UniProt ASAH2, Q9NR71 ASAH2B, P0C7U1
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid –
Comments The enzyme is associated with the plasma membrane [584]. –
Comments: ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.
Alkaline ceramidases
Enzymes → Ceramide turnover → Alkaline ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature alkaline ceramidase 1 alkaline ceramidase 2 alkaline ceramidase 3
HGNC, UniProt ACER1, Q8TDN7 ACER2, Q5QJU3 ACER3, Q9NUN7
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.-
Comments ACER1 is associated with the ER [572]. ACER2 is associated with the Golgi apparatus [657]. ACER3 is associated with the ER and Golgi apparatus [391].
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Ceramide kinase
Enzymes → Ceramide turnover → Ceramide kinase
Nomenclature ceramide kinase
HGNC, UniProt CERK, Q8TCT0
EC number 2.7.1.138: ceramide + ATP -> ceramide 1-phosphate + ADP
Inhibitors NVP 231 (pIC50 7.9) [214]
Comments: A ceramide kinase-like protein has been identiﬁed in the human genome (CERKL, Q49MI3).
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Chromatin modifying enzymes
Enzymes → Chromatin modifying enzymes
Overview: Chromatin modifying enzymes, and other
chromatin-modifying proteins, fall into three broad categories:
writers, readers and erasers. The function of these pro-
teins is to dynamically maintain cell identity and regulate pro-
cesses such as differentiation, development, proliferation and
genome integrity via recognition of speciﬁc ’marks’ (covalent
post-translational modiﬁcations) on histone proteins and DNA
[325]. In normal cells, tissues and organs, precise co-ordination
of these proteins ensures expression of only those genes required
to specify phenotype or which are required at speciﬁc times, for
speciﬁc functions. Chromatin modiﬁcations allow DNA modiﬁ-
cations not coded by the DNA sequence to be passed on through
the genome and underlies heritable phenomena such as X chro-
mosome inactivation, aging, heterochromatin formation, repro-
gramming, and gene silencing (epigenetic control).
To date at least eight distinct types of modiﬁcations are found
on histones. These include small covalent modiﬁcations such as
acetylation, methylation, and phosphorylation, the attachment
of larger modiﬁers such as ubiquitination or sumoylation, and
ADP ribosylation, proline isomerization and deimination. Chro-
matin modiﬁcations and the functions they regulate in cells are
reviewed by Kouzarides (2007) [325].
Writer proteins include the histone methyltransferases, histone
acetyltransferases, some kinases and ubiquitin ligases.
Readers include proteins which contain methyl-lysine-
recognition motifs such as bromodomains, chromodomains,
tudor domains, PHD zinc ﬁngers, PWWP domains and MBT
domains.
Erasers include the histone demethylases and histone deacety-
lases (HDACs and sirtuins).
Dysregulated epigenetic control can be associated with human dis-
eases such as cancer [161], where a wide variety of cellular and pro-
tein abberations are known to perturb chromatin structure, gene
transcription and ultimately cellular pathways [35, 544]. Due to
the reversible nature of epigenetic modiﬁcations, chromatin reg-
ulators are very tractable targets for drug discovery and the devel-
opment of novel therapeutics. Indeed, small molecule inhibitors
of writers (e.g. azacitidine and decitabine target the DNA methyl-
transferases DNMT1 and DNMT3 for the treatment of myelodys-
plastic syndromes [199, 637]) and erasers (e.g. the HDAC in-
hibitors vorinostat, romidepsin and belinostat for the treatment of
T-cell lymphomas [177, 309]) are already being used in the clinic.
The search for the next generation of compounds with improved
speciﬁcity against chromatin-associated proteins is an area of in-
tense basic and clinical research [71]. Current progress in this ﬁeld
is reviewed by Simó-Riudalbas and Esteller (2015) [545].
2.1.1.- Protein arginine N-methyltransferases
Enzymes → Chromatin modifying enzymes → 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT,
EC 2.1.1.-) encompass histone arginine N-methyltransferases
(PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein N-
methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric
or tetrameric enzymes which use S-adenosyl methionine as
a methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and di-
methylated products; these may be symmetric (SDMA) or asym-
metric (NG,NG-dimethyl-L-arginine) versions, where both guani-
dine nitrogens are monomethylated or one of the two is dimethy-
lated, respectively.
Information on members of this family may be found in the online database.
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3.5.1.- Histone deacetylases (HDACs)
Enzymes → Chromatin modifying enzymes → 3.5.1.- Histone deacetylases (HDACs)
Overview: Histone deacetylases act as erasers of epigenetic acety-
lation marks on lysine residues in histones. Removal of the acetyl
groups facilitates tighter packing of chromatin (heterochromatin
formation) leading to transcriptional repression.
The histone deacetylase family has been classiﬁed in to ﬁve sub-
families based on phylogenetic comparison with yeast homo-
logues:
Class I contains HDACs 1, 2, 3 and 8
Class IIa contains HDACs 4, 5, 7 and 9
Class IIb contains HDACs 6 and 10
Class III contains the sirtuins (SIRT1-7)
Class IV contains only HDAC11.
Classes I, II and IV use Zn+ as a co-factor, whereas catalysis by
Class III enzymes requires NAD+ as a co-factor, and members of
this subfamily have ADP-ribosylase activity in addition to protein
deacetylase function [521].
HDACs have more general protein deacetylase activity, being able
to deacetylate lysine residues in non-histone proteins [104] such
as microtubules [270], the hsp90 chaperone [326] and the tumour
suppressor p53 [377].
DysregulatedHDAC activity has been identiﬁed in cancer cells and
tumour tissues [355, 509], making HDACs attractive molecular
targets in the search for novel mechanisms to treat cancer [639].
Several small molecule HDAC inhibitors are already approved
for clinical use: romidepsin, belinostat, vorinostat, panobinostat,
belinostat, valproic acid and tucidinostat. HDACs and HDAC in-
hibitors currently in development as potential anti-cancer thera-
peutics are reviewed by Simó-Riudalbas and Esteller (2015) [545].
Nomenclature histone deacetylase 6
HGNC, UniProt HDAC6, Q9UBN7
EC number 3.5.1.98
Inhibitors trichostatin A (pKi 9) [61], vorinostat (pKi 8.8) [61], romidepsin (pKi 8) [61]
Selective inhibitors ricolinostat (pIC50 8.3) [518]
Further reading on 3.5.1.- Histone deacetylases (HDACs)
Ellmeier W et al. (2018) Histone deacetylase function in CD4+ T cells. Nat. Rev. Immunol. 18:
617-634 [PMID:30022149]
Maolanon AR et al. (2017) Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase
Enzymes. Chembiochem 18: 5-49 [PMID:27748555]
Micelli C et al. (2015) Histone deacetylases: structural determinants of inhibitor selectivity. Drug
Discov Today 20: 718-35 [PMID:25687212]
Millard CJ et al. (2017) Targeting Class I Histone Deacetylases in a "Complex" Environment. Trends
Pharmacol Sci 38: 363-377 [PMID:28139258]
Roche J et al. (2016) Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 121:
451-483 [PMID:27318122]
Zagni C et al. (2017) The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade
After Vorinostat. Med Res Rev 37: 1373-1428 [PMID:28181261]
Further reading on Chromatin modifying enzymes
Angus SP et al. (2018) Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase
Inhibitors in Cancer. Annu Rev Pharmacol Toxicol 58: 209-229 [PMID:28934561]
Bennett RL et al. (2018) Targeting Epigenetics in Cancer. Annu Rev Pharmacol Toxicol 58: 187-207
[PMID:28992434]
Lauschke VM et al. (2018) Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights
and Therapeutic Opportunities. Annu Rev Pharmacol Toxicol 58: 161-185 [PMID:29029592]
Searchable database: http://www.guidetopharmacology.org/index.jsp 3.5.1.- Histone deacetylases (HDACs) S320
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14752/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology (2019) 176, S297–S396
Cyclic nucleotide turnover/signalling
Enzymes → Cyclic nucleotide turnover/signalling
Overview: Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides
are mediated through activation of protein kinases (cAMP- and cGMP-dependent protein kinases), ion channels (cyclic nucleotide-gated, CNG, and hyperpolarization and cyclic nucleotide-gated, HCN)
and guanine nucleotide exchange factors (GEFs, Epac).
Adenylyl cyclases (ACs)
Enzymes → Cyclic nucleotide turnover/signalling → Adenylyl cyclases (ACs)
Overview: Adenylyl cyclase, E.C. 4.6.1.1, converts ATP to
cyclic AMP and pyrophosphate. Mammalian membrane-
delimited adenylyl cyclases (nomenclature as approved by
the NC-IUPHARSubcommittee onAdenylyl cyclases [137])
are typically made up of two clusters of six TM domains separat-
ing two intracellular, overlapping catalytic domains that are the
target for the nonselective activators Gαs (the stimulatory G pro-
tein α subunit) and forskolin (except AC9, [479]). Adenosine
and its derivatives (e.g. 2’,5’-dideoxyadenosine), acting through
the P-site,are inhibitors of adenylyl cyclase activity [594]. Four
families of membranous adenylyl cyclase are distinguishable:
calmodulin (CALM1 CALM2 CALM3, P62158)-stimulated (AC1,
AC3 and AC8), Ca2+- and Gβγ-inhibitable (AC5, AC6 and AC9),
Gβγ-stimulated and Ca2+-insensitive (AC2, AC4 and AC7), and
forskolin-insensitive (AC9) forms. A soluble adenylyl cyclase
(AC10) lacks membrane spanning regions and is insensitive to G
proteins.It functions as a cytoplasmic bicarbonate (pH-insensitive)
sensor [93].
Nomenclature adenylyl cyclase 1 adenylyl cyclase 2 adenylyl cyclase 3 adenylyl cyclase 4 adenylyl cyclase 5
Common abbreviation AC1 AC2 AC3 AC4 AC5
HGNC, UniProt ADCY1, Q08828 ADCY2, Q08462 ADCY3, O60266 ADCY4, Q8NFM4 ADCY5, O95622
EC number 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1
Endogenous activators calmodulin (CALM1 CALM2 CALM3,
P62158), PKC-evoked
phosphorylation [283, 583]
Gβγ, PKC-evoked phosphorylation,
Raf-evoked phosphorylation [91,
145, 381, 588]
calmodulin (CALM1 CALM2 CALM3,
P62158), PKC-evoked
phosphorylation [102, 283]
Gβγ [195] PKC-evoked phophorylation, Gβγ,
Raf-evoked phophorylation [145,
197, 306]
Activators compound 45 (pIC50 7.7) [506] –
Bovine
FD1 [449] – – FD6 [449]
Endogenous inhibitors Gαi, Gαo, Gβγ [588, 589] – RGS2, Gβγ, CaM kinase II-evoked
phosphorylation [142, 546, 633]
PKC-evoked phophorylation [680] Gαi , Ca2+, PKA-evoked
phosphorylation, Gβγ, NO [197,
258, 279, 282, 589]
Inhibitors – SKF-83566 [114] – – NKY80 (pIC50 5.2) [62, 449]
Selective inhibitors ST034307 (pIC50 5.6) [64] – – – –
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Nomenclature adenylyl cyclase 6 adenylyl cyclase 7 adenylyl cyclase 8 adenylyl cyclase 9 adenylyl cyclase 10
Common abbreviation AC6 AC7 AC8 AC9 AC10
HGNC, UniProt ADCY6, O43306 ADCY7, P51828 ADCY8, P40145 ADCY9, O60503 ADCY10, Q96PN6
EC number 4.6.1.1 4.6.1.1 4.6.1.1 4.6.1.1 –
Endogenous activators Gβγ, Raf-evoked phosphorylation
[145, 197]
Gβγ, PKC-evoked phosphorylation
[39, 632]
calmodulin (CALM1 CALM2 CALM3,
P62158) [72]
– Bicarbonate, Ca2+ [93, 357]
Endogenous inhibitors Gαi, Ca2+, PKA-evoked
phosphorylation, PKC-evoked
phosphorylation, NO [94, 258,
335, 589, 667]
– PKA-evoked phosphorylation [643] Ca /calcineurin [2+ 461] –
Inhibitors NKY80 (pIC50 4.8) [62] – – – KH7 (pIC50 5–5.5) [256], LRE1
(pIC50 5) [488]
Comments: Many of the activators and inhibitors listed are only somewhat selective or have not been tested against all AC isoforms [62, 114]. AC3 shows only modest in vitro activation by Ca /CaM.2+
Further reading on Adenylyl cyclases (ACs)
Dessauer CW et al. (2017) International Union of Basic and Clinical Pharmacology. CI. Structures
and Small Molecule Modulators of Mammalian Adenylyl Cyclases. Pharmacol. Rev. 69: 93-139
[PMID:28255005]
Halls ML et al. (2017) Adenylyl cyclase signalling complexes - Pharmacological challenges and op-
portunities. Pharmacol. Ther. 172: 171-180 [PMID:28132906]
Wiggins SV et al. (2018) Pharmacological modulation of the CO2/HCO
−
3 /pH-, calcium-, and ATP-
sensing soluble adenylyl cyclase. Pharmacol Ther 190: 173-186 [PMID:29807057]
Wu L et al. (2016) Adenylate cyclase 3: a new target for anti-obesity drug development. Obes Rev 17:
907-14 [PMID:27256589]
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Exchange protein activated by cyclic AMP (EPACs)
Enzymes → Cyclic nucleotide turnover/signalling → Exchange protein activated by cyclic AMP (EPACs)
Overview: Epacs are members of a family of guanine nu-
cleotide exchange factors (ENSFM00250000000899), which also
includes RapGEF5 (GFR, KIAA0277, MR-GEF, Q92565) and
RapGEFL1 (Link-GEFII, Q9UHV5). They are activated endoge-
nously by cyclic AMP and with some pharmacological selectiv-
ity by 8-pCPT-2’-O-Me-cAMP [158]. Once activated, Epacs in-
duce an enhanced activity of the monomeric G proteins, Rap1
and Rap2 by facilitating binding of guanosine-5’-triphosphate
in place of guanosine 5’-diphosphate, leading to activation of
phospholipase C [524].
Nomenclature Rap guanine nucleotide exchange factor 3 Rap guanine nucleotide exchange factor 4
Common abbreviation Epac1 Epac2
HGNC, UniProt RAPGEF3, O95398 RAPGEF4, Q8WZA2
Inhibitors ESI-09 (pIC50 5.5) [15] HJC 0350 (pIC50 6.5) [89], ESI-09 (pIC50 4.4–5.2) [15, 90]
Further reading on Exchange protein activated by cyclic AMP (EPACs)
Fujita T et al. (2017) The role of Epac in the heart. Cell. Mol. Life Sci. 74: 591-606 [PMID:27549789]
Robichaux WG and Cheng X. (2018) Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology,
and Therapeutics Development. Physiol Rev 98: 919-1053 [PMID:29537337]
Wang P et al. (2017) Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic
targets. Bioorg. Med. Chem. Lett. 27: 1633-1639 [PMID:28283242]
Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Enzymes → Cyclic nucleotide turnover/signalling → Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Overview: 3’,5’-Cyclic nucleotide phosphodiesterases (PDEs, 3’,5’-cyclic-nucleotide 5’-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3’,5’-cyclic nucleotide (usually cyclic AMP or
cyclic GMP). Isobutylmethylxanthine is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2’,3’-cyclic nucleotide 3’-phosphodiesterase
(E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.
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Nomenclature phosphodiesterase 1A phosphodiesterase 1B phosphodiesterase 1C
Common abbreviation PDE1A PDE1B PDE1C
HGNC, UniProt PDE1A, P54750 PDE1B, Q01064 PDE1C, Q14123
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of afﬁnity cyclic GMP > cyclic AMP cyclic GMP > cyclic AMP cyclic GMP = cyclic AMP
Endogenous activators calmodulin (CALM1 CALM2 CALM3, P62158) calmodulin (CALM1 CALM2 CALM3, P62158) calmodulin (CALM1 CALM2 CALM3, P62158)
Endogenous inhibitors – – –
Inhibitors crisaborole (pIC50 5.2) [10] – –
Sub/family-selective inhibitors – – –
Selective inhibitors SCH51866 (pIC50 7.2) [609], vinpocetine (pIC50 5.1)
[372]
SCH51866 (pIC50 7.2) [609] SCH51866 (pIC50 7.2) [609], vinpocetine (pIC50 4.3)
[372]
Comments – – –
Nomenclature phosphodiesterase 2A phosphodiesterase 3A phosphodiesterase 3B
Common abbreviation PDE2A PDE3A PDE3B
HGNC, UniProt PDE2A, O00408 PDE3A, Q14432 PDE3B, Q13370
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of afﬁnity cyclic AMP  cyclic GMP – –
Endogenous activators cyclic GMP – –
Endogenous inhibitors – cyclic GMP cyclic GMP
Inhibitors milrinone (pIC50 <6.5) [571] cilostazol (pIC50 6.7) [571], inamrinone (pIC50 4.8) [547] –
Sub/family-selective inhibitors – – –
Selective inhibitors BAY607550 (pIC50 8.3–8.8) [56], EHNA (pIC50 5.3) [411] cilostamide (pIC50 7.5) [571], anagrelide (pIC50 7.1–7.3)
[295, 395, 405], milrinone (pIC50 6.3–6.4) [156, 571]
cilostamide (pIC50 7.3) [571], cilostazol (pIC50 6.4) [571],
milrinone (pIC50 6) [571], inamrinone (pIC50 4.5) [571]
Comments EHNA is also an inhibitor of adenosine deaminase
(E.C. 3.5.4.4).
– –
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Nomenclature phosphodiesterase 4A phosphodiesterase 4B phosphodiesterase 4C phosphodiesterase 4D phosphodiesterase 5A
Common abbreviation PDE4A PDE4B PDE4C PDE4D PDE5A
HGNC, UniProt PDE4A, P27815 PDE4B, Q07343 PDE4C, Q08493 PDE4D, Q08499 PDE5A, O76074
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of afﬁnity cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic GMP > cyclic AMP
Activators – – – PKA-mediated phosphorylation
[265]
Protein kinase A, protein kinase G
[116]
Inhibitors ibudilast (pIC50 7.3) [319],
RS-25344 (pIC50 7.2) [517]
roﬂumilast (pIC50 9.4) [376],
ibudilast (pIC50 7.2) [319],
RS-25344 (pIC50 6.5) [517]
RS-25344 (pIC50 8.1) [517],
ibudilast (pIC50 6.6) [319]
RS-25344 (pIC50 8.4) [517],
difamilast (pIC50 >7.3) [446],
CBS-3595 (pIC50 6.1) [13]
gisadenaﬁl (pIC50 8.9) [495],
milrinone (pIC50 7.3)
Sub/family-selective inhibitors rolipram (pIC50 9) [623], CDP840
(pKi 8) [465], Ro20-1724 (pIC50
6.5) [623]
rolipram (pIC50 9) [623],
Ro20-1724 (pIC50 6.4) [623]
CDP840 (pKi 7.7) [465], rolipram
(pIC50 6.5) [623], Ro20-1724
(pIC50 5.4) [623]
CDP840 (pKi 8.1) [465], rolipram
(pIC50 7.2) [623], Ro20-1724
(pIC50 6.2) [623]
–
Selective inhibitors YM976 (pIC50 8.3) [17],
apremilast (pIC50 7.8) [522]
– apremilast (pIC50 6.9) [522] apremilast (pIC50 7.5) [522] vardenaﬁl (pIC50 9.7) [60], T0156
(pIC50 9.5) [418], sildenaﬁl (pIC50
8.4–9) [604, 621], tadalaﬁl (pIC50
8.5) [419], SCH51866 (pIC50 7.2)
[609], zaprinast (pIC50 6.8) [604]
Nomenclature phosphodiesterase 6A phosphodiesterase 6B phosphodiesterase 6C phosphodiesterase 6D phosphodiesterase 6G phosphodiesterase 6H
Common abbreviation PDE6A PDE6B PDE6C PDE6D PDE6G PDE6H
HGNC, UniProt PDE6A, P16499 PDE6B, P35913 PDE6C, P51160 PDE6D, O43924 PDE6G, P18545 PDE6H, Q13956
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Inhibitors compound 53 (pIC50 8)
[271]
– sildenaﬁl (pIC50 7.4) [621] – – –
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Nomenclature phosphodiesterase 7A phosphodiesterase 7B phosphodiesterase 8A phosphodiesterase 8B
Common abbreviation PDE7A PDE7B PDE8A PDE8B
HGNC, UniProt PDE7A, Q13946 PDE7B, Q9NP56 PDE8A, O60658 PDE8B, O95263
EC number 3.1.4.17 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of afﬁnity cyclic AMP  cyclic GMP [409] cyclic AMP  cyclic GMP [200] cyclic AMP  cyclic GMP [171] cyclic AMP  cyclic GMP [249]
Inhibitors crisaborole (pIC50 6.1) [10] BRL50481 (pIC50 4.9) [11] – –
Selective inhibitors BRL50481 (pIC50 6.7–6.8) [11, 553] dipyridamole (pIC50 5.7–6) [200, 520],
SCH51866 (pIC50 5.8) [520]
PF-04957325 (pIC50 7.4) [399],
dipyridamole (pIC50 5.1) [171]
dipyridamole (pIC50 4.3) [249]
Comments PDE7A appears to be membrane-bound or
soluble for PDE7A1 and 7A2 splice variants,
respectively
– – –
Nomenclature phosphodiesterase 9A phosphodiesterase 10A phosphodiesterase 11A
Common abbreviation PDE9A PDE10A PDE11A
HGNC, UniProt PDE9A, O76083 PDE10A, Q9Y233 PDE11A, Q9HCR9
EC number 3.1.4.17 3.1.4.17 3.1.4.17
Rank order of afﬁnity cyclic GMP  cyclic AMP [170] cyclic AMP, cyclic GMP [184] cyclic AMP, cyclic GMP [167]
Inhibitors SCH51866 (pIC50 5.8) [170], zaprinast (pIC50 4.5) [170] – tadalaﬁl (pIC50 6.5) [419], BC11-38 (pIC50 6.5) [84]
Selective inhibitors – mardepodect (pIC50 9.4) [613] –
Comments: PDE1A, 1B and 1C appear to act as soluble homod-
imers, while PDE2A is a membrane-bound homodimer. PDE3A
and PDE3B are membrane-bound.
PDE4 isoforms are essentially cyclic AMP speciﬁc. The potency
of YM976 at other members of the PDE4 family has not been re-
ported. PDE4B-D long forms are inhibited by extracellular signal-
regulated kinase (ERK)-mediated phosphorylation [260, 261].
PDE4A-D splice variants can be membrane-bound or cytosolic
[265]. PDE4 isoforms may be labelled with [ H]rolipram3 .
PDE6 is a membrane-bound tetramer composed of two catalytic
chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G
or PDE6H) and the PDE6D chain. The enzyme is essentially
cyclic GMP speciﬁc and is activated by the α-subunit of transducin
(Gαt) and inhibited by sildenaﬁl, zaprinast and dipyridamole with
potencies lower than those observed for PDE5A. Defects in PDE6B
are a cause of retinitis pigmentosa and congenital stationary night
blindness.
Further reading on Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Klussmann E. (2016) Protein-protein interactions of PDE4 family members - Functions, interactions
and therapeutic value. Cell. Signal. 28: 713-8 [PMID:26498857]
Korkmaz-Icöz S et al. (2018) Targeting phosphodiesterase 5 as a therapeutic option against myocar-
dial ischaemia/reperfusion injury and for treating heart failure. Br. J. Pharmacol. 175: 223-231
[PMID:28213937]
Li H et al. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inﬂammatory Diseases. Front
Pharmacol 9: 1048 [PMID:30386231]
Mehta A and Patel BM. (2019) Therapeutic opportunities in colon cancer: Focus on phosphodi-
esterase inhibitors. Life Sci 230: 150-161 [PMID:31125564]
Ntontsi P et al. (2019) Experimental and investigational phosphodiesterase inhibitors in develop-
ment for asthma. Expert Opin Investig Drugs 28: 261-266 [PMID:30678501]
Pauls MM. (2018) The effect of phosphodiesterase-5 inhibitors on cerebral blood ﬂow in humans: A
systematic review. J Cereb Blood Flow Metab 38: 189-203 [29256324]
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Peng T et al. (2018) Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem 150:
742-756 [PMID:29574203]
Svensson F et al. (2018) Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors. J Med Chem
61: 1415-1424 [PMID:28800229]
Wahlang B et al. (2018) Role of cAMP and phosphodiesterase signaling in liver health and disease.
Cell Signal 49: 105-115 [PMID:29902522]
Zagorska A et al. (2018) Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and
Neurodegenerative Drug Discovery. Curr Med Chem 25: 3455-3481 [PMID:29521210]
Cytochrome P450
Enzymes → Cytochrome P450
Overview: The cytochrome P450 enzyme family (CYP450), E.C.
1.14.-.-, were originally deﬁned by their strong absorbance at 450
nm due to the reduced carbon monoxide-complexed haem com-
ponent of the cytochromes. They are an extensive family of haem-
containing monooxygenases with a huge range of both endoge-
nous and exogenous substrates. These include sterols, fat-soluble
vitamins, pesticides and carcinogens as well as drugs. The sub-
strates of some orphan CYP are not known. Listed below are the
human enzymes; their relationship with rodent CYP450 enzyme
activities is obscure in that the species orthologuemay not catalyse
the metabolism of the same substrates. Although the majority of
CYP450 enzyme activities are concentrated in the liver, the extra-
hepatic enzyme activities also contribute to patho/physiological
processes. Genetic variation of CYP450 isoforms is widespread and
likely underlies a signiﬁcant proportion of the individual variation
to drug administration.
CYP1 family
Enzymes → Cytochrome P450 → CYP1 family
Nomenclature CYP1A1 CYP1A2 CYP1B1
HGNC, UniProt CYP1A1, P04798 CYP1A2, P05177 CYP1B1, Q16678
EC number 1.14.1.1 1.14.1.1 1.14.1.1
Inhibitors 5H3’FPE (pIC50 7.4) [359] 5H3’FPE (pIC50 6.4) [359] stilbenes [154]
Comments CYP1A1 is an extra-hepatic enzyme. It shows a preference for
linear planar aromatic molecules [561].
CYP1A2 is constitutively expressed in liver. It shows a
preference for triangular planar aromatic molecules [561].
Mainly expressed in extra-hepatic tissues. Can metabolise
17β-estradiol [154], leukotrienes and eicosanoids [146].
Mutations have been associated with primary congenitial
glaucoma [569]
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CYP2 family
Enzymes → Cytochrome P450 → CYP2 family
Nomenclature CYP2A6 CYP2A7 CYP2A13 CYP2B6 CYP2C8
HGNC, UniProt CYP2A6, P11509 CYP2A7, P20853 CYP2A13, Q16696 CYP2B6, P20813 CYP2C8, P10632
EC number 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1
Substrates nicotine – – – –
Inhibitors – – – ticlopidine (pIC50 6.7) [175], sibutramine (pIC50 5.8)
[27], thiotepa (pKi 5.3) [620]
phenelzine (pKi 5.1) [175]
Comments Metabolises coumarin [660]. CYP2A7 does not
incorporate haem
and is functionally
inactive [185]
Metabolises tobacco
carcinogen,
4-methylnitrosoamino)-
1-(3-pyridyl)-1-butanone
[570].
Substrates include: efavirenz, bupropion,
cyclophosphamide, ketamine, propofol [605].
Converts arachidonic acid to
11(R)-12(S)-epoxyeicosatrienoic acid or
14(R)-15(S)-epoxyeicosatrienoic acid [672]. Drug
substrates include amodiaquine [26].
Nomenclature CYP2C19 CYP2D6 CYP2E1 CYP2F1 CYP2J2 CYP2R1
HGNC, UniProt CYP2C19, P33261 CYP2D6, P10635 CYP2E1, P05181 CYP2F1, P24903 CYP2J2, P51589 CYP2R1, Q6VVX0
EC number 1.14.14.51
(S)-limonene + [reduced
NADPH–hemoprotein
reductase] + O(2) <=>
(-)-trans-carveol + [oxidized
NADPH–hemoprotein
reductase] + H(2)O
1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1 1.14.13.15
Inhibitors compound 51 (pIC50 7.3)
[120]
– compound 23 (pKi 7.4)
[661]
– compound 4 (pIC50 6.8)
[333], terfenadine (pIC50
5.1) [333]
–
Selective inhibitors compound 30 (pKi 7.7)
[178]
– – – – –
Comments Substrates include:
omeprazole, proguanil,
mephenytoin, diazepam
[45, 138, 254].
Substrates include:
debrisoquine, metoprolol,
codeine [365].
Substrates: Ethanol,
p-nitrophenol [386].
Substrate: naphthalene
[345].
Converts arachidonic acid
to 14(R)-15(S)-
epoxyeicosatrienoic acid
[652]. Hydroxylates
albendazole[654].
Expressed in
cardiomyocytes [556].
Converts vitamin D3 to
calcifediol [96].
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CYP3 family
Enzymes → Cytochrome P450 → CYP3 family
Nomenclature CYP3A4 CYP3A5 CYP3A7 CYP3A43
HGNC, UniProt CYP3A4, P08684 CYP3A5, P20815 CYP3A7, P24462 CYP3A43, Q9HB55
EC number 1.14.14.56: 1,8-cineole + NADPH + O2 =
2-exo-hydroxy-1,8-cineole + NADP+ + H2O
1.14.13.97: Taurochenodeoxycholate +
NADPH + O2 = taurohyocholate + NADP+ +
H2O
Lithocholate + NADPH + O2 =
hyodeoxycholate + NADP+ + H2O
1.14.14.55: quinine + NADPH + O2 =
3-hydroxyquinine + NADP+ + H2O2
1.14.14.1 1.14.14.1 1.14.14.1
Substrates nifedipine [225], midazolam [641] – – –
Inhibitors troleandomycin (pKi 7.8) [534], ketoconazole
(pKi 7) [217], ritonavir (pKi >7) [310]
ritonavir (pKi 6.9) [175] – –
Comments Metabolises a vast range of xenobiotics,
including antidepressants, benzodiazepines,
calcium channel blockers, and
chemotherapeutic agents [675]. The active
site is plastic, with both homotropic and
heterotropic cooperativity observed with some
substrates [534]. CYP3A4 catalyses the
25-hydroxylation of trihydroxycholestane in
liver microsomes [189].
CYP3A5 is expressed extrahepatically,
including in the small intestine. It has
overlapping substrate speciﬁcity with CYP3A4
[126, 641].
Fetal form, rarely expressed in adults. Has
overlapping substrate speciﬁcity with CYP3A4
[126, 641].
Fetal expression only and considered an
orphan fCYP [224]. Testosterone may be a
substrate [220].
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CYP4 family
Enzymes → Cytochrome P450 → CYP4 family
Nomenclature CYP4A11 CYP4A22 CYP4B1 CYP4F2 CYP4F3
HGNC, UniProt CYP4A11, Q02928 CYP4A22, Q5TCH4 CYP4B1, P13584 CYP4F2, P78329 CYP4F3, Q08477
EC number 1.14.14.80 1.14.14.80 1.14.14.1 1.14.14.78
1.14.14.79
1.14.14.94
1.14.14.78
1.14.14.79
1.14.14.94
Inhibitors – – – 17-octadecynoic acid (pKi 5.9) [537] –
Comments Converts lauric acid to
12-hydroxylauric acid.
Reported to be enzymatically
inactive [191].
– Responsible for ω-hydroxylation of
LTB4, LXB4 [415], and tocopherols,
including vitamin E [559]
Responsible for ω-hydroxylation of
LTB4, LXB4 [415], and
polyunsaturated fatty acids [168,
241]
Nomenclature CYP4F8 CYP4F11 CYP4F12 CYP4F22 CYP4V2 CYP4X1 CYP4Z1
HGNC, UniProt CYP4F8, P98187 CYP4F11, Q9HBI6 CYP4F12, Q9HCS2 CYP4F22, Q6NT55 CYP4V2, Q6ZWL3 CYP4X1, Q8N118 CYP4Z1, Q86W10
EC number 1.14.14.1 1.14.14.1
1.14.14.78
1.14.14.1 1.14.14.- 1.14.14.79 1.14.14.1 1.14.14.1
Comments Converts PGH2 to
19-hydroxyPGH [2 69]
and 8,9-EET or 11,12-EET
to 18-hydroxy-8,9-EET or
18-hydroxy-11,12-EET
[435].
– AC004597.1
(ENSG00000225607) is
described as being highly
similar to CYP4F12
Converts arachidonic acid
to 16-HETE and 18-HETE
[435].
Converts myristic acid to
14-hydroxymyristic acid
[429].
Converts anandamide to
14,15-
epoxyeicosatrienoic
ethanolamide [566].
Converts lauric acid to
12-hydroxylauric acid.
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CYP5, CYP7 and CYP8 families
Enzymes → Cytochrome P450 → CYP5, CYP7 and CYP8 families
Nomenclature CYP5A1 CYP7A1 CYP7B1 CYP8A1 CYP8B1
Common abbreviation Thromboxane synthase – – Prostacyclin synthase –
HGNC, UniProt TBXAS1, P24557 CYP7A1, P22680 CYP7B1, O75881 PTGIS, Q16647 CYP8B1, Q9UNU6
EC number 5.3.99.5: PGH2 = thromboxane A2 1.14.14.23 1.14.14.29 5.3.99.4 1.14.14.139
1.14.18.8
Inhibitors ozagrel (pIC50 8.4) [259] – – compound 7p (pIC50 >6) [166] –
Comments Inhibited by dazoxiben [489],
camonagrel [222] and furegrelate
sodium (U-63557A: PubChem
CID 23663954) [213].
Converts cholesterol to
7α-hydroxycholesterol [437].
Converts dehydroepiandrosterone
to 7α-DHEA [510].
Converts PGH2 to PGI2 [244].
Inhibited by tranylcypromine [221]
Converts
7α-hydroxycholest-4-en-3-one to
7-alpha,12α-dihydroxycholest-4-
en-3-one (in rabbit) [278] in the
biosynthesis of bile acids.
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CYP11, CYP17, CYP19, CYP20 and CYP21 families
Enzymes → Cytochrome P450 → CYP11, CYP17, CYP19, CYP20 and CYP21 families
Nomenclature CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP20A1 CYP21A2
Common abbreviation – – Aldosterone synthase – Aromatase – –
HGNC, UniProt CYP11A1, P05108 CYP11B1, P15538 CYP11B2, P19099 CYP17A1, P05093 CYP19A1, P11511 CYP20A1, Q6UW02 CYP21A2, P08686
EC number 1.14.15.6 1.14.15.4 1.14.15.4
1.14.15.5
1.14.14.19
1.14.14.32
1.14.14.14 1.14.-.- 1.14.14.16
Inhibitors mitotane [343, 353] metyrapone (pIC50 7.8)
[679], mitotane
osilodrostat (pIC50 9.7)
[662]
abiraterone (pIC50
7.1–8.4) [472, 477]
anastrozole (pIC50 7.8)
[424],
aminoglutethimide
[463]
– (2S,4S)-ketoconazole
(pIC50 5.3) [512] – Rat
Selective inhibitors – – – galeterone (pIC50 6.5)
[238]
letrozole (pKi 10.7)
[401], exemestane
(pIC50 7.3) [105],
testolactone (pKi 4.5)
[118]
– –
Comments Converts cholesterol to
pregnenolone plus
4-methylpentanal.
Converts deoxycortisone
and 11-deoxycortisol to
cortisone and cortisol,
respectively.
Loss-of-function
mutations are associated
with familial adrenal
hyperplasia and
hypertension. Inhibited
by metyrapone [629]
Converts corticosterone
to aldosterone
Converts pregnenolone
and progesterone to
17α-hydroxypregnenolone
and
17α-hydroxyprogesterone,
respectively. Converts
17α-hydroxypregnenolone
and
17α-hydroxyprogesterone
to
dehydroepiandrosterone
and androstenedione,
respectively. Converts
corticosterone to
cortisol.
Converts
androstenedione and
testosterone to estrone
and 17β-estradiol,
respectively. Inhibited by
anastrozole [475], and
letrozole [46]
– Converts progesterone
and
17α-hydroxyprogesterone
to deoxycortisone and
11-deoxycortisol,
respectively
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CYP24, CYP26 and CYP27 families
Enzymes → Cytochrome P450 → CYP24, CYP26 and CYP27 families
Nomenclature CYP24A1 CYP26A1 CYP26B1 CYP26C1 CYP27A1 CYP27B1 CYP27C1
Common abbreviation – – – – Sterol 27-hydroxylase – –
HGNC, UniProt CYP24A1, Q07973 CYP26A1, O43174 CYP26B1, Q9NR63 CYP26C1, Q6V0L0 CYP27A1, Q02318 CYP27B1, O15528 CYP27C1, Q4G0S4
EC number 1.14.15.16 1.14.-.- 1.14.-.- 1.14.-.- 1.14.15.15 1.14.15.18 1.14.19.53
Inhibitors MK-24 (pIC50 8.1)
[298], compound 3a
(pIC50 8.1) [298],
compound 4d (pIC50
4.8) [3]
– – – compound 4d (pIC50
7.2) [3], MK-24 (pIC50
<6) [298]
MK-24 (pIC50 6.3) [298] –
Selective inhibitors – compound 5 (pIC50 9.5)
[212]
– – – – –
Comments Converts
1,25-dihydroxyvitamin D3
(calcitriol) to 1α,24R,25-
trihydroxyvitamin
D3.
Converts retinoic acid to
4-hydroxyretinoic acid.
Inhibited by liarozole
Converts retinoic acid to
4-hydroxyretinoic acid.
Converts retinoic acid to
4-hydroxyretinoic acid
[578].
Converts cholesterol to
27-hydroxycholesterol.
Converts
25-hydroxyvitamin D3 to
1,25-dihydroxyvitamin D3
(calcitriol)
Converts retinol (vitamin
A1) to
3,4-didehydroretinol
(vitamin A2) [328].
CYP39, CYP46 and CYP51 families
Enzymes → Cytochrome P450 → CYP39, CYP46 and CYP51 families
Nomenclature CYP39A1 CYP46A1 CYP51A1
Common abbreviation – Cholesterol 24-hydroxylase Lanosterol 14-α-demethylase
HGNC, UniProt CYP39A1, Q9NYL5 CYP46A1, Q9Y6A2 CYP51A1, Q16850
EC number 1.14.14.26 1.14.14.25 –
Inhibitors – – azalanstat (pKi 9.1) [618]
Comments Converts 24-hydroxycholesterol to
7α,24-dihydroxycholesterol [351].
Converts cholesterol to 24(S)-hydroxycholesterol. Converts lanosterol to 4,4-dimethylcholesta-8.14.24-trienol.
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Further reading on Cytochrome P450
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DNA topoisomerases
Enzymes → DNA topoisomerases
Overview: DNA topoisomerases regulate the supercoiling of nuclear DNA to inﬂuence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the
DNA to allow unwinding, followed by re-attachment to reseal the backbone. Members of the family are targetted in anti-cancer chemotherapy.
Nomenclature DNA topoisomerase I DNA topoisomerase II alpha
HGNC, UniProt TOP1, P11387 TOP2A, P11388
EC number 5.99.1.2 5.99.1.2
Inhibitors irinotecan [148, 586] – Bovine etoposide (pIC50 7.3), teniposide [151] – Mouse
Further reading on DNA topoisomerases
Bansal S et al. (2017) Topoisomerases: Resistance versus Sensitivity, How Far We Can Go? Med Res
Rev 37: 404-438 [PMID:27687257]
Capranico G et al. (2017) Type I DNA Topoisomerases. J. Med. Chem. 60: 2169-2192
[PMID:28072526]
Nagaraja V et al. (2017) DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov.
Today 22: 510-518 [PMID:27856347]
Pommier Y et al. (2016) Roles of eukaryotic topoisomerases in transcription, replication and genomic
stability. Nat. Rev. Mol. Cell Biol. 17: 703-721 [PMID:27649880]
Seol Y et al. (2016) The dynamic interplay between DNA topoisomerases and DNA topology. Biophys
Rev 8: 101-111 [PMID:28510219]
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Endocannabinoid turnover
Enzymes → Endocannabinoid turnover
Overview: The principle endocannabinoids are 2-
acylglycerol esters, such as 2-arachidonoylglycerol (2-
AG), and N-acylethanolamines, such as anandamide (N-
arachidonoylethanolamine, AEA). The glycerol esters and
ethanolamides are synthesised and hydrolysed by parallel, in-
dependent pathways. Mechanisms for release and re-uptake of
endocannabinoids are unclear, although potent and selective
inhibitors of facilitated diffusion of endocannabinoids across
cell membranes have been developed [232]. FABP5 (Q01469)
has been suggested to act as a canonical intracellular endo-
cannabinoid transporter in vivo [99]. For the generation of
2-arachidonoylglycerol, the key enzyme involved is diacylglyc-
erol lipase (DAGL), whilst several routes for anandamide syn-
thesis have been described, the best characterized of which
involves N-acylphosphatidylethanolamine-phospholipase D
(NAPE-PLD, [543]). A transacylation enzyme which forms N-
acylphosphatidylethanolamines has been identiﬁed as a cytosolic
enzyme, PLA2G4E (Q3MJ16) [443]. In vitro experiments indi-
cate that the endocannabinoids are also substrates for oxidative
metabolism via cyclooxygenase, lipoxygenase and cytochrome
P450 enzyme activities [14, 179, 555].
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N-Acylethanolamine turnover
Enzymes → Endocannabinoid turnover → N-Acylethanolamine turnover
Nomenclature N-Acylphosphatidylethanolamine-
phospholipase D
Fatty acid amide hydrolase Fatty acid amide hydrolase-2 N-Acylethanolamine acid amidase
Common abbreviation NAPE-PLD FAAH FAAH2 NAAA
HGNC, UniProt NAPEPLD, Q6IQ20 FAAH, O00519 FAAH2, Q6GMR7 NAAA, Q02083
EC number – 3.5.1.99: anandamide + H2O <=> arachidonic
acid + ethanolamine
oleamide + H2O <=> oleic acid + NH3
3.5.1.99: anandamide + H2O <=>
arachidonic acid + ethanolamine
oleamide + H2O <=> oleic acid +
NH3
3.5.1.-
Rank order of afﬁnity – anandamide > oleamide > N-oleoylethanolamide
> N-palmitoylethanolamine [634]
oleamide > N-oleoylethanolamide >
anandamide >
N-palmitoylethanolamine [634]
N-palmitoylethanolamine > MEA >
SEA ≥ N-oleoylethanolamide >
anandamide [606]
Selective inhibitors – ASP8477 (pIC50 8.4) [628], JNJ1661010 (pIC50
7.8) [308], PF750 (pIC50 6.3–7.8) [7], OL135
(pIC50 7.4) [634], MM-433593 (pIC50 7), URB597
(pIC50 6.3–7) [634], PF3845 (pIC50 6.6) [8]
OL135 (pIC50 7.9–8.4) [305, 634],
URB597 (pIC50 7.5–8.3) [305, 634],
ASP8477 (pIC50 7.2) [628]
F215 (pIC50 8.1) [348, 349], ARN726
(Irreversible inhibition) (pIC50 7.6)
[499], S-OOPP (pIC50 6.4) [557] –
Rat, CCP (pIC50 5.3) [601]
Comments NAPE-PLD activity appears to be
enhanced by polyamines in the
physiological range [362], but fails to
transphosphatidylate with alcohols
[467] unlike
phosphatidylcholine-speciﬁc
phospholipase D.
– The FAAH2 gene is found in many
primate genomes, marsupials, and
other distantly related vertebrates,
but not a variety of lower placental
mammals, including mouse and rat
[634].
–
Comments: Routes for N-acylethanolamine biosynthesis other than through NAPE-PLD activity have been identiﬁed [602].
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2-Acylglycerol ester turnover
Enzymes → Endocannabinoid turnover → 2-Acylglycerol ester turnover
Overview: ABHD12 is a 398-aa protein, with serine hydrolase activity. It has a molecular weight of 45 kDa. A single TM is predicted at 75-95, with an extracellular catalytic domain. ABHD12 is a
monoacylglycerol hydrolase [432], but may also regulate lysophosphatidylserine levels [300]. Loss-of-function mutations in ABHD12 are associated with a disorder known as PHARC (polyneuropathy,
hearing loss, ataxia, retinitis pigmentosa, and cataracts) [172].
Nomenclature Diacylglycerol lipase α Diacylglycerol lipase β Monoacylglycerol lipase αβ-Hydrolase 6 αβ-Hydrolase 12
Common abbreviation DAGLα DAGLβ MAGL ABHD6 –
HGNC, UniProt DAGLA, Q9Y4D2 DAGLB, Q8NCG7 MGLL, Q99685 ABHD6, Q9BV23 ABHD12, Q8N2K0
EC number 3.1.1.- 3.1.1.- 3.1.1.23 3.1.1.23 3.1.1.23
Endogenous substrates diacylglycerol diacylglycerol 2-oleoyl glycerol =
2-arachidonoylglycerol 
anandamide [204]
1-arachidonoylglycerol >
2-arachidonoylglycerol >
1-oleoylglycerol > 2-oleoyl glycerol
[432]
–
Inhibitors LEI105 (pIC50 8.5) [30], DH376 (pIC50
8.2) [441], DO34 (pIC50 8.2) [441],
KT-109 (pIC50 5.6) [268]
DH376 (pIC50 8.6) [441], DO34
(pIC50 8.1) [441], LEI105 (pIC50 8.1)
[30], KT-109 (pIC50 7.1) [268]
MJN110 (pIC50 8) [436] – –
Selective inhibitors – – JJKK 048 (pIC50 9.3) [1], KML29
(pIC50 8.5) [88], JZL184 (pIC50 8.1)
[367]
WWL70 (pIC50 7.2) [346], WWL123
(pIC50 6.4) [25]
DO264 (pIC50 8) [442]
Comments – – – WWL70 has also been suggested to
have activity at oxidative metabolic
pathways independent of ABHD6
[582].
–
Comments on Endocannabinoid turnover: Many of the
compounds described as inhibitors are irreversible and so potency
estimates will vary with incubation time. FAAH2 is not found
in rodents [634] and a limited range of inhibitors have been as-
sessed at this enzyme activity. 2-arachidonoylglycerol has been
reported to be hydrolysed by multiple enzyme activities from
neural preparations [31], including ABHD2 (P08910) [412] and
carboxylesterase 1 (CES1, P23141 [656]). ABHD2 (P08910) has
also been described as a triacylglycerol lipase and ester hydrolase
[384], while ABHD12 (Q8N2K0) is also able to hydrolyse lysophos-
phatidylserine [598]. ABHD12 (Q8N2K0) has been described to be
inhibited selectively by pentacyclic triterpenoids, such as oleano-
lic acid [460].
Further reading on Endocannabinoid turnover
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Eicosanoid turnover
Enzymes → Eicosanoid turnover
Overview: Eicosanoids are 20-carbon fatty acids, where the
usual focus is the polyunsaturated analogue arachidonic acid and
its metabolites. Arachidonic acid is thought primarily to de-
rive from phospholipase A2 action on membrane phosphatidyl-
choline, andmay be re-cycled to form phospholipid through con-
jugation with coenzyme A and subsequently glycerol derivatives.
Oxidative metabolism of arachidonic acid is conducted through
three major enzymatic routes: cyclooxygenases; lipoxygenases
and cytochrome P450-like epoxygenases, particularly CYP2J2. Iso-
prostanes are structural analogues of the prostanoids (hence the
nomenclature D-, E-, F-isoprostanes and isothromboxanes), which
are produced in the presence of elevated free radicals in a non-
enzymaticmanner, leading to suggestions for their use as biomark-
ers of oxidative stress. Molecular targets for their action have yet
to be deﬁned.
Cyclooxygenase
Enzymes → Eicosanoid turnover → Cyclooxygenase
Overview: Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor : oxygen oxidoreductase) activity, catal-
yses the formation of PGG2 from arachidonic acid. Hydroperoxidase activity inherent in the enzyme catalyses the formation of PGH2 from PGG2. COX-1 and -2 can be nonselectively inhibited by
ibuprofen, ketoprofen, naproxen, indomethacin and paracetamol (acetaminophen). PGH2 may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an
apparently tissue-dependent manner.
Nomenclature COX-1 COX-2
HGNC, UniProt PTGS1, P23219 PTGS2, P35354
EC number 1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen
acceptor + H2O + PGH2
arachidonic acid => PGG2 => PGH2
This enzyme is also associated with the following reaction::
docosahexaenoic acid => PGH3
1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen
acceptor + H2O + PGH2
arachidonic acid => PGG2 => PGH2
This enzyme is also associated with the following reaction::
docosahexaenoic acid => PGH3
Selective activators – SC-236 (Inhibition) (pIC50 8) [464]
Inhibitors bromfenac (pIC50 8.1) [22], diclofenac (pIC50 7.9) [697],
meclofenamic acid (pIC50 7.3) [299], ﬂurbiprofen (pIC50 7.1) [627],
fenoprofen (pIC50 6.8) [22], ketoprofen (pIC50 6.5) [70], suprofen (pIC50
6.2) [70]
benzquinamide (pIC50 8.3) [22], ﬂurbiprofen (pIC50 8) [36],
meclofenamic acid (pIC50 7.4) [299], carprofen (pIC50 7) [257], ketorolac
(pIC50 6.9) [615], nimesulide (pIC50 6.2) [453], ketoprofen (pIC50 6.2)
[70]
Selective inhibitors ketorolac (pIC50 9.7) [627], FK-881 (pIC50 8.3) [275], SC-560 (pIC50 8.1)
[551], FR122047 (pIC50 7.5) [440]
celecoxib (pIC50 8.7) [50], valdecoxib (pIC50 8.3) [581], diclofenac
(pIC50 7.7) [54], rofecoxib (pIC50 6.1–6.5) [627], lumiracoxib (pKi 6.5)
[55], meloxicam (pIC50 6.3) [340], etoricoxib (pIC50 6) [503]
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Prostaglandin synthases
Enzymes → Eicosanoid turnover → Prostaglandin synthases
Overview: Subsequent to the formation of PGH2, the
cytochrome P450 activities thromboxane synthase (CYP5A1,
TBXAS1, P24557 , EC 5.3.99.5) and prostacyclin synthase
(CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A2
and prostacyclin (PGI2), respectively. Additionally, multiple en-
zyme activities are able to generate prostaglandin E2 (PGE2),
prostaglandin D2 (PGD2) and prostaglandin F2α (PGF2α). PGD2
can be metabolised to 9α,11β-prostacyclin F2α through the multi-
functional enzyme activity of AKR1C3. PGE2 can be metabolised
to 9α,11β-prostaglandin F2α through the 9-ketoreductase activity
of CBR1. Conversion of the 15-hydroxyecosanoids, including
prostaglandins, lipoxins and leukotrienes to their keto derivatives
by the NAD-dependent enzyme HPGD leads to a reduction in
their biological activity.
Nomenclature CYP5A1 CYP8A1 mPGES1 mPGES2 cPGES L-PGDS
Common abbreviation Thromboxane synthase Prostacyclin synthase – – – –
HGNC, UniProt TBXAS1, P24557 PTGIS, Q16647 PTGES, O14684 PTGES2, Q9H7Z7 PTGES3, Q15185 PTGDS, P41222
EC number 5.3.99.5: PGH2 =
thromboxane A2
5.3.99.4 5.3.99.3: PGH2 = PGE2 5.3.99.3: PGH2 = PGE2 5.3.99.3: PGH2 = PGE2 5.3.99.2: PGH2 = PGD2
Cofactors – – glutathione dihydrolipoic acid – –
Inhibitors ozagrel (pIC50 8.4) [259] compound 7p (pIC50 >6)
[166]
compound 44 (pIC50 9)
[207]
compound 30 (pIC50 <6)
[502]
– –
Selective inhibitors – – compound 39 (pIC50 8.4)
[541]
– – AT-56 (pKi 4.1) [277]
Comments Inhibited by dazoxiben
[489], camonagrel [222] and
furegrelate sodium
(U-63557A: PubChem
CID 23663954) [213].
Converts PGH2 to PGI2
[244]. Inhibited by
tranylcypromine [221]
– – Phosphorylated and
activated by casein kinase 2
(CK2) [317].
Appears to regulate steroid
hormone function by
interaction with dimeric
hsp90 [85, 292].
–
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Nomenclature H-PGDS AKR1C3 CBR1 HPGD
HGNC, UniProt HPGDS, O60760 AKR1C3, P42330 CBR1, P16152 HPGD, P15428
EC number 5.3.99.2: PGH2 = PGD2 1.3.1.20
1.1.1.188: PGD2 + NADP+ = PGF2α + NADPH
+ H+
1.1.1.64
1.1.1.239
1.1.1.213
1.1.1.184
1.1.1.189: PGE2 + NADP+ = PGF2α + NADPH
+ H+
1.1.1.197
1.1.1.141
15-hydroxyprostaglandins =>
15-ketoprostaglandins
LXA4 => 15-keto-lipoxin A4
Cofactors – NADP+ NADP+ –
Inhibitors HQL-79 (pIC50 5.3–5.5) [19] tolfenamic acid (pKi 8.1) [481]
ﬂufenamic acid, indomethacin, ﬂavonoids such
as 2’-Hydroxyﬂavanone (pIC50 6.5) [398, 550]
wedelolactone (pIC50 5.4) [681] compound 3 (pIC50 8.1) [653]
Comments – AKR1C3 also exhibits an hydroxysteroid
dehydrogenase activity.
– –
Comments: YS121 has been reported to inhibit mPGES1 and 5-LOX with a pIC50 value of 5.5 [320].
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Lipoxygenases
Enzymes → Eicosanoid turnover → Lipoxygenases
Overview: The lipoxygenases (LOXs) are a structurally related family of non-heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For
arachidonic acid as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are ﬁve lipoxygenases, the 5S-(arachidonate : oxygen 5-oxidoreductase), 12R-(arachidonate
12-lipoxygenase, 12R-type), 12S-(arachidonate : oxygen 12-oxidoreductase), and two distinct 15S-(arachidonate : oxygen 15-oxidoreductase) LOXs that oxygenate arachidonic acid in different positions
along the carbon chain and form the corresponding 5S-, 12S-, 12R-, or 15S-hydroperoxides, respectively.
Nomenclature 5-LOX 12R-LOX 12S-LOX 15-LOX-1 15-LOX-2 E-LOX
HGNC, UniProt ALOX5, P09917 ALOX12B, O75342 ALOX12, P18054 ALOX15, P16050 ALOX15B, O15296 ALOXE3, Q9BYJ1
EC number 1.13.11.34: arachidonic acid +
O2 = LTA4 + H2O
1.13.11.31
arachidonic acid + O2 =>
12R-HPETE
1.13.11.31
arachidonic acid + O2 =>
12S-HPETE
1.13.11.33:
arachidonic acid + O2 =
15S-HPETE
linoleic acid + O2 =>
13S-HPODE
1.13.11.33:
arachidonic acid + O2 =
15S-HPETE
1.13.11.-
Substrates – methyl arachidonate – – – –
Endogenous substrates arachidonic acid – – – – 12R-HPETE
Endogenous activators 5-LOX activating protein
(ALOX5AP, P20292)
– – – – –
Endogenous inhibitors Protein kinase A-mediated
phosphorylation [379]
– – – – –
Inhibitors – – – ML351 (pIC50 6.7) [485] compound 21n (pIC50
7.3) [636]
–
Selective inhibitors CJ13610 (pIC50 7.2) [169],
PF-04191834 (pIC50 6.6) [396],
zileuton (pIC50 6.4) [81]
– ML355 (pIC50 6.5) [374] compound 34 (pKi >8)
[486]
– –
Comments FLAP activity can be inhibited by
MK-886 [147] and BAY-X1005
[245] leading to a selective
inhibition of 5-LOX activity
– – – Inhibited by
MLS000536924 (pKi 5.6)
[286].
E-LOX metabolises the product
from the 12R-lipoxygenase
(12R-HPETE) to a speciﬁc
epoxyalcohol compound [669].
Comments: An 8-LOX (EC 1.13.11.40, arachidonate:oxygen 8-oxidoreductase) may be the mouse orthologue of 15-LOX-2 [190]. Some general LOX inhibitors are nordihydroguiaretic acid and esculetin.
Zileuton and caffeic acid are used as 5-lipoxygenase inhibitors, while baicalein and CDC are 12-lipoxygenase inhibitors. The speciﬁcity of these inhibitors has not been rigorously assessed with all LOX
forms: baicalein, along with other ﬂavonoids, such as ﬁsetin and luteolin, also inhibits 15-LOX-1 [514].
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Leukotriene and lipoxin metabolism
Enzymes → Eicosanoid turnover → Leukotriene and lipoxin metabolism
Overview: Leukotriene A4 (LTA4), produced by 5-LOX activ-
ity, and lipoxins may be subject to further oxidative metabolism;
ω-hydroxylation is mediated by CYP4F2 and CYP4F3, while β-
oxidation in mitochondria and peroxisomes proceeds in a man-
ner dependent on coenzyme A conjugation. Conjugation of LTA4
at the 6 position with reduced glutathione to generate LTC4 oc-
curs under the inﬂuence of leukotriene C4 synthase, with the
subsequent formation of LTD4 and LTE4, all three of which are
agonists at CysLT receptors. LTD4 formation is catalysed by γ-
glutamyltransferase, and subsequently dipeptidase 2 removes the
terminal glycine from LTD4 to generate LTE4. Leukotriene A4
hydrolase converts the 5,6-epoxide LTA4 to the 5-hydroxylated
LTB4, an agonist for BLT receptors. LTA4 is also acted upon by
12S-LOX to produce the trihydroxyeicosatetraenoic acids lipox-
ins LXA4 and LXB4. Treatment with a LTA4 hydrolase inhibitor in
a murine model of allergic airway inﬂammation increased LXA4
levels, in addition to reducing LTB4, in lung lavage ﬂuid [491].
LTA4 hydrolase is also involved in biosynthesis of resolvin Es.
Aspirin has been reported to increase endogenous forma-
tion of 18S-hydroxyeicosapentaenoate (18S-HEPE) compared
with 18R-HEPE, a resolvin precursor. Both enantiomers may
be metabolised by human recombinant 5-LOX; recombinant
LTA4 hydrolase converted chiral 5S(6)-epoxide-containing inter-
mediates to resolvin E1 and 18S-resolvin E1 [444].
Nomenclature Leukotriene C4 synthase γ-Glutamyltransferase Dipeptidase 1 Dipeptidase 2 Leukotriene A4 hydrolase
HGNC, UniProt LTC4S, Q16873 GGCT, O75223 DPEP1, P16444 DPEP2, Q9H4A9 LTA4H, P09960
EC number 4.4.1.20: LTC4 =
glutathione + LTA4
2.3.2.2: (5-L-glutamyl)-peptide + an
amino acid = a peptide + a 5-L-glutamyl
amino acid
LTC4 + H2O => LTD4 + L-glutamate
3.4.13.19: LTD4 + H2O = LTE4 + glycine 3.4.13.19: LTD4 + H2O = LTE4 + glycine 3.3.2.6
Inhibitors example 36 (pIC50 8.1)
[508], compound 39
(pIC50 <5.5) [541]
GGsTop (pKi 3.8) [235] cilastatin (pKi 6) [215] – bestatin (pKi 5.4) [450]
Comments: LTA4H is a member of a family of arginyl aminopep-
tidases (ENSFM00250000001675), which also includes aminopep-
tidase B (RNPEP, 9H4A4) and aminopeptidase B-like 1 (RNPEPL1,
Q9HAU8). Dipeptidase 1 and 2 are members of a family of mem-
brane dipeptidases, which also includes (DPEP3, Q9H4B8) for
which LTD4 appears not to be a substrate.
Further reading on Eicosanoid turnover
Ackermann JA et al. (2017) The double-edged role of 12/15-lipoxygenase during inﬂammation and
immunity. Biochim. Biophys. Acta 1862: 371-381 [PMID:27480217]
Grosser T et al. (2017) The Cardiovascular Pharmacology of Nonsteroidal Anti-Inﬂammatory Drugs.
Trends Pharmacol. Sci. 38: 733-748 [PMID:28651847]
Haeggstrom JZ. (2018) Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest 128:
2680-2690 [PMID:30108195]
Hafner AK et al. (2019) Beyond leukotriene formation-The noncanonical functions of 5-
lipoxygenase. Prostaglandins Other Lipid Mediat 142: 24-32 [PMID:30930090]
Mitchell JA and Kirkby NS. (2019) Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascu-
lar system. Br J Pharmacol 176: 1038-1050 [PMID:29468666]
Koeberle A et al. (2015) Perspective of microsomal prostaglandin E2 synthase-1 as drug target in
inﬂammation-related disorders. Biochem. Pharmacol. 98: 1-15 [PMID:26123522]
Kuhn H et al. (2015) Mammalian lipoxygenases and their biological relevance. Biochim. Biophys.
Acta 1851: 308-30 [PMID:25316652]
Patrignani P et al. (2015) Cyclooxygenase inhibitors: From pharmacology to clinical read-outs.
Biochim. Biophys. Acta 1851: 422-32 [PMID:25263946]
Rådmark O et al. (2015) 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and
disease. Biochim. Biophys. Acta 1851: 331-9 [PMID:25152163]
Sasaki Y et al. (2017) Role of prostacyclin synthase in carcinogenesis. Prostaglandins Other Lipid Me-
diat. 133: 49-52 [PMID:28506876]
Seo MJ et al. (2017) Prostaglandin synthases: Molecular characterization and involvement in
prostaglandin biosynthesis. Prog. Lipid Res. 66: 50-68 [PMID:28392405]
Vitale P et al. (2016) COX-1 Inhibitors: Beyond Structure Toward Therapy. Med Res Rev 36: 641-71
[PMID:27111555]
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GABA turnover
Enzymes → GABA turnover
Overview: The inhibitory neurotransmitter γ-aminobutyrate
(GABA, 4-aminobutyrate) is generated in neurones by glutamic
acid decarboxylase. GAD1 and GAD2 are differentially expressed
during development, where GAD2 is thought to subserve a trophic
role in early life and is distributed throughout the cytoplasm.
GAD1 is expressed in later life and is more associated with nerve
terminals [160] where GABA is principally accumulated in vesi-
cles through the action of the vesicular inhibitory amino acid
transporter SLC32A1. The role of γ-aminobutyraldehyde de-
hydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is
less clear. Following release from neurons, GABA may interact
with either GABAA or GABAB receptors and may be accumu-
lated in neurones and glia through the action of members of
the SLC6 family of transporters. Successive metabolism through
GABA transaminase and succinate semialdehyde dehydrogenase
generates succinic acid, which may be further metabolized in the
mitochondria in the tricarboxylic acid cycle.
Nomenclature Glutamic acid decarboxylase 1 Glutamic acid decarboxylase 2
Common abbreviation GAD1 GAD2
HGNC, UniProt GAD1, Q99259 GAD2, Q05329
EC number 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2
Endogenous substrates L-glutamic acid, L-aspartic acid L-glutamic acid, L-aspartic acid
Products GABA GABA
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate
Selective inhibitors s-allylglycine s-allylglycine
Comments L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-alanine [65]. Autoantibodies
against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).
Nomenclature aldehyde dehydrogenase 9 family member A1 4-aminobutyrate aminotransferase aldehyde dehydrogenase 5 family member A1
Common abbreviation – GABA-T SSADH
HGNC, UniProt ALDH9A1, P49189 ABAT, P80404 ALDH5A1, P51649
EC number 1.2.1.19: 4-aminobutanal + NAD + H2O = GABA + NADH +
H+
1.2.1.47: 4-trimethylammoniobutanal + NAD + H2O =
4-trimethylammoniobutanoate + NADPH + 2H+
1.2.1.3: an aldehyde + H2O + NAD = a carboxylate + 2H+ +
NADH
2.6.1.19: GABA + α-ketoglutaric acid = L-glutamic acid +
4-oxobutanoate
2.6.1.22: (S)-3-amino-2-methylpropanoate +
α-ketoglutaric acid = 2-methyl-3-oxopropanoate +
L-glutamic acid
1.2.1.24: 4-oxobutanoate + NAD + H2O = succinic acid +
NADH + 2H+
4-hydroxy-trans-2-nonenal + NAD + H2O =
4-hydroxy-trans-2-nonenoate + NADH + 2H+
Cofactors NAD pyridoxal 5-phosphate NAD [536]
Inhibitors – vigabatrin (Irreversible inhibition) (pKi 3.1) [356, 542] 4-acryloylphenol (pIC50 6.5) [587]
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Further reading on GABA turnover
Koenig MK et al. (2017) Phenotype of GABA-transaminase deﬁciency. Neurology 88: 1919-1924
[PMID:28411234]
Lee H et al. (2015) Ornithine aminotransferase versus GABA aminotransferase: implications for the
design of new anticancer drugs. Med Res Rev 35: 286-305 [PMID:25145640]
Glycerophospholipid turnover
Enzymes → Glycerophospholipid turnover
Overview: Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).
Phosphoinositide-speciﬁc phospholipase C
Enzymes → Glycerophospholipid turnover → Phosphoinositide-speciﬁc phospholipase C
Overview: Phosphoinositide-speciﬁc phospholipase C (PLC,
EC 3.1.4.11), catalyses the hydrolysis of PIP2 to IP3 and 1,2-
diacylglycerol, each of which have major second messenger func-
tions. Two domains, X and Y, essential for catalytic activity,
are conserved in the different forms of PLC. Isoforms of PLC-β
are activated primarily by G protein-coupled receptors through
members of the Gq/11 family of G proteins. The receptor-
mediated activation of PLC-γ involves their phosphorylation by
receptor tyrosine kinases (RTK) in response to activation of a vari-
ety of growth factor receptors and immune system receptors. PLC-
1 may represent a point of convergence of signalling via both G
protein-coupled and catalytic receptors. Ca2+ ions are required for
catalytic activity of PLC isoforms and have been suggested to be
the major physiological form of regulation of PLC-δ activity. PLC
has been suggested to be activated non-selectively by the small
molecule m3M3FBS [29], although this mechanism of action has
been questioned [330]. The aminosteroid U73122 has been de-
scribed as an inhibitor of phosphoinositide-speciﬁc PLC [552], al-
though its selectivity among the isoforms is untested and it has
been reported to occupy the H1 histamine receptor [272].
Nomenclature PLCβ1 PLCβ2 PLCβ3 PLCβ4
HGNC, UniProt PLCB1, Q9NQ66 PLCB2, Q00722 PLCB3, Q01970 PLCB4, Q15147
EC number 3.1.4.11: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H O = 1D-2 myo-inositol 1,4,5-trisphosphate + diacylglycerol
Endogenous activators Gαq, Gα11, Gβγ [255, 459, 554] Gα16, Gβγ, Rac2 (RAC2, P15153) [75, 273,
274, 341, 459]
Gαq, Gβγ [80, 341, 459] Gαq [288]
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Nomenclature PLCγ1 PLCγ2 PLCδ1 PLCδ3 PLCδ4
HGNC, UniProt PLCG1, P19174 PLCG2, P16885 PLCD1, P51178 PLCD3, Q8N3E9 PLCD4, Q9BRC7
EC number 3.1.4.11: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol
Endogenous activators PIP3 [28] PIP3, Rac1 (RAC1, P63000), Rac2
(RAC2, P15153), Rac3 (RAC3,
P60763) [28, 470, 619]
Transglutaminase II, p122-RhoGAP
{Rat}, spermine, Gβγ [229, 262,
425, 459]
– –
Endogenous inhibitors – – Sphingomyelin [462] – –
Inhibitors – CCT129957 (pIC50 5.5) [498] – – –
Nomenclature PLC1 PLCζ1 PLCη1 PLCη2
HGNC, UniProt PLCE1, Q9P212 PLCZ1, Q86YW0 PLCH1, Q4KWH8 PLCH2, O75038
EC number 3.1.4.11: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol
Endogenous activators Ras, rho [558, 645] – – Gβγ [677]
Comments: A series of PLC-like proteins (PLCL1, Q15111; PLCL2, Q9UPR0 and PLCH1, Q4KWH8) form a family with PLCδ and PLCζ1 isoforms, but appear to lack catalytic activity.
PLC-δ2 has been cloned from bovine sources [407].
Further reading on Phosphoinositide-speciﬁc phospholipase C
Cocco L et al. (2015) Phosphoinositide-speciﬁc phospholipase C in health and disease. J. Lipid Res.
56: 1853-60 [PMID:25821234]
Cockcroft S et al. (2016) Topological organisation of the phosphatidylinositol 4,5-bisphosphate-
phospholipase C resynthesis cycle: PITPs bridge the ER-PM gap. Biochem. J. 473: 4289-4310
[PMID:27888240]
Litosch I. (2015) Regulating G protein activity by lipase-independent functions of phospholipase C.
Life Sci. 137: 116-24 [PMID:26239437]
Nakamura Y et al. (2017) Regulation and physiological functions of mammalian phospholipase C. J.
Biochem. 161: 315-321 [PMID:28130414]
Swann K et al. (2016) The sperm phospholipase C-ζ and Ca2+ signalling at fertilization in mammals.
Biochem. Soc. Trans. 44: 267-72 [PMID:26862214]
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Phospholipase A2
Enzymes → Glycerophospholipid turnover → Phospholipase A2
Overview: Phospholipase A2 (PLA2, EC 3.1.1.4) cleaves
the sn-2 fatty acid of phospholipids, primarily phos-
phatidylcholine, to generate lysophosphatidylcholine and
arachidonic acid. Most commonly-used inhibitors (e.g.
bromoenol lactone, arachidonyl triﬂuoromethyl ketone or
methyl arachidonyl ﬂuorophosphonate) are either non-selective
within the family of phospholipase A2 enzymes or have activity
against other eicosanoid-metabolising enzymes.
Secreted or extracellular forms: sPLA2-1B, sPLA2-2A, sPLA2-
2D, sPLA2-2E, sPLA2-2F, sPLA2-3, sPLA2-10 and sPLA2-12A
Cytosolic, calcium-dependent forms: cPLA2-4A, cPLA2-4B,
cPLA2-4C, cPLA2-4D, cPLA2-4E and cPLA2-4F
Other forms: PLA2-G5, iPLA2-G6, PLA2-G7 and PAFAH2
(platelet-activating factor acetylhydrolase 2)
Nomenclature sPLA2-1B sPLA2-2A sPLA2-2D sPLA2-2E sPLA2-2F sPLA2-3
HGNC,
UniProt
PLA2G1B, P04054 PLA2G2A,
P14555
PLA2G2D, Q9UNK4 PLA2G2E, Q9NZK7 PLA2G2F, Q9BZM2 PLA2G3,
Q9NZ20
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4
Inhibitors compound 28xvii (pIC50 8.9) [231] – compound 12e (pIC50 8.1) [452] compound 12e (pIC50 8.1) [452] compound 12e (pIC50 7.3) [452] –
Comments – – – – – –
Nomenclature cPLA2-4A cPLA2-4B cPLA2-4C cPLA2-4D cPLA2-4E cPLA2-4F
HGNC, UniProt PLA2G4A, P47712 PLA2G4B, P0C869 PLA2G4C, Q9UP65 PLA2G4D, Q86XP0 PLA2G4E, Q3MJ16 PLA2G4F, Q68DD2
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4
Inhibitors compound 57 (pIC50 8.4) [375] – – – – –
Comments cPLA -4A also expresses lysophospholipase2
(EC 3.1.1.5) activity [539].
– – – – –
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Nomenclature PLA2-G5 iPLA2-G6 PLA2-G7 sPLA2-10 sPLA2-12A platelet activating factor acetylhydrolase 2
HGNC, UniProt PLA2G5, P39877 PLA2G6, O60733 PLA2G7, Q13093 PLA2G10, O15496 PLA2G12A, Q9BZM1 PAFAH2, Q99487
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.47
Inhibitors compound 12e (pIC50
7.5) [452]
– darapladib (pIC50 10) [51] compound 12e (pIC50
7.7) [452]
– –
Selective inhibitors– – rilapladib (Competitive)
(pIC50 9.6) [640]
– – –
Comments – – – – – PAFAH2 also expresses PAF hydrolase activity (EC 3.1.1.47)
Comments: The sequence of PLA2-2C suggests a lack of catalytic
activity, while PLA2-12B (GXIIB, GXIII sPLA2-like) appears to be
catalytically inactive [513]. A further fragment has been identiﬁed
with sequence similarities to Group II PLA2 members. Otoconin
90 (OC90) shows sequence homology to PLA2-G10.
A binding protein for secretory phospholipase A2 has been identi-
ﬁed which shows modest selectivity for sPLA2-1B over sPLA2-2A,
and also binds snake toxin phospholipase A2 [16]. The binding
protein appears to have clearance function for circulating secre-
tory phospholipase A2, as well as signalling functions, and is a
candidate antigen for idiopathic membraneous nephropathy [38].
PLA2-G7 and PAFAH2 also express platelet-activating factor acetyl-
hydrolase activity (EC 3.1.1.47).
Further reading on Phospholipase A2
Astudillo AM. (2019) Selectivity of phospholipid hydrolysis by phospholipase A2 enzymes in acti-
vated cells leading to polyunsaturated fatty acid mobilization. Biochim Biophys Acta Mol Cell Biol
Lipids 1864: 772-783 [PMID:30010011]
Kita Y etal. (2019) Cytosolic phospholipase A2 and lysophospholipid acyltransferases. Biochim Bio-
phys Acta Mol Cell Biol Lipids 1864: 838-845 [PMID:30905348]
Mouchlis VD and Dennis EA. (2019) Phospholipase A2 catalysis and lipid. mediator lipidomics.
Biochim Biophys Acta Mol Cell Biol Lipids 1864: 766-771 [PMID:30905345]
Murakami M et al. (2019) Group IID, IIE, IIF and III secreted phospholipase A2s. Biochim Biophys
Acta Mol Cell Biol Lipids. 1864: 803-818 [PMID:30905347]
Samuchiwal SK and Balestrieri B. (2019) Harmful and protective roles of group V phospholipase A2:
Current perspectives and future directions. Biochim Biophys Acta Mol Cell Biol Lipids 1864: 819-
826 [PMID:30308324]
Shayman JA and Tesmer JJG. (2019) Lysosomal phospholipase A2. Biochim Biophys Acta Mol Cell Biol
Lipids. 1864: 932-940 [PMID:30077006]
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Phosphatidylcholine-speciﬁc phospholipase D
Enzymes → Glycerophospholipid turnover → Phosphatidylcholine-speciﬁc phospholipase D
Overview: Phosphatidylcholine-speciﬁc phospholipase D (PLD, EC 3.1.4.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols,
such as butanol in a transphosphatidylation reaction [490].
Nomenclature PLD1 PLD2
HGNC, UniProt PLD1, Q13393 PLD2, O14939
EC number 3.1.4.4 3.1.4.4
A phosphatidylcholine + H2O <=> choline + a phosphatidate
Endogenous activators ADP-ribosylation factor 1 (ARF1, P84077), PIP2, RhoA, PKC evoked phosphorylation, RalA
[233, 378]
ADP-ribosylation factor 1 (ARF1, P84077), PIP2 [369], oleic acid [519]
Endogenous inhibitors Gβγ [478] Gβγ [478]
Inhibitors FIPI (pIC50 8) [530] –
Selective inhibitors compound 69 (pIC50 7.3) [530] VU0364739 (pIC50 7.7) [339]
Comments: A lysophospholipase D activity (ENPP2,
Q13822, also known as ectonucleotide pyrophos-
phatase/phosphodiesterase 2, phosphodiesterase I, nucleotide
pyrophosphatase 2, autotaxin) has been described, which not
only catalyses the production of lysophosphatidic acid (LPA)
from lysophosphatidylcholine, but also cleaves ATP (see God-
ing et al., 2003 [209]). Additionally, an N-acylethanolamine-
speciﬁc phospholipase D (NAPEPLD, Q6IQ20) has been char-
acterized, which appears to have a role in the generation of
endocannabinoids/endovanilloids, including anandamide [448].
This enzyme activity appears to be enhanced by polyamines in
the physiological range [362] and fails to transphosphatidylate
with alcohols [467].
Three further, less well-characterised isoforms are PLD3 (PLD3,
Q8IV08, other names Choline phosphatase 3, HindIII K4L ho-
molog, Hu-K4), PLD4 (PLD4, Q96BZ4, other names Choline
phosphatase 4, Phosphatidylcholine-hydrolyzing phospholipase,
D4C14orf175 UNQ2488/PRO5775) and PLD5 (PLD5, Q8N7P1).
PLD3 has been reported to be involved in myogenesis [451]. PLD4
is described not to have phospholipase D catalytic activity [665],
but has been associated with inﬂammatory disorders [447, 574,
593]. Sequence analysis suggests that PLD5 is catalytically inac-
tive.
Further reading on Phosphatidylcholine-speciﬁc phospholipase D
Brown HA et al. (2017) Targeting phospholipase D in cancer, infection and neurodegenerative dis-
orders. Nat Rev Drug Discov 16: 351-367 [PMID:28209987]
Frohman MA. (2015) The phospholipase D superfamily as therapeutic targets. Trends Pharmacol. Sci.
36: 137-44 [PMID:25661257]
Nelson RK et al. (2015) Physiological and pathophysiological roles for phospholipase D. J. Lipid Res.
56: 2229-37 [PMID:25926691]
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Lipid phosphate phosphatases
Enzymes → Glycerophospholipid turnover → Lipid phosphate phosphatases
Overview: Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to
generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase which acts
as a tumour suppressor by reducing cellular levels of PI 3,4,5-P, thereby toning down activity of PDK1 and PKB. Loss-of-function mutations are frequently identiﬁed as somatic mutations in cancers.
Nomenclature Lipin1 Lipin2 Lipin3 PPA2A PPA2B PPA3A phosphatase and
tensin homolog
Common abbreviation – – – – – – PTEN
HGNC, UniProt LPIN1, Q14693 LPIN2, Q92539 LPIN3, Q9BQK8 PLPP1, O14494 PLPP3, O14495 PLPP2, O43688 PTEN, P60484
EC number 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.67
3.1.3.48
3.1.3.16
Substrates – phosphatidic acid – – phosphatidic acid – phosphatidylinositol
(3,4,5)-trisphosphate
Further reading on Lipid phosphate phosphatases
Knafo S and Esteban JA. (2017) PTEN: Local and Global Modulation of Neuronal Function in Health
and Disease. Trends Neurosci 40: 83-91 [PMID:28081942]
Lee YR et al. (2018) The functions and regulation of the PTEN tumour suppressor: new modes and
prospects. Nat Rev Mol Cell Biol 19: 547-562 [PMID:29858604]
Yehia L et al. (2019) PTEN-opathies: from biological insights to evidence-based precision medicine.
J Clin Invest 129: 452-464 [PMID:30614812]
Phosphatidylinositol kinases
Enzymes → Glycerophospholipid turnover → Phosphatidylinositol kinases
Overview:
Phosphatidylinositol may be phosphorylated at either 3- or 4- po-
sitions on the inositol ring by PI 3-kinases or PI 4-kinases, respec-
tively.
Phosphatidylinositol 3-kinases
Phosphatidylinositol 3-kinases (PI3K, provisional nomenclature)
catalyse the introduction of a phosphate into the 3-position
of phosphatidylinositol (PI), phosphatidylinositol 4-phosphate
(PIP) or phosphatidylinositol 4,5-bisphosphate (PIP2). There
is evidence that PI3K can also phosphorylate serine/threonine
residues on proteins. In addition to the classes described be-
low, further serine/threonine protein kinases, including ATM
(Q13315) and mTOR (P42345), have been described to phos-
phorylate phosphatidylinositol and have been termed PI3K-
related kinases. Structurally, PI3Ks have common motifs of
at least one C2, calcium-binding domain and helical domains,
alongside structurally-conserved catalytic domains. Wortmannin
and LY 294002 are widely-used inhibitors of PI3K activities.
Wortmannin is irreversible and shows modest selectivity between
Class I and Class II PI3K, while LY294002 is reversible and selective
for Class I compared to Class II PI3K.
Class I PI3Ks (EC 2.7.1.153) phosphorylate phosphatidyli-
nositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-
trisphosphate and are heterodimeric, matching catalytic and reg-
ulatory subunits. Class IA PI3Ks include p110α, p110β and p110δ
catalytic subunits, with predominantly p85 and p55 regulatory
subunits. The single catalytic subunit that forms Class IB PI3K is
p110γ. Class IA PI3Ks are more associated with receptor tyrosine
kinase pathways, while the Class IB PI3K is linkedmore with GPCR
signalling.
Searchable database: http://www.guidetopharmacology.org/index.jsp Phosphatidylinositol kinases S349
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Class II PI3Ks (EC 2.7.1.154) phosphorylate phosphatidylinos-
itol to generate phosphatidylinositol 3-phosphate (and possibly
phosphatidylinositol 4-phosphate to generate phosphatidylinos-
itol 3,4-bisphosphate). Three monomeric members exist, PI3K-
C2α, β and β, and include Ras-binding, Phox homology and two
C2domains.
The only class III PI3K isoform (EC 2.7.1.137) is a heterodimer
formed of a catalytic subunit (VPS34) and regulatory subunit
(VPS15).
Phosphatidylinositol 4-kinases
Phosphatidylinositol 4-kinases (EC 2.7.1.67) generate phos-
phatidylinositol 4-phosphate and may be divided into higher
molecular weight type III and lower molecular weight type II
forms.
1-phosphatidylinositol 4-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → 1-phosphatidylinositol 4-kinase family
Nomenclature phosphatidylinositol 4-kinase alpha phosphatidylinositol 4-kinase beta
Common abbreviation PI4KIIIα/PIK4CA PI4KIIIβ/PIK4CB
HGNC, UniProt PI4KA, P42356 PI4KB, Q9UBF8
EC number 2.7.1.67 2.7.1.67
Endogenous activation – PKD-mediated phosphorylation [247]
Sub/family-selective inhibitors wortmannin (pIC50 6.7–6.8) [203, 408] wortmannin (pIC50 6.7–6.8) [203, 408]
Selective inhibitors – PIK-93 (pIC50 7.7) [34, 316]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1-phosphatidylinositol 4-kinase family S350
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Phosphatidylinositol-4-phosphate 3-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Phosphatidylinositol-4-phosphate 3-kinase family
Nomenclature phosphatidylinositol-4-phosphate 3-kinase catalytic subunit
type 2 alpha
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit
type 2 beta
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit
type 2 gamma
Common abbreviation C2α/PIK3C2A C2β/PIK3C2B C2γ/PIK3C2G
HGNC, UniProt PIK3C2A, O00443 PIK3C2B, O00750 PIK3C2G, O75747
EC number 2.7.1.154 2.7.1.154 2.7.1.154
Inhibitors torin 2 (pIC50 7.6) [363] PI-103 (pIC50 8) [248] –
Phosphatidylinositol 3-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Phosphatidylinositol 3-kinase family
Nomenclature phosphatidylinositol 3-kinase catalytic subunit type 3
Common abbreviation VPS34
HGNC, UniProt PIK3C3, Q8NEB9
EC number 2.7.1.137
Phosphatidylinositol-4,5-bisphosphate 3-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Phosphatidylinositol-4,5-bisphosphate 3-kinase family
Overview: PI3K activation is one of the most important signal transduction pathways used to transmit signals from cell-surface receptors to regulate intracellular processes (cell growth, survival,
proliferation and movement). PI3K catalytic (and regulatory) subunits play vital roles in normal cell function and in disease. Progress made in developing PI3K-targeted agents as potential therapeutics
for treating cancer and other diseases is reviewed by Fruman et al. (2017) [182].
Searchable database: http://www.guidetopharmacology.org/index.jsp Phosphatidylinositol-4,5-bisphosphate 3-kinase family S351
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Nomenclature phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
Common abbreviation PI3Kα PI3Kβ
HGNC, UniProt PIK3CA, P42336 PIK3CB, P42338
EC number 2.7.1.153
2.7.11.1
2.7.1.153
Inhibitors PIK-75 (pIC50 9.5) [248], gedatolisib (pIC50 9.4) [612], PF-04691502 (pKi 9.2) [360],
PI-103 (pIC50 8.7) [497], BGT-226 (pIC50 8.4) [392], KU-0060648 (pIC50 8.4) [76],
dactolisib (pIC50 8.4) [388], apitolisib (pIC50 8.3) [573], PIK-75 (pIC50 8.2) [316]
KU-0060648 (pIC50 9.3) [76], PI-103 (pIC50 8.5) [497], AZD6482 (pIC50 8) [438],
ZSTK474 (pIC50 7.4–7.8) [651, 658], apitolisib (pIC50 7.6) [573], BGT-226 (pIC50 7.2)
[392]
Sub/family-selective inhibitors pictilisib (pIC50 8.5) [174] pictilisib (pIC50 7.5) [174]
Selective inhibitors GSK1059615 (pIC50 8.7) [315] –
Nomenclature phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
Common abbreviation PI3Kγ PI3Kδ
HGNC, UniProt PIK3CG, P48736 PIK3CD, O00329
EC number 2.7.1.153 2.7.1.153
Inhibitors dactolisib (pIC50 8.3) [388], apitolisib (pIC50 7.8) [573], PI-103 (pIC50 7.8) [497],
BGT-226 (pIC50 7.4) [392], ZSTK474 (pIC50 7.3–7.3) [651, 658], TG-100-115 (pIC50
7.1) [456], alpelisib (pIC50 6.6) [187], KU-0060648 (pIC50 6.2) [76]
KU-0060648 (pIC50 >10) [76], idelalisib (in vitro activity against recombinant enzyme)
(pIC50 8.6) [336], PI-103 (pIC50 8.5) [497], ZSTK474 (pIC50 8.2–8.3) [651, 658],
apitolisib (pIC50 8.2) [573], dactolisib (pIC50 8.1) [388], alpelisib (pIC50 6.5) [187]
Sub/family-selective inhibitors pictilisib (pIC50 7.1) [174] pictilisib (pIC50 8.5) [174]
Selective inhibitors CZC 24832 (pIC50 7.6) [42] –
1-phosphatidylinositol-3-phosphate 5-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → 1-phosphatidylinositol-3-phosphate 5-kinase family
Nomenclature phosphoinositide kinase, FYVE-type zinc ﬁnger containing
HGNC, UniProt PIKFYVE, Q9Y2I7
EC number 2.7.1.150: ATP + 1-phosphatidyl-1D-myo-inositol 3-phosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate
Searchable database: http://www.guidetopharmacology.org/index.jsp 1-phosphatidylinositol-3-phosphate 5-kinase family S352
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Type I PIP kinases (1-phosphatidylinositol-4-phosphate 5-kinase family)
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Type I PIP kinases (1-phosphatidylinositol-4-phosphate 5-kinase family)
Overview: Type I PIP kinases are required for the production of the second messenger phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(4)P [487]. This enzyme family is
also known as type I PIP(5)Ks.
Nomenclature phosphatidylinositol-4-phosphate 5-kinase type 1 alpha phosphatidylinositol-4-phosphate 5-kinase type 1 gamma
Common abbreviation PIP5K1A PIP5K1C
HGNC, UniProt PIP5K1A, Q99755 PIP5K1C, O60331
EC number 2.7.1.68 2.7.1.68
Inhibitors ISA-2011B [532] –
Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family)
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family)
Overview: Type II PIP kinases are essential for the production of the second messenger phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(5)P [487]. This enzyme family
is also known as type II PIP(5)Ks.
Nomenclature phosphatidylinositol-5-phosphate 4-kinase type 2
alpha
phosphatidylinositol-5-phosphate 4-kinase type 2
beta
phosphatidylinositol-5-phosphate 4-kinase type 2
gamma
Common abbreviation PIP4K2A PIP4K2B PIP4K2C
HGNC, UniProt PIP4K2A, P48426 PIP4K2B, P78356 PIP4K2C, Q8TBX8
EC number 2.7.1.149
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
<=> ADP + 1-phosphatidyl-1D-myo-inositol
4,5-bisphosphate
2.7.1.149 2.7.1.149
Searchable database: http://www.guidetopharmacology.org/index.jsp Type II PIP kinases (1-phosphatidylinositol S353
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-
5-phosphate 4-kinase family)
Sphingosine kinase
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Sphingosine kinase
Overview: SPHK1 and SPHK2 are encoded by different genes
with some redundancy of function; genetic deletion of both
Sphk1 and Sphk2, but not either alone, is embryonic lethal in
mice. There are splice variants of each isoform (SphK1a-c and
SphK2a, b), distinguished by their N-terminal sequences. SPHK1
and SPHK2 differ in tissue distribution, sub-cellular localisation,
biochemical properties and regulation. They regulate discrete
pools of S1P. Receptor stimulation induces SPHK1 translocation
from the cytoplasm to the plasma membrane. SPHK1 transloca-
tion is regulated by phosphorylation/dephosphorylation, speciﬁc
protein:protein interactions and interaction with speciﬁc lipids at
the plasma membrane. SPHK1 is a dimeric protein, as conﬁrmed
by its crystal structure which forms a positive cluster, between pro-
tomers, essential for interaction with anionic phospholipids in the
plasma membrane. SPHK2 is localised to the ER or associated with
mitochondria or shuttles in/out of the nucleus, regulated by phos-
phorylation. Intracellular targets of nuclear S1P include the cat-
alytic subunit of telomerase (TERT) and regulators of gene expres-
sion including histone deacetylases (HDAC 1/2) and peroxisome
proliferator-activated receptor gamma (PPARγ). SPHK2 phospho-
rylates the pro-drug FTY720 (ﬁngolimod, which is used to treat
some forms of multiple sclerosis) to a mimic of S1P and that acts
as a functional antagonist of S1P1 receptors. Inhibitors of SPHK1
and SPHK2 have therapeutic potential in many diseases.
Nomenclature sphingosine kinase 1 sphingosine kinase 2
Common abbreviation SPHK1 SPHK2
HGNC, UniProt SPHK1, Q9NYA1 SPHK2, Q9NRA0
EC number 2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
dihydrosphingosine + ATP = sphingosine 1-phosphate + ADP
2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
dihydrosphingosine + ATP = sphingosine 1-phosphate + ADP
Cofactors Mg2+ [536] Mg2+
Inhibitors SKI II (pKi 4.8) [181], MP-A08 (pIC50 4.6) [474] MP-A08 (pKi 5.2) [474], SKI II (pKi 5.1) [196]
Selective inhibitors PF-543 (pKi 8.4) [527] SLC4101431 (pKi 7.1) [100], compound 27d (pIC50 6.8) [526], opaganib (pKi 5) [181],
ROMe (pKi 4.8) [354]
Comments SK1 inhibitors induce its proteasomal degradation [373, 404]. SK1 crystal structures conﬁrm
that it is dimeric [5]; there is no crystal structure available for SK2.
There is no crystal structure available for SK2.
Comments: MP-A08 is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (opaganib) has known off-target effects on dihydroceramide desaturase (DEGS1) [404,
610]) and induces proteasomal degradation of SK1 [404]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma
(to view ClinicalTrials.gov list click here).
Further reading on Sphingosine kinase
Adams DR et al. (2016) Sphingosine Kinases: Emerging Structure-Function Insights. Trends Biochem.
Sci. 41: 395-409 [PMID:27021309]
Lynch KR et al. (2016) Sphingosine kinase inhibitors: a review of patent literature (2006-2015). Expert
Opin Ther Pat 26: 1409-1416 [PMID:27539678]
Pitman MR et al. (2016) Recent advances in the development of sphingosine kinase inhibitors. Cell.
Signal. 28: 1349-63 [PMID:27297359]
Pulkoski-Gross MJ et al. (2018) An intrinsic lipid-binding interface controls sphingosine kinase 1
function. J. Lipid Res. 59: 462-474 [PMID:29326159]
Pyne NJ et al. (2017) Sphingosine Kinase 2 in Autoimmune/Inﬂammatory Disease and the Develop-
ment of Sphingosine Kinase 2 Inhibitors. Trends Pharmacol. Sci. 38: 581-591 [PMID:28606480]
Pyne S et al. (2018) Sphingosine Kinases as Druggable Targets. Handb Exp Pharmacol [PMID:29460151]
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Nomenclature phosphatidylinositol-4,
5-bisphosphate
3-kinase catalytic
subunit gamma
phosphatidylinositol 4-
kinase type 2 beta
phosphatidylinositol-4,
5-bisphosphate
3-kinase catalytic
subunit delta
phosphatidylinositol-4-
phosphate 3-kinase
catalytic subunit type 2
alpha
phosphatidylinositol-4-
phosphate 3-kinase
catalytic subunit type 2
beta
phosphatidylinositol-4-
phosphate 3-kinase
catalytic subunit type 2
gamma
phosphatidylinositol 3-
kinase catalytic subunit
type 3
Common abbreviation PI3Kγ PI4KIIβ/PI4K2B PI3Kδ C2α/PIK3C2A C2β/PIK3C2B C2γ/PIK3C2G VPS34
HGNC, UniProt PIK3CG, P48736 PI4K2B, Q8TCG2 PIK3CD, O00329 PIK3C2A, O00443 PIK3C2B, O00750 PIK3C2G, O75747 PIK3C3, Q8NEB9
EC number 2.7.1.153 2.7.1.67 2.7.1.153 2.7.1.154 2.7.1.154 2.7.1.154 2.7.1.137
Inhibitors dactolisib (pIC50 8.3)
[388], apitolisib (pIC50
7.8) [573], PI-103
(pIC50 7.8) [497],
BGT-226 (pIC50 7.4)
[392], ZSTK474 (pIC50
7.3–7.3) [651, 658],
TG-100-115 (pIC50 7.1)
[456], alpelisib (pIC50
6.6) [187],
KU-0060648 (pIC50
6.2) [76]
– KU-0060648 (pIC50
>10) [76], idelalisib (in
vitro activity against
recombinant enzyme)
(pIC50 8.6) [336],
PI-103 (pIC50 8.5)
[497], ZSTK474 (pIC50
8.2–8.3) [651, 658],
apitolisib (pIC50 8.2)
[573], dactolisib (pIC50
8.1) [388], alpelisib
(pIC50 6.5) [187]
torin 2 (pIC50 7.6)
[363]
PI-103 (pIC50 8) [248] – –
Sub/family-selective inhibitors pictilisib (pIC50 7.1)
[174]
adenosine (pIC50
4.5–5) [577]
pictilisib (pIC50 8.5)
[174]
– – – –
Selective inhibitors CZC 24832 (pIC50 7.6)
[42]
– – – – – –
Comments: Wortmannin also inhibits type III phosphatidylinositol 4-kinases and polo-like kinase [364]. PIK93 also inhibits PI 3-kinases [316]. Adenosine activates adenosine receptors.
Further reading on Phosphatidylinositol kinases
Raphael J et al. (2018) Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic
review and meta-analysis. Eur J Cancer 91: 38-46 [PMID:29331750]
Wang D et al. (2019) Upstream regulators of phosphoinositide 3-kinase and their role in diseases. J
Cell Physiol. [PMID:30710358]
Goncalves MD et al. (2018) Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J
Med 379: 2052-2062 [PMID:30462943]
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Phosphatidylinositol phosphate kinases
Enzymes → Glycerophospholipid turnover → Phosphatidylinositol phosphate kinases
Overview: PIP2 is generated by phosphorylation of PI 4-phosphate or PI 5-phosphate by type I PI 4-phosphate 5-kinases or type II PI 5-phosphate 4-kinases.
Nomenclature phosphatidylinositol-
4-phosphate 5-kinase type 1
alpha
phosphatidylinositol-
4-phosphate 5-kinase type 1
beta
phosphatidylinositol-
4-phosphate 5-kinase type 1
gamma
phosphatidylinositol-
5-phosphate 4-kinase type 2
alpha
phosphatidylinositol-
5-phosphate 4-kinase type 2
beta
phosphatidylinositol-
5-phosphate 4-kinase type 2
gamma
Common abbreviation PIP5K1A PIP5K1B PIP5K1C PIP4K2A PIP4K2B PIP4K2C
HGNC, UniProt PIP5K1A, Q99755 PIP5K1B, O14986 PIP5K1C, O60331 PIP4K2A, P48426 PIP4K2B, P78356 PIP4K2C, Q8TBX8
EC number 2.7.1.68 2.7.1.68 2.7.1.68 2.7.1.149
ATP + 1-phosphatidyl-1D-
myo-inositol 5-phosphate
<=> ADP + 1-phosphatidyl-
1D-myo-inositol
4,5-bisphosphate
2.7.1.149 2.7.1.149
Inhibitors ISA-2011B [532] – – – – –
Further reading on Glycerophospholipid turnover
Cauvin C et al. (2015) Phosphoinositides: Lipids with informative heads and mastermind functions
in cell division. Biochim. Biophys. Acta 1851: 832-43 [PMID:25449648]
Irvine RF. (2016) A short history of inositol lipids. J. Lipid Res. 57: 1987-1994 [PMID:27623846]
Poli A et al. (2016) Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate
Kinases and Phospholipases C. J. Cell. Physiol. 231: 1645-55 [PMID:26626942]
Haem oxygenase
Enzymes → Haem oxygenase
Overview: Haem oxygenase (heme,hydrogen-donor:oxygen oxidoreductase (α-methene-oxidizing, hydroxylating)), E.C. 1.14.99.3, converts heme into biliverdin and carbonmonoxide, utilizing NADPH
as cofactor.
Searchable database: http://www.guidetopharmacology.org/index.jsp Haem oxygenase S356
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Nomenclature Haem oxygenase 1 Haem oxygenase 2
Common abbreviation HO1 HO2
HGNC, UniProt HMOX1, P09601 HMOX2, P30519
EC number 1.14.14.18
Protoheme + 3 [reduced NADPH-hemoprotein reductase] + 3 O(2) <=> biliverdin +
Fe(2+) + CO + 3 [oxidized NADPH-hemoprotein reductase] + 3 H(2)O
1.14.14.18
Protoheme + 3 [reduced NADPH–hemoprotein reductase] + 3 O(2) <=> biliverdin +
Fe(2+) + CO + 3 [oxidized NADPH–hemoprotein reductase] + 3 H(2)O
Inhibitors – compound 1 (pIC50 3.5) [616] – Rat
Comments: The existence of a third non-catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene [250]. The chemical tin protoporphyrin IX
acts as a haem oxygenase inhibitor in rat liver with an IC50 value of 11 nM [152].
Further reading on Haem oxygenase
Magierowska K et al. (2018) Emerging role of carbon monoxide in regulation of cellular pathways
and in the maintenance of gastric mucosal integrity. Pharmacol Res 129: 56-64 [PMID:29360501]
Rochette L et al. (2018) Redox Functions of Heme Oxygenase-1 and Biliverdin Reductase in Diabetes
Trends. Endocrinol Metab. 29: 74-85 [PMID:29249571]
Salerno L et al. (2017) Heme oxygenase-1: A new druggable target in the management of chronic
and acute myeloid leukemia. Eur J Med Chem. 142: 163-178 [PMID:28756878]
Sebastian VP et al. (2018) Heme Oxygenase-1 as a Modulator of Intestinal Inﬂammation Develop-
ment and Progression. Front Immunol. 9: 1956 [PMID:30258436]
Tomczyk M et al. (2019) Modulation of the monocyte/macrophage system in heart failure by target-
ing heme oxygenase-1. Vascul Pharmacol. 112: 79-90 [PMID:30213580]
Vijayan V et al. (2018) The macrophage heme-heme oxygenase-1 system and its role in inﬂamma-
tion. Biochem Pharmacol. 153: 159-167 [PMID:29452096]
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Hydrogen sulphide synthesis
Enzymes → Hydrogen sulphide synthesis
Overview: Hydrogen sulﬁde is a gasotransmitter, with similar-
ities to nitric oxide and carbon monoxide. Although the en-
zymes indicated below have multiple enzymatic activities, the fo-
cus here is the generation of hydrogen sulphide (H2S) and the
enzymatic characteristics are described accordingly. Cystathion-
ine β-synthase (CBS) and cystathionine γ-lyase (CSE) are pyridoxal
phosphate (PLP)-dependent enzymes. 3-mercaptopyruvate sulfur-
transferase (3-MPST) functions to generate H2S; only CAT is PLP-
dependent, while 3-MPST is not. Thus, this third pathway is some-
times referred to as PLP-independent. CBS and CSE are predomi-
nantly cytosolic enzymes, while 3-MPST is found both in the cy-
tosol and the mitochondria. For an authoritative review on the
pharmacological modulation of H2S levels, see Szabo and Papa-
petropoulos, 2017 [575].
Nomenclature Cystathionine β-synthase Cystathionine γ-lyase L-Cysteine:2-oxoglutarate aminotransferase 3-Mercaptopyruvate sulfurtransferase
Common abbreviation CBS CSE CAT MPST
HGNC, UniProt CBS, P35520 CTH, P32929 KYAT1, Q16773 MPST, P25325
EC number 4.2.1.22 4.4.1.1 4.4.1.13 2.8.1.2
Endogenous substrates L-cysteine (Km 6×10−3M) [92],
L-homocysteine [92]
L-cysteine L-cysteine 3-mercaptopyruvic acid (Km 1.2×10−3M)
[426]
Products cystathionine NH3, pyruvic acid NH3, pyruvic acid pyruvic acid
Cofactors pyridoxal 5-phosphate pyridoxal 5-phosphate pyridoxal 5-phosphate Zn2+
Inhibitors aminooxyacetic acid (pIC50 5.1) [20] aminoethoxyvinylglycine (pIC50 6) [20],
aminooxyacetic acid (pIC50 6) [20],
β-Cyano-L-alanine (pIC50 5.8) [20],
propargylglycine (pIC50 4.4) [20]
– I3MT-3 (pIC50 5.6) [237]
Further reading on Hydrogen sulphide synthesis
Asimakopoulou A et al. (2013) Selectivity of commonly used pharmacological inhibitors for cys-
tathionine β synthase (CBS) and cystathionine γ lyase (CSE). Br J Pharmacol. 169: 922-32
[PMID:23488457]
Szabo C et al. (2017) International Union of Basic and Clinical Pharmacology. CII: Pharmacological
Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol. Rev. 69:
497-564 [PMID:28978633]
Hydrolases
Enzymes → Hydrolases
Overview: Listed in this section are hydrolases not accumulated
in other parts of the Concise Guide, such as monoacylglycerol
lipase and acetylcholinesterase. Pancreatic lipase is the predom-
inant mechanism of fat digestion in the alimentary system; its
inhibition is associated with decreased fat absorption. CES1 is
present at lower levels in the gut than CES2 (P23141), but pre-
dominates in the liver, where it is responsible for the hydrolysis
of many aliphatic, aromatic and steroid esters. Hormone-sensitive
lipase is also a relatively non-selective esterase associated with
steroid ester hydrolysis and triglyceride metabolism, particularly
in adipose tissue. Endothelial lipase is secreted from endothelial
cells and regulates circulating cholesterol in high density lipopro-
teins.
Searchable database: http://www.guidetopharmacology.org/index.jsp Hydrolases S358
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Nomenclature pancreatic lipase lipase E, hormone sensitive
type
lipase G, endothelial type carboxylesterase 1 ectonucleoside triphosphate
diphosphohydrolase 1
ectonucleoside triphosphate
diphosphohydrolase 2
Systematic nomenclature – – – – CD39 CD39L1
Common abbreviation PNLIP LIPE LIPG CES1 NTPDase-1 NTPDase-2
HGNC, UniProt PNLIP, P16233 LIPE, Q05469 LIPG, Q9Y5X9 CES1, P23141 ENTPD1, P49961 ENTPD2, Q9Y5L3
EC number 3.1.1.3 3.1.1.79 3.1.1.3 3.1.1.1 3.6.1.5
Hydrolyzes NTPs to
nucleotide
monophosphates (NMPs): A
nucleoside 5’-triphosphate
+ 2 H2O <=> a nucleoside
5’-phosphate + 2 phosphate
3.6.1.-
Hydrolyzes extracellular
nucleotide 5’-triphosphates:
NTP>NMP + 2 phosphate
Inhibitors orlistat (pIC50 8.9) [66] – – – – –
Selective inhibitors – – – – – PSB-6426 (pKi 5.1) [63]
Comments – – – – ENTPD1 sequentially
converts extracellular purine
nucleotides (ATP and ADP)
to the monophosphate
form. Adenosine is then
generated by the action of
Ecto-5’-Nucleotidase
(CD73). ENTPD1 is the
rate-limiting step.
Extracellular ATP acts as a
damage-associated
molecular pattern (DAMP)
that activates innate
immune cells through
adenosine-induced
activation of P2X and P2Y
purinogenic receptors.
–
Further reading on Hydrolases
Allard B et al.. (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Immunol Rev. 276: 121-144 [PMID:28258700]
Kishore BK et al. (2018) CD39-adenosinergic axis in renal pathophysiology and therapeutics. Puriner-
gic Signal 14: 109-120 [PMID:29332180]
Rasmussen HB et al. (2018) Carboxylesterase 1 genes: systematic review and evaluation of existing
genotyping procedures. Drug Metab Pers Ther 33: 3-14 [PMID:29427553]
Zou LW et al. (2018) Carboxylesterase Inhibitors: An Update. Curr Med Chem. 25: 1627-1649
[PMID:29210644]
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Inositol phosphate turnover
Enzymes → Inositol phosphate turnover
Overview: The sugar alcohol D-myo-inositol is a component of
the phosphatidylinositol signalling cycle, where the principal sec-
ond messenger is inositol 1,4,5-trisphosphate, IP3, which acts at
intracellular ligand-gated ion channels, IP3 receptors to elevate
intracellular calcium. IP3 is recycled to inositol by phosphatases
or phosphorylated to form other active inositol polyphosphates.
Inositol produced from dephosphorylation of IP3 is recycled
into membrane phospholipid under the inﬂuence of phos-
phatidyinositol synthase activity (CDP-diacylglycerol-inositol 3-
phosphatidyltransferase [EC 2.7.8.11]).
Inositol 1,4,5-trisphosphate 3-kinases
Enzymes → Inositol phosphate turnover → Inositol 1,4,5-trisphosphate 3-kinases
Overview: Inositol 1,4,5-trisphosphate 3-kinases (E.C. 2.7.1.127, ENSFM00250000001260) catalyse the generation of inositol 1,3,4,5-tetrakisphosphate (IP4) from IP3. IP3 kinase activity is enhanced in
the presence of calcium/calmodulin (CALM1 CALM2 CALM3, P62158) [113].
Information on members of this family may be found in the online database.
Inositol polyphosphate phosphatases
Enzymes → Inositol phosphate turnover → Inositol polyphosphate phosphatases
Overview: Members of this family exhibit phosphatase activ-
ity towards IP3, as well as towards other inositol derivatives, in-
cluding the phospholipids PIP2 and PIP3. With IP3 as substrate,
1-phosphatase (EC 3.1.3.57) generates 4,5,-IP2, 4-phosphatases
(EC 3.1.3.66, ENSFM00250000001432) generate 1,5,-IP2 and 5-
phosphatases (E.C. 3.1.3.36 or 3.1.3.56) generate 1,4,-IP2.
Information on members of this family may be found in the online database.
Comments: In vitro analysis suggested IP3 and IP4 were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that PIP2 and PIP3 were more efﬁciently hydrolysed [523].
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Inositol monophosphatase
Enzymes → Inositol phosphate turnover → Inositol monophosphatase
Overview: Inositol monophosphatase (E.C. 3.1.3.25, IM-
Pase, myo-inositol-1(or 4)-phosphate phosphohydrolase) is a
magnesium-dependent homodimer which hydrolyses myo-
inositol monophosphate to generatemyo-inositol and phosphate.
Glycerol may be a physiological phosphate acceptor. Li+ is a nons-
elective un-competitive inhibitor more potent at IMPase 1 (pKi ca.
3.5, [402]; pIC50 3.2, [445]) than IMPase 2 (pIC50 1.8-2.1, [445]).
IMPase activity may be inhibited competitively by L690330 (pKi
5.5, [402]), although the enzyme selectivity is not yet established.
Nomenclature IMPase 1 IMPase 2
HGNC, UniProt IMPA1, P29218 IMPA2, O14732
EC number 3.1.3.25 3.1.3.25
Rank order of afﬁnity inositol 4-phosphate > inositol 3-phosphate > inositol 1-phosphate [402] –
Inhibitors Li+ (pKi 3.5) [402] –
Comments: Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder [548, 549, 666]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears
to mimic the effects of Li+ in mice [121, 122].
Further reading on Inositol phosphate turnover
Irvine R. (2016) A tale of two inositol trisphosphates. Biochem. Soc. Trans. 44: 202-11
[PMID:26862207]
Livermore TM et al. (2016) Phosphate, inositol and polyphosphates. Biochem. Soc. Trans. 44: 253-9
[PMID:26862212]
Miyamoto A et al. (2017) Probes for manipulating and monitoring IP_3. Cell Calcium 64: 57-64
[PMID:27887748]
Windhorst S et al. (2017) Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-expressed
and functions as an oncogene in several tumor types. Biochem. Pharmacol. 137: 1-9
[PMID:28377279]
Kinases (EC 2.7.x.x)
Enzymes → Kinases (EC 2.7.x.x)
Overview: Protein kinases (E.C. 2.7.11.-) use the co-substrate ATP
to phosphorylate serine and/or threonine residues on target pro-
teins. Analysis of the human genome suggests the presence of 518
protein kinases in man (divided into 15 subfamilies), with over
100 protein kinase-like pseudogenes [390]. It is beyond the scope
of the Concise Guide to list all these protein kinase activities, but
full listings are available on the ’Detailed page’ provided for each
enzyme.
Most inhibitors of these enzymes have been assessed in cell-free
investigations and so may appear to ’lose’ potency and selectiv-
ity in intact cell assays. In particular, ambient ATP concentrations
may be inﬂuential in responses to inhibitors, since the majority
are directed at the ATP binding site [128] .
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Rho kinase
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → DMPK family → Rho kinase
Overview: Rho kinase (also known as P160ROCK, Rho-activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as ARHGEF1
(Q92888, p115-RhoGEF), which in turn may be activated by Gα12/13 subunits [327].
Nomenclature Rho associated coiled-coil containing protein kinase 1 Rho associated coiled-coil containing protein kinase 2
Systematic nomenclature ROCK1 ROCK2
Common abbreviation Rho kinase 1 Rho kinase 2
HGNC, UniProt ROCK1, Q13464 ROCK2, O75116
EC number 2.7.11.1 2.7.11.1
Inhibitors RKI-1447 (pIC50 >9) [473], Y27632 (pIC50 5.9–7.3) [383, 648], fasudil (pKi 7) [496],
Y27632 (pKi 6.8) [607], fasudil (pIC50 5.5–5.6) [383, 496]
RKI-1447 (pIC50 >9) [473], compound 11d [DOI: 10.1039/c0md00194e] (pIC50 >9)
[95], GSK269962A (pIC50 8.4) [149], compound 32 (pIC50 8.4) [58], compound 22
(pIC50 7.7) [648], Y27632 (pIC50 6.3–7.2) [383, 648], Y27632 (pKi 6.8–6.9) [383, 607],
fasudil (pIC50 5.9–5.9) [383, 496]
Selective inhibitors GSK269962A (pIC50 8.8) [149] –
Further reading on Rho kinase
Feng Y et al. (2016) Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. J. Med. Chem.
59: 2269-300 [PMID:26486225]
Nishioka T et al. (2015) Developing novel methods to search for substrates of protein kinases such
as Rho-kinase. Biochim. Biophys. Acta 1854: 1663-6 [PMID:25770685]
Shimokawa H et al. (2016) RhoA/Rho-Kinase in the Cardiovascular System. Circ. Res. 118: 352-66
[PMID:26838319]
Protein kinase C (PKC) family
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family
Overview: Protein kinase C is the target for the tumour-
promoting phorbol esters, such as tetradecanoyl-β-phorbol acetate
(TPA, also known as phorbol 12-myristate 13-acetate).
Classical protein kinase C isoforms: PKCα, PKCβ, and PKCγ
are activated by Ca2+ and diacylglycerol, and may be inhib-
ited by GF109203X, calphostin C, Gö 6983, chelerythrine and
Ro31-8220.
Novel protein kinase C isoforms: PKCδ, PKC, PKCη, PKC  and
PKCμ are activated by diacylglycerol and may be inhibited by
calphostin C, Gö 6983 and chelerythrine.
Atypical protein kinase C isoforms:PKCι, PKCζ .
Searchable database: http://www.guidetopharmacology.org/index.jsp Protein kinase C (PKC) family S362
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14752/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology (2019) 176, S297–S396
Alpha subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Alpha subfamily
Nomenclature protein kinase C beta protein kinase C gamma
Common abbreviation PKCβ PKCγ
HGNC, UniProt PRKCB, P05771 PRKCG, P05129
EC number 2.7.11.13 2.7.11.13
Inhibitors sotrastaurin (pIC50 8.7) [617], Gö 6983 (pIC50 8.1) [223], GF109203X (pIC50 7.8) [600] –
Bovine, 7-hydroxystaurosporine (pIC50 7.5) [535]
Gö 6983 (pIC50 8.2) [223], 7-hydroxystaurosporine (pIC50 7.5) [535]
Selective inhibitors ruboxistaurin (pIC50 8.2) [289], enzastaurin (pIC50 7.5) [165], CGP53353 (pIC50 6.4) [86] –
Delta subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Delta subfamily
Nomenclature protein kinase C alpha protein kinase C delta
Common abbreviation PKCα PKCδ
HGNC, UniProt PRKCA, P17252 PRKCD, Q05655
EC number 2.7.11.13 2.7.11.13
Activators – ingenol mebutate (pKi 9.4) [307]
Inhibitors sotrastaurin (pIC50 8.7) [617], Gö 6983 (pIC50 8.1) [223], 7-hydroxystaurosporine (pIC50
7.5) [535]
sotrastaurin (pIC50 8.9) [617], Gö 6983 (pIC50 8) [223]
Searchable database: http://www.guidetopharmacology.org/index.jsp Delta subfamily S363
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Eta subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) family → Eta subfamily
Nomenclature protein kinase C epsilon
Common abbreviation PKC
HGNC, UniProt PRKCE, Q02156
EC number 2.7.11.13
Inhibitors sotrastaurin (pIC50 8.2) [617]
Further reading on Protein kinase C (PKC) family
Igumenova TI. (2015) Dynamics and Membrane Interactions of Protein Kinase C. Biochemistry 54:
4953-68 [PMID:26214365]
Newton AC et al. (2017) Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends
Pharmacol. Sci. 38: 438-447 [PMID:28283201]
Salzer E et al. (2016) Protein Kinase C δ: a Gatekeeper of Immune Homeostasis. J. Clin. Immunol. 36:
631-40 [PMID:27541826]
FRAP subfamily
Enzymes → Kinases (EC 2.7.x.x) → Atypical → Phosphatidyl inositol 3’ kinase-related kinases (PIKK) family → FRAP subfamily
Nomenclature mechanistic target of rapamycin kinase
Common abbreviation mTOR
HGNC, UniProt MTOR, P42345
EC number 2.7.11.1
Inhibitors ridaforolimus (pIC50 9.7) [505], torin 1 (pIC50 9.5) [361], sapanisertib (pIC50 9) [267], sapanisertib (pKi 8.9) [267], gedatolisib (pIC50 8.8) [612], dactolisib (pIC50 8.2) [388], PP121
(pIC50 8) [18], XL388 (pIC50 8) [580], PF-04691502 (pKi 7.8) [360], apitolisib (pKi 7.8) [573]
Selective inhibitors everolimus (pIC50 8.7) [531], PP-242 (pIC50 8.1) [18], temsirolimus (pIC50 5.8) [323]
Further reading on FRAP subfamily
Hukelmann JL et al. (2016) The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat.
Immunol. 17: 104-12 [PMID:26551880]
Saxton RA et al. (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 169: 361-371
[PMID:28388417]
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Cyclin-dependent kinase (CDK) family
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Cyclin-dependent kinase (CDK) family
Overview: Five of the cyclin-dependent kinases (CDKs: 7, 8, 9, 12, and 13) are involved in the phosphorylation of serine residues in the C-terminal domain of RNA polymerase II, the enzyme that is
responsible for the transcription of protein-coding genes into mRNA in eukaryotes. Phosphorylation of RNA polymerase II at Ser5 is essential for transcriptional initiation, and phosphorylation of Ser
2 contributes to transcriptional elongation and termination. All ﬁve of the C-terminal domain kinases can phosphorylate Ser5, but only CDK9, CDK12, and CDK13 can phosphorylate at Ser2 [59, 321,
352].
CDK4 subfamily
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Cyclin-dependent kinase (CDK) family → CDK4 subfamily
Nomenclature cyclin dependent kinase 4 cyclin dependent kinase 6
Common abbreviation CDK4 CDK6
HGNC, UniProt CDK4, P11802 CDK6, Q00534
EC number 2.7.11.22 2.7.11.22
Inhibitors R547 (pKi 9) [135], palbociclib (pIC50 8) [183], Ro-0505124 (pIC50 7.7) [144], riviciclib
(pIC50 7.2) [297], alvocidib (pKi 7.2) [79]
palbociclib (pIC50 7.8) [183]
Comments on Cyclin-dependent kinase (CDK) family: The development of CDK inhibitors as anticancer drugs is reviewed in [576], with detailed content covering CDK4 and CDK6 inhibitors that
are under clinical evaluation. Data produced by Jorda et al. (2018) highlights the caution that must be used when deploying commercially available CDK inhibitors as pharmacological probes [296], as
most of them are more promiscuous in their selectivity than indicated. To make their ﬁndings easily accessible the Jorda data is hosted on the cyclin-dependent kinase inhibitor database (CDKiDB).
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GSK subfamily
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Glycogen synthase kinase (GSK) family → GSK subfamily
Nomenclature glycogen synthase kinase 3 beta
Common abbreviation GSK3B
HGNC, UniProt GSK3B, P49841
EC number 2.7.11.26
Inhibitors CHIR-98014 (pIC50 9.2) [504], LY2090314 (pIC50 9) [157], CHIR-99021 (pIC50 8.2) [504], SB 216763 (pIC50 ∼8.1) [109], 1-azakenpaullone (pIC50 7.7) [331], SB-415286 (pIC50 ∼7.4)
[109], IM-12 (pIC50 7.3) [525]
Selective inhibitors AZD2858 (pKi 8.3) [41]
Comments Due to its Tau phosphorylating activity, small molecule inhibitors of GSK-3β are being investigated as potential treatments for Alzheimer’s disease (AD) [41]. GSK-3β also plays a role in
canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised that small molecule inhibitors of GSK-3β may
provide effective therapeutics for the treatment of diseases characterised by low bone mass [393].
Further reading on GSK subfamily
Beurel E et al. (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharma-
col. Ther. 148: 114-31 [PMID:25435019]
Domoto T et al. (2016) Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and
resistance to therapy. Cancer Sci. 107: 1363-1372 [PMID:27486911]
Khan I et al. (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J Med
Chem 125: 464-477 [PMID:27689729]
Maqbool M et al. (2016) Pivotal role of glycogen synthase kinase-3: A therapeutic target for
Alzheimer’s disease. Eur J Med Chem 107: 63-81 [PMID:26562543]
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Polo-like kinase (PLK) family
Enzymes → Kinases (EC 2.7.x.x) → Other protein kinases → Polo-like kinase (PLK) family
Nomenclature polo like kinase 4
Common abbreviation PLK4
HGNC, UniProt PLK4, O00444
EC number 2.7.11.21
Inhibitors CFI-400945 (pIC50 8.6) [397]
STE7 family
Enzymes → Kinases (EC 2.7.x.x) → STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases → STE7 family
Nomenclature mitogen-activated protein kinase kinase 1 mitogen-activated protein kinase kinase 2
Common abbreviation MEK1 MEK2
HGNC, UniProt MAP2K1, Q02750 MAP2K2, P36507
EC number 2.7.12.2 2.7.12.2
Inhibitors trametinib (pIC50 9–9.1) [206, 659], PD 0325901 (pIC50 8.1) [243] trametinib (pIC50 8.7) [659]
Allosteric modulators binimetinib (Negative) (pIC50 7.9) [468], refametinib (Negative) (pIC50 7.7) [281],
CI-1040 (Negative) (pKd 6.9) [130]
binimetinib (Negative) (pIC50 7.9) [468], refametinib (Negative) (pIC50 7.3) [281]
Selective allosteric modulators cobimetinib (Negative) (pIC50 9.1) [500] –
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Abl family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Abl family
Nomenclature ABL proto-oncogene 1, non-receptor tyrosine kinase
Common abbreviation Abl
HGNC, UniProt ABL1, P00519
EC number 2.7.10.2
Inhibitors compound 8h (pIC50 9.7) [596], dasatinib (pIC50 9.6) [314], compound 24 (pIC50 9.3) [136], PD-173955 (pKd 9.2) [130], bosutinib (pIC50 9) [210], PD-173955 (pIC50 ∼8.3) [427],
bafetinib (pIC50 7.6–8.2) [264, 319], ponatinib (pIC50 8.1) [269], nilotinib (pIC50 7.8) [439], PP121 (pIC50 7.7) [18], imatinib (pIC50 6.7) [264], GNF-5 (pIC50 6.7) [673]
Ack family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Ack family
Nomenclature tyrosine kinase non receptor 2
Common abbreviation Ack
HGNC, UniProt TNK2, Q07912
EC number 2.7.10.2
Inhibitors compound 30 (pIC50 9) [143]
Searchable database: http://www.guidetopharmacology.org/index.jsp Ack family S368
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Janus kinase (JakA) family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Janus kinase (JakA) family
Overview: Janus kinases (JAKs) are a fam.ily of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). They are essential for cytokine signalling and are strongly linked to both cancer and
inﬂammatory diseases.
Nomenclature Janus kinase 1 Janus kinase 2 Janus kinase 3 tyrosine kinase 2
Common abbreviation JAK1 JAK2 JAK3 Tyk2
HGNC, UniProt JAK1, P23458 JAK2, O60674 JAK3, P52333 TYK2, P29597
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors ruxolitinib (pIC50 8.5–10.1) [236,
483], ﬁlgotinib (pIC50 8) [608]
ilginatinib (pIC50 9.1) [431], BMS-911543 (pIC50 9) [480],
AT-9283 (pIC50 8.9) [266], XL019 (pIC50 8.7) [176], fedratinib
(pIC50 8.5) [389, 638], gandotinib (pIC50 8.4) [385]
AT-9283 (pIC50 9) [266] –
Selective inhibitors – compound 1d (pIC50 >9) [624] – –
Comments – The JAK2V617F mutation, which causes constitutive activation, plays
an oncogenic role in the pathogenesis of the myeloproliferative
disorders, polycythemia vera, essential thrombocythemia, and
idiopathic myeloﬁbrosis [74, 133]. Small molecule compounds
which inhibit aberrant JAK2 activity are being developed as novel
anti-cancer pharmaceuticals.
– –
Src family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Src family
Overview: Activation of Src-family kinases leads to both stimu-
latory and inhibitory signaling responses, with cell-speciﬁc and
signaling pathway-speciﬁc outcomes and redundancy of kinase
function.
Immune system:
In immune cells Src kinases are involved in many signalling
pathways, including ITAM- and ITIM-domain-containing
receptor signaling, integrin signaling, and responses to
chemokines/chemoattractants, cytokines, innate immune stim-
uli and a large variety of non-immune cell speciﬁc stimuli (UV
irradiation, heat, osmotic shock etc.). In many cases Src ki-
nases signal to MAP kinase or NF-κB pathways, but they can
also modulate other pathways through less well characterized
mechanisms.
The primary T cell Src kinases are Lck and Fyn; the main B cell
Srcs are Lyn, Fyn and Blk. Mast cells express Fyn and Lyn, with
low expression of Src.
Searchable database: http://www.guidetopharmacology.org/index.jsp Src family S369
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Nomenclature BLK proto-oncogene, Src family
tyrosine kinase
fyn related Src family tyrosine
kinase
FYN proto-oncogene, Src family
tyrosine kinase
LYN proto-oncogene, Src family
tyrosine kinase
SRC proto-oncogene,
non-receptor tyrosine kinase
Common abbreviation Blk FRK Fyn Lyn Src
HGNC, UniProt BLK, P51451 FRK, P42685 FYN, P06241 LYN, P07948 SRC, P12931
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors – – PP1 (pIC50 8.2) [239] bafetinib (pIC50 8) [264] WH-4-023 (pIC50 8.2) [394],
PD166285 (pKi 8.1) [458],
PP121 (pIC50 7.8) [18],
ENMD-2076 (pIC50 7.7) [476]
Tec family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Tec family
Nomenclature BMX non-receptor tyrosine kinase Bruton tyrosine kinase TXK tyrosine kinase
Common abbreviation Etk Btk TXK
HGNC, UniProt BMX, P51813 BTK, Q06187 TXK, P42681
EC number 2.7.10.2 2.7.10.2 2.7.10.2
Inhibitors compound 38 (pIC50 9.1) [347], ibrutinib (pIC50 9.1) [371], compound 31
(pIC50 8.7) [347]
ibrutinib (pIC50 9.3) [457], compound 31 (pIC50 8.4) [347], compound 38
(pIC50 >8.4) [347]
–
Selective inhibitors BMX-IN-1 (pIC50 8.1) [358] CGI1746 (pIC50 8.7) [140], CHMFL-BTK-11 (Irreversible inhibition) (pIC50 7.6)
[649]
–
Searchable database: http://www.guidetopharmacology.org/index.jsp Tec family S370
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RAF family
Enzymes → Kinases (EC 2.7.x.x) → TKL: Tyrosine kinase-like → RAF family
Nomenclature B-Raf proto-oncogene, serine/threonine kinase Raf-1 proto-oncogene, serine/threonine kinase
Common abbreviation B-Raf c-Raf
HGNC, UniProt BRAF, P15056 RAF1, P04049
EC number 2.7.11.1 2.7.11.1
Inhibitors GDC-0879 (pIC50 9.7–9.9) [130, 240], dabrafenib (pIC50 8.5) [337], regorafenib (pIC50
7.6) [670], vemurafenib (pIC50 7) [625], PLX-4720 (pKd 6.5) [130], compound 2 (pKd 6.3)
[263], CHIR-265 (pKd 5.9) [130]
–
Selective inhibitors – GW5074 (pIC50 8.1) [101]
Further reading on Kinases (EC 2.7.x.x)
Eglen R et al. (2011) Drug discovery and the human kinome: recent trends. Pharmacol. Ther. 130:
144-56 [PMID:21256157]
Graves LM et al. (2013) The dynamic nature of the kinome. Biochem. J. 450: 1-8 [PMID:23343193]
Liu Q et al. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol.
20: 146-59 [PMID:23438744]
Martin KJ et al. (2012) Selective kinase inhibitors as tools for neuroscience research. Neuropharma-
cology 63: 1227-37 [PMID:22846224]
Tarrant MK et al. (2009) The chemical biology of protein phosphorylation. Annu. Rev. Biochem. 78:
797-825 [PMID:19489734]
Wu-Zhang AX et al. (2013) Protein kinase C pharmacology: reﬁning the toolbox. Biochem. J. 452:
195-209 [PMID:23662807]
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Lanosterol biosynthesis pathway
Enzymes → Lanosterol biosynthesis pathway
Overview: Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG-CoA reductase pathway. The ﬁrst two steps
(formation of acetoacetyl CoA and the mitochondrial generation of (S)-3-hydroxy-3-methylglutaryl-CoA) are also associated with oxidation of fatty acids.
Nomenclature acetyl-CoA acetyltransferase 1 acetyl-CoA acetyltransferase 2 hydroxymethylglutaryl-CoA synthase 1 hydroxymethylglutaryl-CoA synthase 2
HGNC, UniProt ACAT1, P24752 ACAT2, Q9BWD1 HMGCS1, Q01581 HMGCS2, P54868
EC number 2.3.1.9: 2acetyl CoA = acetoacetyl CoA +
coenzyme A
2.3.1.9: 2acetyl CoA = acetoacetyl CoA +
coenzyme A
2.3.3.10: acetyl CoA + H2O+ acetoacetyl CoA ->
(S)-3-hydroxy-3-methylglutaryl-CoA +
coenzyme A
2.3.3.10: acetyl CoA + H2O+acetoacetyl CoA ->
(S)-3-hydroxy-3-methylglutaryl-CoA +
coenzyme A
Comments – – HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial (HMGCoA synthase 2)
versions; the former associated with (R)-mevalonate synthesis and the latter with ketogenesis.
Searchable database: http://www.guidetopharmacology.org/index.jsp Lanosterol biosynthesis pathway S372
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Nomenclature hydroxymethylglutaryl-CoA reductase
HGNC, UniProt HMGCR, P04035
EC number 1.1.1.34: (S)-3-hydroxy-3-methylglutaryl-CoA + NADPH ->(R)-mevalonate + coenzyme A + NADP+
Reaction mechanism:: First step: (S)-3-hydroxy-3-methylglutaryl-CoA + NADPH -> mevaldyl-CoA + NADP+
Second step: mevaldyl-CoA + H2O -> (R)-mevalonate + NADP+
Inhibitors lovastatin (Competitive) (pKi 9.2) [12], rosuvastatin (Competitive) (pIC50 8.3) [280], cerivastatin (Competitive) (pKi 8.2) [77], atorvastatin (Competitive)
(pIC50 8.1) [280], cerivastatin (Competitive) (pIC50 8) [595], simvastatin (Competitive) (pIC50 8) [280], ﬂuvastatin (Competitive)
Comments HMGCoA reductase is associated with intracellular membranes; enzymatic activity is inhibited by phosphorylation by AMP-activated kinase.
The enzymatic reaction is a three-step reaction involving the intermediate generation of mevaldehyde-CoA and mevaldehyde.
Nomenclature
HGNC, UniProt
EC number
Comments
mevalonate kinase
MVK, Q03426
2.7.1.36: ATP + (R)-mevalonate -> ADP + (R)-5-phosphomevalonate
–Mevalonate kinase activity is regulated by the downstream products farnesyl
diphosphate and geranyl diphosphate as an example of feedback inhibition.
phosphomevalonate kinase diphosphomevalonate decarboxylase
PMVK, Q15126 MVD, P53602
2.7.4.2: ATP + (R)-5-phosphomevalonate = ADP +
(R)-5-diphosphomevalonate
4.1.1.33: ATP + (R)-5-diphosphomevalonate ->
ADP + isopentenyl diphosphate + CO2 + PO34-
–
(pIC50 7.6) [280]
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Nomenclature isopentenyl-diphosphate -isomerase 1 isopentenyl-diphosphate -isomerase 2 geranylgeranyl diphosphate synthase
HGNC, UniProt IDI1, Q13907 IDI2, Q9BXS1 GGPS1, O95749
EC number 5.3.3.2: isopentenyl diphosphate = dimethylallyl diphosphate 5.3.3.2: isopentenyl diphosphate = dimethylallyl diphosphate 2.5.1.29: trans,trans-farnesyl diphosphate + isopentenyl
diphosphate ->geranylgeranyl diphosphate + diphosphate
2.5.1.10: geranyl diphosphate + isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate +diphosphate
2.5.1.1: dimethylallyl diphosphate + isopentenyl diphosphate =
geranyl diphosphate +diphosphate
Nomenclature farnesyl diphosphate synthase squalene synthase squalene monooxygenase lanosterol synthase
HGNC, UniProt FDPS, P14324 FDFT1, P37268 SQLE, Q14534 LSS, P48449
EC number 2.5.1.10: geranyl diphosphate +
isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate +
diphosphate
2.5.1.1: dimethylallyl diphosphate +
isopentenyl diphosphate =
geranyl diphosphate + diphosphate
2.5.1.21:
2trans,trans-farnesyl diphosphate ->
presqualene diphosphate + diphosphate
presqualene diphosphate + NAD(P)H +
H+ -> squalene + diphosphate +
NAD(P)+
1.14.13.132: H+ + NADPH + O2 +
squalene = H2O + NADP+ +
(S)-2,3-epoxysqualene
5.4.99.7: (S)-2,3-epoxysqualene = lanosterol
Cofactors – NADPH – –
Inhibitors risedronate (pIC50 8.4) [43],
zoledronic acid (pKi 7.1) [153],
alendronate (pIC50 6.3) [43]
zaragozic acid A (pKi 10.1) [44] – Rat,
zaragozic acid A (pIC50 9.2) [597]
– –
Selective inhibitors ibandronic acid (pKi 6.7) [153],
pamidronic acid (pIC50 6.7) [153]
– – –
Searchable database: http://www.guidetopharmacology.org/index.jsp Lanosterol biosynthesis pathway S373
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Further reading on Lanosterol biosynthesis pathway
Moutinho M et al. (2017) The mevalonate pathway in neurons: It’s not just about cholesterol. Exp.
Cell Res. 360: 55-60 [PMID:28232115]
Mullen PJ et al. (2016) The interplay between cell signalling and the mevalonate pathway in cancer.
Nat. Rev. Cancer 16: 718-731 [PMID:27562463]
Ness GC. (2015) Physiological feedback regulation of cholesterol biosynthesis: Role of translational
control of hepatic HMG-CoA reductase and possible involvement of oxylanosterols. Biochim.
Biophys. Acta 1851: 667-73 [PMID:25701719]
Porter TD. (2015) Electron Transfer Pathways in Cholesterol Synthesis. Lipids 50: 927-36
[PMID:26344922]
Samaras K et al. (2016) Does statin use cause memory decline in the elderly? Trends Cardiovasc. Med.
26: 550-65 [PMID:27177529]
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Nucleoside synthesis and metabolism
Enzymes → Nucleoside synthesis and metabolism
Overview: The de novo synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahy-
drofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate
dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.
Nomenclature dihydrofolate reductase phosphoribosylglycinamide
formyltransferase,
phosphoribosylglycinamide
synthetase,
phosphoribosylaminoimidazole
synthetase
dihydroorotate
dehydrogenase (quinone)
inosine monophosphate
dehydrogenase 1
inosine monophosphate
dehydrogenase 2
thymidylate synthetase
Common abbreviation DHFR GART DHODH IMPDH1 IMPDH2 TYMS
HGNC, UniProt DHFR, P00374 GART, P22102 DHODH, Q02127 IMPDH1, P20839 IMPDH2, P12268 TYMS, P04818
EC number 1.5.1.3 2.1.2.2
6.3.3.1
6.3.4.13
1.3.5.2 1.1.1.205 1.1.1.205 2.1.1.45
Inhibitors – pemetrexed (pKi 5) [540] –
Mouse
teriﬂunomide (pKi 7.5) [253] mycophenolic acid (pIC50
7.7) [433]
mycophenolic acid (pIC50
7.7) [433]
–
Selective inhibitors methotrexate (pKi 8.9) [511] – – – – raltitrexed (pIC50 6.5) [194]
Searchable database: http://www.guidetopharmacology.org/index.jsp Nucleoside synthesis and metabolism S374
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Nomenclature purine nucleoside phosphorylase xanthine dehydrogenase ribonucleotide reductase
catalytic subunit M1
ribonucleotide reductase
regulatory subunit M2
ribonucleotide reductase
regulatory TP53 inducible
subunit M2B
Common abbreviation PNP XDH ribonucleotide reductase M1 ribonucleotide reductase M2 ribonucleotide reductase M2B
(TP53 inducible)
HGNC, UniProt PNP, P00491 XDH, P47989 RRM1, P23921 RRM2, P31350 RRM2B, Q7LG56
EC number 1.4.2.1
Purine-nucleoside phosphorylase: Purine
nucleoside + phosphate <=> purine +
alpha-D-ribose 1-phosphate
Purine deoxynucleoside + phosphate <=> purine +
2’-deoxy-alpha-D-ribose 1-phosphate
1.17.1.4 1.17.14.1 1.17.4.1 1.17.1.4
Inhibitors – febuxostat (pIC50 8.9) [162] – – –
Comments: TYMS allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. PNP allows separation of a nucleoside into the nucleobase and ribose phosphate for
nucleotide salvage. XDH generates urate in the purine degradation pathway. Post-translational modiﬁcations of XDH convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion
of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species.
Further reading on Nucleoside synthesis and metabolism
Day RO et al. (2016) Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci (Lond).
130: 2167-2180 [PMID:27798228]
Okafor ON et al. (2017) Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol Ther.
172: 139-150 [PMID:27916655]
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Paraoxonase (PON) family
Enzymes → Paraoxonase (PON) family
Overview: Paraoxonases (PON) are calcium-dependent esterases, whichmay be involved in lipoprotein turnover and the conversion of lactone statin prodrugs, as well as being targets of organophosphates,
such as the insecticide paraoxon.
Nomenclature paraoxonase 1 paraoxonase 2 paraoxonase 3
Common abbreviation PON1 PON2 PON3
HGNC, UniProt PON1, P27169 PON2, Q15165 PON3, Q15166
EC number 3.1.8.1
An aryl dialkyl phosphate + H(2)O <=> dialkyl phosphate + an aryl
alcohol
3.1.1.2
A phenyl acetate + H(2)O <=> a phenol + acetate
3.1.1.81
An N-acyl-L-homoserine lactone + H(2)O <=> an
N-acyl-L-homoserine
3.1.1.2
A phenyl acetate + H(2)O <=> a phenol + acetate
3.1.1.81
A N-acyl-L-homoserine lactone + H(2)O <=> a
N-acyl-L-homoserine
3.1.8.1
An aryl dialkyl phosphate + H(2)O <=> dialkyl
phosphate + an aryl alcohol
3.1.1.2
A phenyl acetate + H(2)O <=> a phenol + acetate
3.1.1.81
A N-acyl-L-homoserine lactone + H(2)O <=> a
N-acyl-L-homoserine
Comments PON1 forms homodimers. Loss-of-function mutations in PON1 are
associated with microvascular complications of diabetes [303, 304].
PON2 forms heterotrimers [150]. PON3 likely forms heterodimers in vivo [150].
Further reading on Paraoxonase
Dardiotis E et al. (2019) Paraoxonase-1 genetic polymorphisms in organophosphate metabolism.
Toxicology. 411: 24-31 [PMID:30359673]
Lioudaki S et al. (2019) Paraoxonase-1: Characteristics and Role in Atherosclerosis and Carotid Artery
Disease. Curr Vasc Pharmacol. 17: 141-146 [PMID:29189170]
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Peptidases and proteinases
Enzymes → Peptidases and proteinases
Overview: Peptidases and proteinases hydrolyse peptide bonds,
and can be simply divided on the basis of whether terminal
peptide bonds are cleaved (exopeptidases and exoproteinases) at
the amino terminus (aminopeptidases) or carboxy terminus (car-
boxypeptidases). Non-terminal peptide bonds are cleaved by en-
dopeptidases and endoproteinases, which are divided into serine
endopeptidases (EC 3.4.21.-), cysteine endopeptidases (EC 3.4.22.-
), aspartate endopeptidases (EC 3.4.23.-), metalloendopeptidases
(EC 3.4.24.-) and threonine endopeptidases (EC 3.4.25.-).
Since it is beyond the scope of the Guide to list all peptidase and
proteinase activities, this summary focuses on selected enzymes
of signiﬁcant pharmacological interest that have ligands (mostly
small-molecules) directed against them. For those interested in
detailed background we recommend the MEROPS database [493]
(with whom we collaborate) as an information resource [494].
A1: Pepsin
Enzymes → Peptidases and proteinases → AA: Aspartic (A) Peptidases → A1: Pepsin
Nomenclature renin
HGNC, UniProt REN, P00797
EC number 3.4.23.15
Inhibitors aliskiren (pIC50 9.2) [655]
A22: Presenilin
Enzymes → Peptidases and proteinases → AD: Aspartic (A) Peptidases → A22: Presenilin
Overview: Presenilin (PS)-1 or -2 act as the catalytic compo-
nent/essential co-factor of the γ-secretase complex responsible for
the ﬁnal carboxy-terminal cleavage of amyloid precursor protein
(APP) [302] in the generation of amyloid beta (Aβ) [9, 579]. Given
that the accumulation and aggregation of Aβ in the brain is piv-
otal in the development of Alzheimer’s disease (AD), inhibition
of PS activity is one mechanism being investigated as a therapeu-
tic option for AD [211]. Several small molecule inhibitors of PS-1
have been investigated, with some reaching early clinical trials,
but none have been formally approved. Dewji et al. (2015) have
reported that small peptide fragments of human PS-1 can signif-
icantly inhibit Aβ production (total Aβ, Aβ40 and Aβ42) both in
vitro and when infused in to the brains of APP transgenic mice
[139]. The most active small peptides in this report were P4 and
P8, from the amino-terminal domain of PS-1.
Information on members of this family may be found in the online database.
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C14: Caspase
Enzymes → Peptidases and proteinases → CD: Cysteine (C) Peptidases → C14: Caspase
Overview: Caspases, (E.C. 3.4.22.-) which derive their name
from Cysteine ASPartate-speciﬁc proteASES, include at least two
families; initiator caspases (caspases 2, 8, 9 and 10), which are able
to hydrolyse and activate a second family of effector caspases (cas-
pases 3, 6 and 7), which themselves are able to hydrolyse further
cellular proteins to bring about programmed cell death. Caspases
are heterotetrameric, being made up of two pairs of subunits, gen-
erated by a single gene product, which is proteolysed to form the
mature protein. Members of the mammalian inhibitors of apop-
tosis proteins (IAP) are able to bind the procaspases, thereby pre-
venting maturation to active proteinases.
Information on members of this family may be found in the online database.
Comments: CARD16 (Caspase recruitment domain-containing protein 16, caspase-1 inhibitor COP, CARD only domain-containing protein 1, pseudo interleukin-1β converting enzyme, pseudo-ICE,
ENSG00000204397) shares sequence similarity with some of the caspases.
M1: Aminopeptidase N
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M1: Aminopeptidase N
Overview: Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this
enzyme family may be monomeric or multi-subunit complexes, and many are zinc metalloenzymes [590].
Nomenclature Leukotriene A4 hydrolase
HGNC, UniProt LTA4H, P09960
EC number 3.3.2.6
Inhibitors bestatin (pKi 5.4) [450]
Searchable database: http://www.guidetopharmacology.org/index.jsp M1: Aminopeptidase N S378
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M2: Angiotensin-converting (ACE and ACE2)
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M2: Angiotensin-converting (ACE and ACE2)
Nomenclature Angiotensin-converting enzyme
Common abbreviation ACE
HGNC, UniProt ACE, P12821
EC number 3.4.15.1
Substrates Ac-SDKP
Endogenous substrates angiotensin I (AGT, P01019) > angiotensin II (AGT, P01019)
Inhibitors zofenoprilat (pKi 9.4) [329] – Rabbit, captopril (pKi 8.4) [410], zofenopril
Selective inhibitors perindoprilat (pIC50 9) [83], cilazaprilat (pIC50 8.7) [630] – Rabbit, imidaprilat (pIC50 8.7) [507], lisinopril-tryptophan (C-domain assay) (pIC50
8.2) [631], RXP-407 (N-domain selective inhibition) (pIC50 8.1) [538], fosinoprilat (pIC50 8) [131] – Rabbit, enalaprilat (pIC50 7.5) [98],
benazeprilat (pIC50 6.6) [342]
Comments Reports of ACE GPI hydrolase activity [322] have been refuted [344]
M10: Matrix metallopeptidase
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M10: Matrix metallopeptidase
Overview: Matrix metalloproteinases (MMP) are calcium- and zinc-dependent proteinases regulating the extracellular matrix and are often divided (e.g. [614]) on functional and structural bases into
gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type-MMP (MT-MMP).
Nomenclature MMP2 MMP8
HGNC, UniProt MMP2, P08253 MMP8, P22894
EC number 3.4.24.24 3.4.24.34
Selective inhibitors ARP100 [603] –
Comments MMP2 is categorised as a gelatinase with substrate speciﬁcity for
gelatinase A.
MMP8 is categorised as a collagenase.
Comments: A number of small molecule ‘broad spectrum’ inhibitors of MMP have been described, including marimastat and batimastat.
Tissue inhibitors of metalloproteinase (TIMP) proteins are endogenous inhibitors acting to chelate MMP proteins: TIMP1 (TIMP1, P01033), TIMP2 (TIMP2, P16035), TIMP3 (TIMP3, P35625),
TIMP4 (TIMP4, Q99727)
Searchable database: http://www.guidetopharmacology.org/index.jsp M10: Matrix metallopeptidase S379
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M12: Astacin/Adamalysin
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M12: Astacin/Adamalysin
Overview: ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited
products.
ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited products.
Information on members of this family may be found in the online database.
Comments: Additional ADAM familymembers include AC123767.2 (cDNA FLJ58962, moderately similar to mouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21-like protein, ENSG00000235812),
AC136428.3-2 (ENSG00000185520) and ADAMDEC1 (decysin 1, ENSG00000134028).
Other ADAMTS family members include AC104758.12-5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3-1 (ENSG00000225577), and AC126339.6-1 (ENSG00000225734).
M28: Aminopeptidase Y
Enzymes → Peptidases and proteinases → MH: Metallo (M) Peptidases → M28: Aminopeptidase Y
Nomenclature Folate hydrolase (prostate-speciﬁc membrane antigen) 1
HGNC, UniProt FOLH1, Q04609
EC number 3.4.17.21
Antibodies capromab (Binding)
Comments Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate
(L-glutamic acid). In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly
expressed in the prostate, and its expression is up-regulated in cancerous tissue. A tagged version of the antibody capromab has been used for imaging
purposes.
Comments: Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate. In the gut, the enzyme assists in
the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up-regulated in cancerous tissue. A tagged version of
the antibody capromab has been used for imaging purposes.
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M19: Membrane dipeptidase
Enzymes → Peptidases and proteinases → MJ: Metallo (M) Peptidases → M19: Membrane dipeptidase
Nomenclature Dipeptidase 1
HGNC, UniProt DPEP1, P16444
EC number 3.4.13.19: LTD4 + H2O = LTE4 + glycine
Inhibitors cilastatin (pKi 6) [215]
S1: Chymotrypsin
Enzymes → Peptidases and proteinases → PA: Serine (S) Peptidases → S1: Chymotrypsin
Nomenclature complement C1r coagulation factor II, thrombin coagulation factor X
HGNC, UniProt C1R, P00736 F2, P00734 F10, P00742
EC number 3.4.21.41 3.4.21.5 3.4.21.6
Inhibitors nafamostat (pIC50 4.9) [251] lepirudin (pKi 13) [626], desirudin (pKi 12.7) [293], AZ12971554 (pKi 9.5)
[21], melagatran (pKi 8.7) [228], bivalirudin (pKi 8.6) [646], dabigatran (pKi
8.3) [246], argatroban (pKi 7.7) [276]
apixaban (pKi 10.1) [647], rivaroxaban (pKi 9.4) [466], edoxaban (pKi 9.2)
[471]
Selective inhibitors – Dup-714 (pKi 10.4) [192], AR-H067637 (pIC50 8.4) [132] –
Nomenclature elastase, neutrophil expressed plasminogen plasminogen activator, tissue type serine protease 1 tryptase alpha/beta 1
HGNC, UniProt ELANE, P08246 PLG, P00747 PLAT, P00750 PRSS1, P07477 TPSAB1, Q15661
EC number 3.4.21.37 3.4.21.7 3.4.21.68 3.4.21.4 3.4.21.59
Inhibitors alvelestat (pKi 8) [568], sivelestat
(pIC50 7.4) [119]
aprotinin {Bovine} (Binding) (pIC50
6.8) [560], tranexamic acid
(Binding) (pIC50 3.6) [560]
– nafamostat (pIC50 7.8) [251] nafamostat (pIC50 10) [422]
Selective inhibitors – 6-aminocaproic acid (Binding)
(pIC50 4.4) [97]
– – gabexate (pIC50 8.5) [159]
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T1: Proteasome
Enzymes → Peptidases and proteinases → PB: Threonine (T) Peptidases → T1: Proteasome
Overview: The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex [106]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and
Glu adjacent to the cleavage site. The β5 subunit is the principal target of the approved drug proteasome inhibitor bortezomib.
Nomenclature proteasome subunit beta 5
HGNC, UniProt PSMB5, P28074
EC number 3.4.25.1
Inhibitors bortezomib (pIC50 7.7) [428]
Selective inhibitors ixazomib (pKi 9) [332]
S8: Subtilisin
Enzymes → Peptidases and proteinases → SB: Serine (S) Peptidases → S8: Subtilisin
Overview: One member of this family has garnered intense in-
terest as a clinical drug target. As liver PCSK9 acts to maintain
cholesterol homeostasis, it has become a target of intense in-
terest for clinical drug development. Inhibition of PCSK9 can
lower low-density cholesterol (LDL-C) by clearing LDLR-bound
LDL particles, thereby lowering circulating cholesterol levels. It
is hypothesised that this action may improve outcomes in pa-
tients with atherosclerotic cardiovascular disease [368, 516, 567].
Therapeutics which inhibit PCSK9 are viewed as potentially lu-
crative replacements for statins, upon statin patent expiry. Sev-
eral monoclonal antibodies including alirocumab, evolocumab,
bococizumab, RG-7652 and LY3015014 are under development.
One RNAi therapeutic, code named ALN-PCS02, is also in devel-
opment [123, 173, 180].
Information on members of this family may be found in the online database.
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S9: Prolyl oligopeptidase
Enzymes → Peptidases and proteinases → SC: Serine (S) Peptidases → S9: Prolyl oligopeptidase
Nomenclature dipeptidyl peptidase 4
HGNC, UniProt DPP4, P27487
EC number 3.4.14.5
Endogenous substrates glucagon-like peptide 1 (GCG, P01275)
Inhibitors saxagliptin (pKi 9.2) [226], linagliptin (pKi 9) [155], sitagliptin (pIC50 8.1) [129], vildagliptin (pKi 7.8) [226]
Selective inhibitors ZY15557 (Competitive) (pKi 8.3) [285]
Poly ADP-ribose polymerases
Enzymes → Poly ADP-ribose polymerases
Overview: The Poly ADP-ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in
DNA, allowing the recruitment of repair enzymes by the synthesis of NAD-derived ADP-ribose polymers, which are subsequently degraded by a glycohydrolase (PARG, Q86W56).
Nomenclature poly(ADP-ribose) polymerase 1 poly(ADP-ribose) polymerase 2 poly (ADP-ribose) polymerase 3
Common abbreviation PARP1 PARP2 PARP3
HGNC, UniProt PARP1, P09874 PARP2, Q9UGN5 PARP3, Q9Y6F1
EC number 2.4.2.30 2.4.2.30 –
Further reading on Poly ADP-ribose polymerases
Berger NA et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-
oncological diseases. Br J Pharmacol. 175: 192-222 [PMID:28213892]
Faraoni I et al. (2019) Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia
and related disorders. Biochem Pharmacol [PMID:31028744]
Zeniou M et al. (2019) Therapeutic considerations of PARP in stem cell biology: Relevance in cancer
and beyond. Biochem Pharmacol [PMID:31202733]
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Prolyl hydroxylases
Enzymes → Prolyl hydroxylases
Overview: Hypoxia-inducible factors (HIFs) are rapidly-
responding sensors of reductions in local oxygen tensions,
prompting changes in gene transcription. Listed here are the
4-prolyl hydroxylase family, members of which have been iden-
tiﬁed to hydroxylate proline residues in HIF1α (HIF1A; Q16665)
leading to an increased degradation through proteasomal hydrol-
ysis. This action requires molecular oxygen and 2-oxoglutarate,
and so reduced oxygen tensions prevents HIF1α hydroxylation,
allowing its translocation to the nucleus and dimerisation with
HIF1β (also known as ARNT; P27540), thereby allowing interac-
tion with the genome as a transcription factor.
Nomenclature egl-9 family hypoxia inducible factor 2 egl-9 family hypoxia inducible factor 1 egl-9 family hypoxia inducible factor 3
Common abbreviation PHD1 PHD2 PHD3
HGNC, UniProt EGLN2, Q96KS0 EGLN1, Q9GZT9 EGLN3, Q9H6Z9
EC number 1.14.11.29 1.14.11.29 1.14.11.29
Further reading on Prolyl hydroxylases
Joharapurkar AA et al. (2018) Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Ane-
mia Associated with Chronic Diseases. J Med Chem 61: 6964-6982 [PMID:29712435]
Lanigan SM and O’Connor JJ. (2019) Prolyl hydroxylase domain inhibitors: can multiple mecha-
nisms be an opportunity for ischemic stroke? Neuropharmacology 148: 117-130 [PMID:30578795]
Singh L et al. (2018) Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular
metabolism in cancer cells. Drug Discov Today 23: 1873-1882 [PMID:29772209]
Vasta JD and Raines RT et al. (2018) Collagen Prolyl 4-Hydroxylase as a Therapeutic Target. J Med
Chem 61: 10403-10411 [PMID:29986141]
Watts ER and Walmsley SR. (2019) Inﬂammation and Hypoxia: HIF and PHD Isoform Selectivity.
Trends Mol Med 25: 33-46 [PMID:30442494]
Sphingosine 1-phosphate turnover
Enzymes → Sphingosine 1-phosphate turnover
Overview: S1P (sphingosine 1-phosphate) is a bioactive lipid
which, after release from cells via certain transporters, acts as
a ligand for a family of ﬁve S1P-speciﬁc G protein-coupled re-
ceptors (S1P1-5). However, it also has a number of intracellu-
lar targets. S1P is formed by the ATP-dependent phosphoryla-
tion of sphingosine, catalysed by two isoforms of sphingosine
kinase (EC 2.7.1.91). It can be dephosphorylated back to sph-
ingosine by sphingosine 1-phosphate phosphatase (EC 3.1.3) or
cleaved into phosphoethanolamine and hexadecenal by sphingo-
sine 1-phosphate lyase (EC 4.1.2.27). Recessive mutations in the
S1P lyase (SPL) gene underlie a recently identiﬁed sphingolipi-
dosis: SPL Insufﬁciency Syndrome (SPLIS). In general, S1P pro-
motes cell survival, proliferation, migration, adhesion and inhibi-
tion of apoptosis. Intracellular S1P affects epigenetic regulation,
endosomal processing, mitochondrial function and cell prolifera-
tion/senescence. S1P has myriad physiological functions, includ-
ing vascular development, lymphocyte trafﬁcking and neurogen-
esis. However, S1P is also involved in a number of diseases such
as cancer, inﬂammation and ﬁbrosis. Therefore, its GPCRs and
enzymes of synthesis and degradation are a major focus for drug
discovery.
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Sphingosine kinase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine kinase
Overview: SPHK1 and SPHK2 are encoded by different genes
with some redundancy of function; genetic deletion of both
Sphk1 and Sphk2, but not either alone, is embryonic lethal in
mice. There are splice variants of each isoform (SphK1a-c and
SphK2a, b), distinguished by their N-terminal sequences. SPHK1
and SPHK2 differ in tissue distribution, sub-cellular localisation,
biochemical properties and regulation. They regulate discrete
pools of S1P. Receptor stimulation induces SPHK1 translocation
from the cytoplasm to the plasma membrane. SPHK1 transloca-
tion is regulated by phosphorylation/dephosphorylation, speciﬁc
protein:protein interactions and interaction with speciﬁc lipids at
the plasma membrane. SPHK1 is a dimeric protein, as conﬁrmed
by its crystal structure which forms a positive cluster, between pro-
tomers, essential for interaction with anionic phospholipids in the
plasma membrane. SPHK2 is localised to the ER or associated with
mitochondria or shuttles in/out of the nucleus, regulated by phos-
phorylation. Intracellular targets of nuclear S1P include the cat-
alytic subunit of telomerase (TERT) and regulators of gene expres-
sion including histone deacetylases (HDAC 1/2) and peroxisome
proliferator-activated receptor gamma (PPARγ). SPHK2 phospho-
rylates the pro-drug FTY720 (ﬁngolimod, which is used to treat
some forms of multiple sclerosis) to a mimic of S1P and that acts
as a functional antagonist of S1P1 receptors. Inhibitors of SPHK1
and SPHK2 have therapeutic potential in many diseases.
Nomenclature sphingosine kinase 1 sphingosine kinase 2
Common abbreviation SPHK1 SPHK2
HGNC, UniProt SPHK1, Q9NYA1 SPHK2, Q9NRA0
EC number 2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
dihydrosphingosine + ATP = sphingosine 1-phosphate + ADP
2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
dihydrosphingosine + ATP = sphingosine 1-phosphate + ADP
Cofactors Mg2+ [536] Mg2+
Inhibitors SKI II (pKi 4.8) [181], MP-A08 (pIC50 4.6) [474] MP-A08 (pKi 5.2) [474], SKI II (pKi 5.1) [196]
Selective inhibitors PF-543 (pKi 8.4) [537] SLC4101431 (pKi 7.1) [100], compound 27d (pIC50 6.8) [526], opaganib (pKi 5) [181],
ROMe (pKi 4.8) [354]
Comments SK1 inhibitors induce its proteasomal degradation [373, 404]. SK1 crystal structures conﬁrm
that it is dimeric [5]; there is no crystal structure available for SK2.
There is no crystal structure available for SK2.
Comments: MP-A08 is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (opaganib) has known off-target effects on dihydroceramide desaturase (DEGS1) [404,
610]) and induces proteasomal degradation of SK1 [404]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma
(to view ClinicalTrials.gov list click here).
Further reading on Sphingosine kinase
Adams DR et al. (2016) Sphingosine Kinases: Emerging Structure-Function Insights. Trends Biochem.
Sci. 41: 395-409 [PMID:27021309]
Lynch KR et al. (2016) Sphingosine kinase inhibitors: a review of patent literature (2006-2015). Expert
Opin Ther Pat 26: 1409-1416 [PMID:27539678]
Pitman MR et al. (2016) Recent advances in the development of sphingosine kinase inhibitors. Cell.
Signal. 28: 1349-63 [PMID:27297359]
Pulkoski-Gross MJ et al. (2018) An intrinsic lipid-binding interface controls sphingosine kinase 1
function. J. Lipid Res. 59: 462-474 [PMID:29326159]
Pyne NJ et al. (2017) Sphingosine Kinase 2 in Autoimmune/Inﬂammatory Disease and the Develop-
ment of Sphingosine Kinase 2 Inhibitors. Trends Pharmacol. Sci. 38: 581-591 [PMID:28606480]
Pyne S et al. (2018) Sphingosine Kinases as Druggable Targets. Handb Exp Pharmacol [PMID:29460151]
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Sphingosine 1-phosphate phosphatase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine 1-phosphate phosphatase
Nomenclature sphingosine-1-phosphate phosphatase 1 sphingosine-1-phosphate phosphatase 2
Common abbreviation SGPP1 SGPP2
HGNC, UniProt SGPP1, Q9BX95 SGPP2, Q8IWX5
EC number 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate
Comments Depletion of S1P phosphohydrolase-1 (SPP1), which degrades intracellular S1P,
induces the unfolded protein response and endoplasmic reticulum stress-induced
autophagy [382].
–
Comments: SGPP1 and SGPP2 are non-redundant endoplasmic reticulum enzymes that dephosphorylate intracellular S1P. The phenotype of Sgpp1(-/-) mice differ with genetic background. Sgpp2(-/-)
mice are also available. No speciﬁc SGPP inhibitors available [382].
Further reading on Sphingosine 1-phosphate phosphatase
Allende ML et al. (2013) Sphingosine-1-phosphate phosphatase 1 regulates keratinocyte differentia-
tion and epidermal homeostasis. J. Biol. Chem. 288: 18381-91 [PMID:23637227]
Huang WC et al. (2016) Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal
integrity, and contributes to ulcerative colitis in mice and humans. FASEB J. 30: 2945-58
[PMID:27130484]
Lépine S et al. (2011) Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced au-
tophagy. Cell Death Differ. 18: 350-61 [PMID:20798685]
Mandala SM et al. (2000) Molecular cloning and characterization of a lipid phosphohydrolase that
degrades sphingosine-1- phosphate and induces cell death. Proc. Natl. Acad. Sci. U.S.A. 97:
7859-64 [PMID:10859351]
Taguchi Y et al. (2016) Sphingosine-1-phosphate Phosphatase 2 Regulates Pancreatic Islet β-Cell En-
doplasmic Reticulum Stress and Proliferation. J. Biol. Chem. 291: 12029-38 [PMID:27059959]
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Sphingosine 1-phosphate lyase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine 1-phosphate lyase
Nomenclature sphingosine-1-phosphate lyase 1
HGNC, UniProt SGPL1, O95470
EC number 4.1.2.27: sphingosine 1-phosphate -> phosphoethanolamine + hexadecenal
dihydrosphingosine 1-phosphate -> phosphoethanolamine + hexadecanal
Cofactors pyridoxal 5-phosphate
Inhibitors compound 31 (pIC50 6.7) [242, 366, 529, 635]
Comments: THI (2-Acetyl-5-tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations [528].
Recessive mutations in the S1P lyase (SGPL1) gene underlie a recently identiﬁed sphingolipidosis: SPL Insufﬁciency Syndrome (SPLIS) [103].
A Phase 2 clinical trial of LX3305 (LX2931) for rheumatoid arthritis has been completed (see NCT00903383).
Further reading on Sphingosine 1-phosphate lyase
Bamborschke D et al. (2018) A novel mutation in sphingosine-1-phosphate lyase causing congenital
brain malformation. Brain Dev. 40: 480-483 [PMID:29501407]
Choi YJ et al. (2019) Sphingosine phosphate lyase insufﬁciency syndrome (SPLIS): A novel inborn
error of sphingolipid metabolism. Adv Biol Regul 71: 128-140 [PMID:30274713]
Lovric S et al. (2017) Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis
and adrenal insufﬁciency. J. Clin. Invest. 127: 912-928 [PMID:28165339]
Prasad R et al. (2017) Sphingosine-1-phosphate lyase mutations cause primary adrenal insufﬁciency
and steroid-resistant nephrotic syndrome. J. Clin. Invest. 127: 942-953 [PMID:28165343]
Thyroid hormone turnover
Enzymes → Thyroid hormone turnover
Overview:
The thyroid hormones triiodothyronine and thyroxine, usually
abbreviated as triiodothyronine and T4, respectively, are synthe-
sized in the thyroid gland by sequential metabolism of tyrosine
residues in the glycosylated homodimeric protein thyroglobulin
(TG, P01266) under the inﬂuence of the haem-containing protein
iodide peroxidase. Iodide peroxidase/TPO is a haem-containing
enzyme, from the same structural family as eosinophil peroxidase
(EPX, P11678), lactoperoxidase (LPO, P22079) and myeloperoxi-
dase (MPO, P05164). Circulating thyroid hormone is bound to
thyroxine-binding globulin (SERPINA7, P05543).
Tissue deiodinases
These are 1 TM selenoproteins that remove an iodine from
T4 (3,3’,5,5’-tetraiodothyronine) to generate triiodothyronine
(3,3’,5-triiodothyronine, a more potent agonist at thyroid hor-
mone receptors) or rT3 (rT3, 3,3’,5’-triiodothyronine, a relatively
inactive analogue). DIO1 is also able to deiodinate RT3 to form
3,3’-diidothyronine (T2). Iodotyrosine deiodinase is a 1TM ho-
modimeric enzyme.
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Nomenclature thyroid peroxidase iodothyronine deiodinase 1 iodothyronine deiodinase 2 iodothyronine deiodinase 3 iodotyrosine deiodinase
Common abbreviation TPO DIO1 DIO2 DIO3 IYD
HGNC, UniProt TPO, P07202 DIO1, P49895 DIO2, Q92813 DIO3, P55073 IYD, Q6PHW0
EC number 1.11.1.8:
[Thyroglobulin]-L-tyrosine +
H2O2 + H+ + I- ->
[Thyroglobulin]-3,5,3’-triiodo-L-
thyronine +
[thyroglobulin]-aminoacrylate +
H2O
1.97.1.10: T4 -> triiodothyronine
rT3 -> T2
1.97.1.10: T4 -> triiodothyronine
rT3 -> T2
1.97.1.11: T4 -> triiodothyronine
rT3 -> T2
1.22.1.1: 3-iodotyrosine ->
L-tyrosine + I-
3,5-diiodo-L-tyrosine ->
3-iodotyrosine + I-
Cofactors Ca2+ – – – ﬂavin adenine dinucleotide,
NADPH
Inhibitors methimazole [430],
propylthiouracil [430]
– – – –
Comments Carbimazole is a pro-drug for
methimazole
– – – –
Further reading on Thyroid hormone turnover
Darras VM et al. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear
thyroid hormone receptor-mediated impact on vertebrate development. Biochim. Biophys. Acta
1849: 130-41 [PMID:24844179]
Gereben B et al. (2015) Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat
Rev Endocrinol 11: 642-652 [PMID:26416219]
Mondal S et al. (2017) Novel thyroid hormone analogues, enzyme inhibitors andmimetics, and their
action. Mol. Cell. Endocrinol. 458: 91-104 [PMID:28408161]
Schweizer U et al. (2015) New insights into the structure and mechanism of iodothyronine deiodi-
nases. J. Mol. Endocrinol. 55: R37-52 [PMID:26390881]
van der Spek AH et al. (2017) Thyroid hormone metabolism in innate immune cells. J. Endocrinol.
232: R67-R81 [PMID:27852725]
1.14.13.9 Kynurenine 3-monooxygenase
Enzymes → 1.14.13.9 Kynurenine 3-monooxygenase
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Nomenclature kynurenine 3-monooxygenase
HGNC, UniProt KMO, O15229
EC number 1.14.13.9
L-kynurenine + NADPH + O2 <=> 3-hydroxy-L-kynurenine + NADP(+) + H2O
Comments Kynurenine 3-monooxygenase participates in metabolism of the essential amino acid tryptophan.
Further reading on 1.14.13.9 Kynurenine 3-monooxygenase
Dounay AB et al. (2015) Challenges and Opportunities in the Discovery of New Therapeutics Target-
ing the Kynurenine Pathway. J. Med. Chem. 58: 8762-82 [PMID:26207924]
Erhardt S et al. (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neurophar-
macology 112: 297-306 [PMID:27245499]
Fujigaki H et al. (2017) L-Tryptophan-kynurenine pathway enzymes are therapeutic target for
neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology 112: 264-274
[PMID:26767951]
Smith JR et al. (2016) Kynurenine-3-monooxygenase: a review of structure, mechanism, and in-
hibitors. Drug Discov. Today 21: 315-24 [PMID:26589832]
Song P et al. (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular dis-
eases. Cell. Mol. Life Sci. 74: 2899-2916 [PMID:28314892]
2.5.1.58 Protein farnesyltransferase
Enzymes → 2.5.1.58 Protein farnesyltransferase
Overview: Farnesyltransferase is a member of the prenyltrans-
ferases family which also includes geranylgeranyltransferase types
I (EC 2.5.1.59) and II (EC 2.5.1.60) [82]. Protein farnesyltransferase
catalyses the post-translational formation of a thioether linkage
between the C-1 of an isoprenyl group and a cysteine residue
fourth from the C-terminus of a protein (ie to the CaaX motif,
where ’a’ is an aliphatic amino acid and ’X’ is usually serine, me-
thionine, alanine or glutamine; leucine for EC 2.5.1.59) [188]. Far-
nesyltransferase is a dimer, composed of an alpha and beta subunit
and requires Mg2+ and Zn2+ ions as cofactors. The active site is lo-
cated between the subunits. Prenylation creates a hydrophobic
domain on protein tails which acts as a membrane anchor.
Substrates of the prenyltransferases include Ras, Rho, Rab, other
Ras-related small GTP-binding proteins, G-protein γ-subunits, nu-
clear lamins, centromeric proteins and many proteins involved in
visual signal transduction.
In relation to the causative association between oncogenic Ras
proteins and cancer, farnesyltransferase has become an important
mechanistic drug discovery target.
Information on members of this family may be found in the online database.
Further reading on 2.5.1.58 Protein farnesyltransferase
Gao S et al. (2016) The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the Brain.
Mol. Neurobiol. 53: 6925-6937 [PMID:26666664]
Shen M et al. (2015) Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism,
inhibitors and molecular modeling. Drug Discov. Today 20: 267-76 [PMID:25450772]
Shen Y et al. (2015) The Recent Development of Farnesyltransferase Inhibitors as Anticancer and
Antimalarial Agents. Mini Rev Med Chem 15: 837-57 [PMID:25963569]
Wang M et al. (2016) Protein prenylation: unique fats make their mark on biology. Nat. Rev. Mol.
Cell Biol. 17: 110-22 [PMID:26790532]
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3.5.1.- Histone deacetylases (HDACs)
Enzymes → 3.5.1.- Histone deacetylases (HDACs)
Overview: Histone deacetylases act as erasers of epigenetic acety-
lation marks on lysine residues in histones. Removal of the acetyl
groups facilitates tighter packing of chromatin (heterochromatin
formation) leading to transcriptional repression.
The histone deacetylase family has been classiﬁed in to ﬁve sub-
families based on phylogenetic comparison with yeast homo-
logues:
Class I contains HDACs 1, 2, 3 and 8
Class IIa contains HDACs 4, 5, 7 and 9
Class IIb contains HDACs 6 and 10
Class III contains the sirtuins (SIRT1-7)
Class IV contains only HDAC11.
Classes I, II and IV use Zn+ as a co-factor, whereas catalysis by
Class III enzymes requires NAD+ as a co-factor, and members of
this subfamily have ADP-ribosylase activity in addition to protein
deacetylase function [521].
HDACs have more general protein deacetylase activity, being able
to deacetylate lysine residues in non-histone proteins [104] such
as microtubules [270], the hsp90 chaperone [326] and the tumour
suppressor p53 [377].
DysregulatedHDAC activity has been identiﬁed in cancer cells and
tumour tissues [355, 509], making HDACs attractive molecular
targets in the search for novel mechanisms to treat cancer [639].
Several small molecule HDAC inhibitors are already approved
for clinical use: romidepsin, belinostat, vorinostat, panobinostat,
belinostat, valproic acid and tucidinostat. HDACs and HDAC in-
hibitors currently in development as potential anti-cancer thera-
peutics are reviewed by Simó-Riudalbas and Esteller (2015) [545].
Nomenclature histone deacetylase 6
HGNC, UniProt HDAC6, Q9UBN7
EC number 3.5.1.98
Inhibitors trichostatin A (pKi 9) [61], vorinostat (pKi 8.8) [61], romidepsin (pKi 8) [61]
Selective inhibitors ricolinostat (pIC50 8.3) [518]
Further reading on 3.5.1.- Histone deacetylases (HDACs)
Ellmeier W et al. (2018) Histone deacetylase function in CD4+ T cells. Nat. Rev. Immunol. 18:
617-634 [PMID:30022149]
Maolanon AR et al. (2017) Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase
Enzymes. Chembiochem 18: 5-49 [PMID:27748555]
Micelli C et al. (2015) Histone deacetylases: structural determinants of inhibitor selectivity. Drug
Discov. Today 20: 718-35 [PMID:25687212]
Millard CJ et al. (2017) Targeting Class I Histone Deacetylases in a "Complex" Environment. Trends
Pharmacol. Sci. 38: 363-377 [PMID:28139258]
Roche J et al. (2016) Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 121:
451-483 [PMID:27318122]
Zagni C et al. (2017) The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade
After Vorinostat. Med Res Rev 37: 1373-1428 [PMID:28181261]
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3.5.3.15 Peptidyl arginine deiminases (PADI)
Enzymes → 3.5.3.15 Peptidyl arginine deiminases (PADI)
Overview: In humans, the peptidyl arginine deiminases (PADIs;
HGNC family link) are a family of ﬁve enzymes, PADI1-4 and
PADI6. PADIs catalyze the deimination of protein L-arginine
residues to L-citrulline and ammonia, generating peptidyl-
citrulline on histones, ﬁbrinogen, and other biologically rele-
vant proteins. The human isozymes exhibit tissue-speciﬁc expres-
sion patterns [294]. Overexpression and/or increased PADI activ-
ity is observed in several diseases, including rheumatoid arthri-
tis, Alzheimer’s disease, multiple sclerosis, lupus, Parkinson’s dis-
ease, and cancer [47]. Pharmacological PADI inhibition reverses
protein-hypercitrullination and disease in mouse models of mul-
tiple sclerosis [423].
Information on members of this family may be found in the online database.
Further reading on 3.5.3.15 Peptidyl arginine deiminases (PADI)
Koushik S et al. (2017) PAD4: pathophysiology, current therapeutics and future perspective in
rheumatoid arthritis. Expert Opin. Ther. Targets 21: 433-447 [PMID:28281906]
Tu R et al. (2016) Peptidyl Arginine Deiminases and Neurodegenerative Diseases. Curr. Med. Chem.
23: 104-14 [PMID:26577926]
Whiteley CG. (2014) Arginine metabolising enzymes as targets against Alzheimers’ disease. Neu-
rochem. Int. 67: 23-31 [PMID:24508404]
3.6.5.2 Small monomeric GTPases
Enzymes → 3.6.5.2 Small monomeric GTPases
Overview: small G-proteins, are a family of hydrolase enzymes that can bind and hydrolyze guanosine triphosphate (GTP). They are a type of G-protein found in the cytosol that are homologous to
the alpha subunit of heterotrimeric G-proteins, but unlike the alpha subunit of G proteins, a small GTPase can function independently as a hydrolase enzyme to bind to and hydrolyze a guanosine
triphosphate (GTP) to form guanosine diphosphate (GDP). The best-known members are the Ras GTPases and hence they are sometimes called Ras subfamily GTPases.
RAS subfamily
Enzymes → 3.6.5.2 Small monomeric GTPases → RAS subfamily
Overview: The RAS proteins (HRAS, NRAS and KRAS) are small
membrane-localised G protein-like molecules of 21 kd. They act as
an on/off switch linking receptor and non-receptor tyrosine kinase
activation to downstream cytoplasmic or nuclear events. Binding
of GTP activates the switch, and hydrolysis of the GTP to GDP
inactivates the switch.
The RAS proto-oncogenes are the most frequently mutated class
of proteins in human cancers. Common mutations compromise
the GTP-hydrolysing ability of the proteins causing constitutive
activation [564], which leads to increased cell proliferation and
decreased apoptosis [674]. Because of their importance in onco-
genic transformation these proteins have become the targets of
intense drug discovery effort [33].
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp RAS subfamily S391
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Further reading on RAS subfamily
Dorard C et al. (2017) Deciphering the RAS/ERK pathway in vivo. Biochem. Soc. Trans. 45: 27-36
[PMID:28202657]
Keeton AB et al. (2017) The RAS-Effector Interaction as a Drug Target. Cancer Res. 77: 221-226
[PMID:28062402]
Lu S et al. (2016) Ras Conformational Ensembles, Allostery, and Signaling. Chem. Rev. 116: 6607-65
[PMID:26815308]
Ostrem JM et al. (2016) Direct small-molecule inhibitors of KRAS: from structural insights to
mechanism-based design. Nat Rev Drug Discov 15: 771-785 [PMID:27469033]
Papke B et al. (2017) Drugging RAS: Know the enemy. Science 355: 1158-1163 [PMID:28302824]
Quah SY et al. (2016) Pharmacological modulation of oncogenic Ras by natural products and their
derivatives: Renewed hope in the discovery of novel anti-Ras drugs. Pharmacol. Ther. 162: 35-57
[PMID:27016467]
Simanshu DK et al. (2017) RAS Proteins and Their Regulators in Human Disease. Cell 170: 17-33
[PMID:28666118]
RAB subfamily
Enzymes → 3.6.5.2 Small monomeric GTPases → RAB subfamily
Overview: The Rab family of proteins is a member of the Ras su-
perfamily of monomeric G proteins. Rab GTPases regulate many
steps of membrane trafﬁc, including vesicle formation, vesicle
movement along actin and tubulin networks, and membrane fu-
sion. These processes make up the route through which cell sur-
face proteins are trafﬁcked from the Golgi to the plasma mem-
brane and are recycled. Surface protein recycling returns proteins
to the surface whose function involves carrying another protein or
substance inside the cell, such as the transferrin receptor, or serves
as a means of regulating the number of a certain type of protein
molecules on the surface ( see HGNC RAB, 65 genes ).
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp RAB subfamily S392
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